UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-K
(Mark One)
☒
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2019
OR
☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM TO
Commission file number 001-36591
Otonomy, Inc.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of
incorporation or organization)
26-2590070
(I.R.S. Employer
Identification No.)
4796 Executive Drive
San Diego, California 92121
(Address of principal executive offices and Zip Code)
(619) 323-2200
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Common stock, par value $0.001 per share
Trading Symbol(s)
OTIC
Name of each exchange on which registered
The NASDAQ Stock Market LLC
(The NASDAQ Global Select Market)
Securities registered pursuant to Section 12(g) of the Act: None
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. YES ☐ NO ☒
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. YES ☐ NO ☒
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES ☒ NO ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12
months (or for such shorter period that the registrant was required to submit such files). YES ☒ NO ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,”
“accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Non-accelerated filer
Emerging growth company
☐
☐
☐
Accelerated filer
Smaller reporting company
☒
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section
13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). YES ☐ NO ☒
The aggregate market value of the common stock held by non-affiliates of the registrant as of June 28, 2019 (the last business day of the registrant’s most recently completed second fiscal quarter) was approximately $77.9 million
based on the closing price of the registrant’s common stock, as reported by the NASDAQ Global Select Market on June 28, 2019 of $2.75 per share. Shares of the registrant’s common stock held by each executive officer, director and
holder of 10% or more of the outstanding common stock have been excluded in that such persons may be deemed to be affiliates. This calculation does not reflect a determination that certain persons are affiliates of the registrant for
any other purpose.
As of February 21, 2020, the number of outstanding shares of the registrant’s common stock, par value $0.001 per share, was 30,814,211.
As noted herein, the information called for by Part III is incorporated by reference to specified portions of the registrant’s definitive proxy statement to be filed in conjunction with the registrant’s 2020 Annual Meeting of
Stockholders, which is expected to be filed not later than 120 days after the registrant’s fiscal year ended December 31, 2019.
DOCUMENTS INCORPORATED BY REFERENCE
OTONOMY, INC.
ANNUAL REPORT ON FORM 10-K
FOR THE YEAR ENDED DECEMBER 31, 2019
TABLE OF CONTENTS
Item 1.
Item 1A.
Item 1B.
Item 2.
Item 3.
Item 4.
Item 5.
Item 6.
Item 7.
Item 7A.
Item 8.
Item 9.
Item 9A.
Item 9B.
PART I
Business
Risk Factors
Unresolved Staff Comments
Properties
Legal Proceedings
Mine Safety Disclosures
PART II
Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
Selected Financial Data
Management’s Discussion and Analysis of Financial Condition and Results of Operations
Quantitative and Qualitative Disclosures About Market Risk
Financial Statements
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
Controls and Procedures
Other Information
PART III
Item 10.
Item 11.
Item 12.
Item 13.
Item 14.
Directors, Executive Officers and Corporate Governance
Executive Compensation
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Certain Relationships and Related Transactions, and Director Independence
Principal Accounting Fees and Services
PART IV
Item 15.
Item 16.
Exhibits, Financial Statement Schedules
Form 10-K Summary
Signatures
1
Page
4
24
60
60
60
60
61
61
62
73
74
100
100
102
103
103
103
103
103
104
106
107
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Annual Report on Form 10-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995,
which statements involve substantial risks and uncertainties. Forward-looking statements generally relate to future events or our future financial or operating
performance. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “could,” “estimate,”
“expects,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” the negative of those terms, and similar expressions that
convey uncertainty of future events or outcomes. Forward-looking statements contained in this Annual Report on Form 10-K include, but are not limited to,
statements about:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
our expectations regarding our OTIPRIO co-promotion partnerships;
our expectations regarding our clinical development of OTIVIDEX, including availability of top-line results from the ongoing Phase 3 trial
by the end of the third quarter of 2020 and expectations that one additional successful pivotal trial is sufficient to support the United States
registration of OTIVIDEX in Ménière’s disease;
our expectations regarding the clinical development of OTO-313, including availability of top-line results from the ongoing Phase 1/2 clinical
trial in tinnitus patients by the end of the second quarter of 2020;
our expectations regarding the clinical development of OTO-413, including availability of top-line results from the ongoing Phase 1/2 clinical
trial in hearing loss patients in the second half of 2020;
the timing or likelihood of regulatory filings and approvals;
our expectations regarding the future development of other product candidates, including but not limited to our development plans for our
OTO-510 and OTO-6XX programs;
our expectations regarding our strategic collaboration with Applied Genetic Technologies Corporation (AGTC) to develop and
commercialize a gene therapy for congenital hearing loss;
the potential for commercialization of our product candidates, if approved;
our expectations and statements regarding the benefits, pricing, market size, opportunity and growth potential for OTIVIDEX, OTO-313,
OTO-413 and our other product candidates, if approved for commercial use;
our expectations and statements regarding the adoption and use of OTIPRIO and OTIVIDEX, OTO-313 and OTO-413, if approved;
our expectations regarding potential coverage and reimbursement relating to OTIPRIO, and OTIVIDEX, OTO-313 and OTO-413, if
approved, or any other approved product candidates;
our plans regarding the use of contract manufacturers for the production of our product candidates for clinical trials and, if approved,
commercial use;
our plans and ability to effectively establish and manage our own sales and marketing capabilities, or seek and establish collaborative
partners, to commercialize our products;
our ability to advance product candidates into, and successfully complete, clinical trials;
the implementation of our business model, strategic plans for our business, products and technology;
the initiation, timing, progress and results of future nonclinical studies and clinical trials;
the scope of protection we are able to establish and maintain for intellectual property rights covering our products and technology;
estimates of our expenses, future revenue, capital requirements and our needs for additional financing;
our expectations regarding the benefits of the loan provided by Oxford Finance LLC and the potential extension of the interest only period;
our financial performance;
2
•
•
accounting principles, policies and estimates; and
developments and projections relating to our competitors and our industry.
These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including but not limited to: our limited operating
history and our expectation that we will incur significant losses for the foreseeable future; our ability to obtain additional financing; our dependence on the
clinical, regulatory and commercial success of OTIVIDEX and advancement of additional product candidates, such as OTO-313 and OTO-413, through clinical
development to regulatory approval and commercialization, the uncertainties inherent in the clinical drug development process, including, without limitation,
our ability to adequately demonstrate the safety and efficacy of our product candidates, the nonclinical and clinical results for our product candidates, which may
not support further development, and challenges related to patient enrollment in clinical trials; our ability to obtain regulatory approval for our product candidates;
side effects or adverse events associated with our product candidates; competition in the biopharmaceutical industry; our dependence on third parties to conduct
nonclinical studies and clinical trials; the timing and outcome of hospital pharmacy and therapeutics reviews and other facility reviews; the impact of coverage
and reimbursement decisions by third-party payors on the pricing and market acceptance of OTIPRIO; our dependence on third parties for the manufacture of
OTIPRIO and our product candidates; our dependence on a small number of suppliers for raw materials; our ability to protect our intellectual property related to
OTIPRIO and our product candidates in the United States and throughout the world; expectations regarding potential market size, opportunity and growth;
our ability to manage operating expenses; implementation of our business model and strategic plans for our business, products and technology; the risk of the
occurrence of any event, change or other circumstance that could give rise to the termination of promotional or collaboration agreements; the risks of the
occurrence of any event, change or other circumstances that could impact our ability to repay or comply with the terms of the loan provided by Oxford Finance
LLC; and other risks. These forward-looking statements reflect our beliefs and views with respect to future events and are based on estimates and assumptions as
of the date of this Annual Report on Form 10-K and are subject to risks and uncertainties. We discuss many of these risks in greater detail in the section titled
“Risk Factors” included in Part I, Item 1A and elsewhere in this report. Moreover, we operate in a very competitive and rapidly changing environment. New risks
emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to
which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make.
Given these uncertainties, you should not place undue reliance on these forward-looking statements. We qualify all the forward-looking statements in this Annual
Report on Form 10-K by these cautionary statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or
to update the reasons actual results could differ materially from those anticipated in any forward-looking statements, whether as a result of new information,
future events or otherwise.
Otonomy, the Otonomy logo, OTIPRIO, OTIVIDEX and other trademarks or service marks of Otonomy appearing in this report are the property of
Otonomy. Trade names, trademarks and service marks of other companies appearing in this report are the property of their respective holders. We have generally
omitted the ®, ™ and other designations, as applicable, in this report.
You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in
the forward-looking statements will be achieved or occur. Moreover, neither we nor any other person assumes responsibility for the accuracy and
completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date
of this Annual Report on Form 10-K to conform these statements to actual results or to changes in our expectations, except as required by law.
You should read this Annual Report on Form 10-K and the documents that we reference in this Annual Report on Form 10-K and have filed with the
Securities and Exchange Commission (SEC) as exhibits to this Annual Report on Form 10-K with the understanding that our actual future results, levels of
activity, performance, and events and circumstances may be materially different from what we expect.
3
Item 1. BUSINESS
Overview
PART I
Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. We pioneered the application of
drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is
covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière’s
disease, hearing loss and tinnitus.
OTIVIDEX is a steroid in development for the treatment of Ménière’s disease. Two Phase 3 trials in Ménière’s disease patients were completed in the
second half of 2017. The AVERTS-2 trial, conducted in Europe, achieved its primary endpoint (p value = 0.029), while the AVERTS-1 trial, conducted in the
United States, did not (p value = 0.62). Based on a Type C meeting with the United States Food and Drug Administration (FDA), we believe that one
additional successful pivotal trial is sufficient to support the United States registration of OTIVIDEX in Ménière’s disease. We are enrolling patients in a
Phase 3 trial for Ménière’s disease with results expected by the end of the third quarter of 2020.
OTO-313 is a sustained-exposure formulation of gacyclidine, a potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist, in
development for the treatment of tinnitus. We are enrolling patients in a Phase 1/2 clinical trial for OTO-313 for the treatment of tinnitus with results expected
by the end of the second quarter of 2020.
OTO-413 is a sustained exposure formulation of brain-derived neurotrophic factor (BDNF) in development for the repair of cochlear synaptopathy,
an underlying pathology in age-related and noise-induced hearing loss that manifests as speech-in-noise hearing difficulty. We are enrolling patients in a
Phase 1/2 clinical trial for OTO-413 for the treatment of hearing loss with results expected in the second half of 2020.
We also have preclinical stage programs addressing prevention of cisplatin-induced hearing loss (OTO-510) and hair cell regeneration for severe
hearing loss (OTO-6XX). In October 2019, we entered into a strategic collaboration with AGTC to co-develop and co-commercialize an adeno-associated
virus (AAV)-based gene therapy to restore hearing in patients with congenital hearing loss caused by a mutation in the gap junction beta 2 gene (GJB2).
In addition, we developed, received FDA approval for and commercially launched OTIPRIO (ciprofloxacin otic suspension) for use during
tympanostomy tube placement (TTP) surgery in pediatric patients. OTIPRIO was also approved by the FDA for the treatment of acute otitis externa (AOE).
We entered into a co-promotion agreement with Mission Pharmacal Company (Mission) in August 2018 and with Glenmark Therapeutics Inc., USA
(Glenmark) in April 2019 to support the promotion of OTIPRIO for the treatment of AOE in physician offices. In July 2019, Glenmark informed us of its
early discontinuation of OTIPRIO promotional support activities due to the delay in FDA approval of its Ryaltris™ allergy product, and the impact of such
delay on its business operations. In September 2019, we reached a settlement with Glenmark regarding the financial and contractual terms impacted by this
decision that included committed payments by Glenmark totaling $1.0 million. In August 2019, Mission informed us of its non-renewal of the co-promotion
agreement.
4
Our Product Pipeline
The following table summarizes the status of our product candidates currently in development and the indications for our approved product, and is
followed by a brief description of each program:
Program (Compound)
OTIVIDEX (dexamethasone)
OTO-313 (gacyclidine)
OTO-413 (BDNF)
OTO-510 (otoprotectant)
OTO-6XX (hair cell regeneration)
GJB2 gene therapy collaboration
OTIPRIO (ciprofloxacin)
Target Population
Ménière’s Disease
Tinnitus
Synaptopathy Hearing Loss
Cisplatin-Induced Hearing Loss
Severe Hearing Loss
Congenital Hearing Loss
TTP Surgery
Acute Otitis Externa
Status or Upcoming Milestone
Phase 3 trial results by end of 3Q20
Phase 1/2 trial results by end of 2Q20
Phase 1/2 trial results in 2H20
Preclinical development
Preclinical development
Preclinical development
Seeking co-promotion partnerships
OTIVIDEX: Sustained-Exposure Steroid for Ménière’s Disease
OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Ménière’s disease. Ménière’s
disease is a chronic condition characterized by acute vertigo attacks, tinnitus, fluctuating hearing loss and a feeling of aural fullness. The underlying cause of
Ménière’s disease is not well understood and there is no known cure. There are more than 850,000 patients diagnosed with Ménière’s disease in the United
States and there are currently no FDA-approved drug treatments. Typical first line treatment in the United States is observance of a low-salt diet and off-label
use of diuretics. Oral and intratympanic (IT) steroids are used in a subset of Ménière’s patients who have persistent or severe symptoms. Patients who are
unresponsive to steroid treatment may resort to surgical or chemical ablation, which can cause irreversible hearing loss.
In November 2017, we announced positive results from the AVERTS-2 Phase 3 clinical trial for OTIVIDEX conducted in Europe. The clinical trial
achieved its primary endpoint of count of definitive vertigo days (DVD) by Poisson Regression analysis in Month 3 for OTIVIDEX vs. placebo (p value =
0.029) based on analysis of all 174 Ménière’s disease patients enrolled in the trial. The OTIVIDEX group demonstrated a 6.2-day reduction in the mean
reported number of DVD from baseline to Month 3 with a 2.5-day mean difference between OTIVIDEX and placebo in Month 3. For subjects who completed
daily diaries through Month 3 (n=105), there was a 68% reduction in vertigo frequency from baseline to Month 3 in the OTIVIDEX group vs. 40% for
placebo. In January 2018, we reported that a number of additional efficacy endpoints were also statistically significant for the 111 patients who were enrolled
in the AVERTS-2 trial through Month 3 at the time of study termination, including count of DVD by Poisson Regression analysis (p value = 0.014).
In August 2017, we announced negative results from the AVERTS-1 Phase 3 clinical trial conducted in the United States that enrolled a total of 165
patients with Ménière’s disease. The clinical trial missed its primary endpoint, count of DVD by Poisson Regression analysis in Month 3 (p value = 0.62), and
also failed to achieve statistical significance (p value < 0.05) for any of the key secondary vertigo endpoints at Month 3. Patients in both the OTIVIDEX and
placebo groups showed similar reductions in the number and severity of vertigo episodes during the three-month observation period. OTIVIDEX patients
reported a 58% reduction from baseline in vertigo frequency in Month 3 vs. 55% for placebo patients.
The clinically significant treatment benefit demonstrated by OTIVIDEX versus placebo in AVERTS-2 was consistent with our expectations from the
Phase 2b trial. We believe that the AVERTS-1 trial failed due to a significantly higher placebo response and was not attributable to a difference in patient
demographics or baseline characteristics compared to AVERTS-2. A review of the AVERTS trials including consultation with outside experts suggests that
the higher placebo response was primarily due to increased patient expectation bias in the U.S. trial. We completed a Type C meeting with the FDA in March
2018 that included a review of the AVERTS and other clinical trial results. Based on FDA feedback, we believe that one additional successful pivotal trial is
sufficient to support the U.S. registration of OTIVIDEX in Ménière’s disease. We are enrolling patients in a Phase 3 trial for Ménière’s disease with top-line
results expected by the end of the third quarter of 2020.
5
OTO-313: Sustained-Exposure NMDA Receptor Antagonist for Tinnitus
OTO-313 is a sustained-exposure formulation of the NMDA receptor antagonist gacyclidine in development for the treatment of tinnitus. Tinnitus is
often described as a ringing in the ear but can also sound like roaring, clicking, hissing or buzzing. People with severe tinnitus may have trouble hearing,
working and sleeping. At this time, there is no cure for tinnitus and there are no FDA-approved drugs for the treatment of this debilitating condition.
Historic and emerging clinical data provide support for the use of NMDA receptor antagonists, including gacyclidine, for the treatment of tinnitus.
Mechanistically, agents from this therapeutic class may act to reduce dysfunctional activity resulting from injury to the hearing organ, or cochlea, and be
perceived by the patient as tinnitus. Several clinical trials have demonstrated reductions in the severity of tinnitus and improvement in the functional status of
patients following treatment with an NMDA receptor antagonist. We expect that the results of these trials will be instructive in the design and implementation
of our OTO-313 clinical development program.
The goal of our OTO-313 program is to develop a sustained-exposure formulation of gacyclidine that will provide a course of treatment from a single
IT injection. A Phase 1 clinical safety trial in normal healthy volunteers has been successfully completed using OTO-311, a poloxamer-based formulation of
gacyclidine, with no safety concerns observed. We have shifted development to OTO-313, an alternative formulation of gacyclidine that has improved
properties compared to OTO-311. We are enrolling patients in a Phase 1/2 clinical trial of OTO-313 for the treatment of tinnitus with top-line results expected
by the end of the second quarter of 2020.
Development Programs for the Treatment of Sensorineural Hearing Loss
Hearing loss is a large and growing unmet need with estimates by the World Health Organization that more than 360 million people worldwide have
disabling levels of loss. This leads to social isolation, lower quality of life and higher rates of dementia and depression. Common causes include aging, noise,
exposure to ototoxic drugs and genetics, with increased noise exposure from use of recreational music devices accelerating the onset of hearing loss. The
pathologies of hearing loss typically involve damage to hair cells and/or spiral ganglion neurons in the inner ear. As briefly described below, we are
advancing four distinct hearing loss programs targeting different pathologies: repair of cochlear synaptopathy for treatment of speech-in-noise hearing
difficulty (OTO-413), protection of hair cells from ototoxic drugs including cisplatin chemotherapy (OTO-510), hair cell regeneration for treatment of severe
hearing loss (OTO-6XX), and a gene therapy for the most common cause of congenital hearing loss (GJB2).
OTO-413: Neurotrophic Growth Factor for Speech-in-Noise Hearing Difficulty
Cochlear synaptopathy is a hearing pathology caused by damage to ribbon synapses that has become an active focus of otology research in the last
decade. Ribbon synapses are critical to hearing because they connect sound transducers in the cochlea called hair cells to auditory nerve fibers, which carry
the electrical sound impulse to the brain for interpretation. Damage to ribbon synapses can be caused by exposure to loud noise and/or aging, and results in
hearing problems in the presence of background noise referred to as speech-in-noise hearing difficulty. This condition is estimated to affect approximately 3%
of the U.S. population, and is expected to grow significantly in the younger population because of exposure to excessive noise through widespread use of
personal listening devices. Hearing aids provide limited benefit for speech-in-noise hearing problems and there is no FDA-approved drug treatment for this
condition.
OTO-413 is a proprietary formulation of BDNF which is a naturally occurring protein involved in neuron growth and repair. Nonclinical studies by
us and other research groups have demonstrated that local administration of BDNF repairs ribbon synapses damaged due to noise trauma or exposure to
ototoxic chemicals and restores hearing function. We are enrolling patients in a Phase 1/2 clinical trial of OTO-413 for the treatment of speech-in-noise
hearing difficulty with top-line results expected in the second half of 2020.
6
OTO-510: Otoprotectant for Cisplatin-Induced Hearing Loss
Cisplatin and other platinum-based chemotherapeutic agents are routinely used in treating numerous tumor types with approximately 500,000 patients
including 5,000 children treated each year in the United States according to market estimates. While use of platinum agents has contributed to improved
patient survival, ototoxicity and associated permanent hearing loss is well documented in the clinical literature. In particular, hearing loss has been reported in
up to 90% of children and young adults treated with platinum-based agents. This adversely affects speech and language development and has been associated
with academic and social difficulties which can have a significant impact on patients and their families. At this time, there is no FDA-approved drug
treatment to protect against platinum-based ototoxicity.
We established feasibility of conducting clinical trials in patients undergoing cisplatin chemotherapy through a small Phase 2 trial with OTIVIDEX in
pediatric patients, and have identified a therapeutic target that offers a potentially higher level of otoprotection than steroids based on nonclinical studies. This
program, called OTO-510, is focused on the development of a sustained-exposure otoprotectant for local delivery to preserve hearing without protecting the
tumor.
OTO-6XX: Hair Cell Regeneration for Severe Hearing Loss
Auditory hair cells are specialized sensory cells in the cochlea that convert sound vibrations into a signal that can be transmitted to the brain for
interpretation as hearing. Unlike non-mammalian species such as birds that are able to naturally regenerate hair cells, a human is born with approximately
15,000 auditory hair cells per cochlea that do not regenerate. As a result, the loss of hair cells due to damage from excessive noise, physical trauma, exposure
to ototoxic chemicals, or through the natural aging process is irreversible and results in permanent hearing loss. The treatment of hearing loss is a significant
unmet need with approximately 360 million people worldwide having a disabling level of loss including approximately 6.6 million people in the U.S. with
severe hearing loss. Hearing aids provide limited benefit and there are no FDA-approved drugs to treat hearing loss.
Considerable interest and attention has been focused by otology researchers over the past several decades for ways to regenerate auditory hair cells as
an approach to treating severe hearing loss. This effort has included extensive research with non-mammalian species that do regenerate hair cells to identify
pathways for therapeutic intervention. Targeting one of these pathways, we have demonstrated regeneration of hair cells in a nonclinical proof-of-concept
model using a class of small molecules formulated for sustained-exposure local delivery, and have selected a lead compound for development.
GJB2 Gene Therapy Program for Congenital Hearing Loss
In October 2019, Otonomy and AGTC announced a strategic collaboration to co-develop and co-commercialize an AAV-based gene therapy to
restore hearing in patients with sensorineural hearing loss caused by a mutation in the GJB2 gene – the most common cause of congenital hearing loss.
Mutations in GJB2 account for approximately 30% of all genetic hearing loss cases. Patients with this mutation can have severe-to-profound deafness in both
ears that is identified in screening tests routinely performed in newborns.
Under the collaboration agreement, Otonomy and AGTC will equally share the program costs and any revenue or other proceeds related to the
program. The agreement provides for technology sharing and establishment of joint intellectual property as appropriate. The parties may consider including
additional genetic hearing loss targets in the future.
OTIPRIO: Sustained-Exposure Topical Antibacterial for Otic Infections
OTIPRIO is a single-dose, physician-administered antibacterial that was approved by the FDA in December 2015 for the treatment of pediatric
patients with bilateral otitis media with effusion undergoing TTP surgery and was approved in March 2018 for the treatment of patients with AOE. OTIPRIO
is the only product approved by the FDA for use during TTP surgery and is the only single-dose topical antibacterial approved for the treatment of AOE. We
have also completed a successful End-of-Phase 2 review with the FDA for OTIPRIO in patients with acute otitis media with tympanostomy tubes (AOMT).
Based on FDA feedback, we believe that registration would require a single, sham controlled, pivotal Phase 3 trial enrolling approximately 200 pediatric
patients with AOMT.
7
We provided promotional support for OTIPRIO using an internal sales force beginning in the first quarter of 2016 which continued into the fourth
quarter of 2017. In November 2017, we announced the discontinuation of promotional support for OTIPRIO in order to significantly reduce operating
expenses related to the product, however, OTIPRIO continues to be available for purchase by customers. Net sales of OTIPRIO totaled $0.6 million, $0.7
million and $1.2 million, as of December 31, 2019, 2018 and 2017, respectively. We entered into a co-promotion partnership with Mission in August 2018
and with Glenmark in April 2019 to support the promotion of OTIPRIO for the treatment of AOE in physician offices. In July 2019, Glenmark informed us of
its early discontinuation of OTIPRIO promotional support activities due to the delay in FDA approval of its Ryaltris allergy product, and the impact of such
delay on its business operations. In September 2019, we reached a settlement with Glenmark regarding the financial and contractual terms impacted by this
decision that included committed payments by Glenmark totaling $1.0 million. In August 2019, Mission informed us of its non-renewal of the co-promotion
agreement.
Our Proprietary Otic Drug Delivery Technologies
To overcome many of the limitations of delivering drugs to the ear, we have developed multiple proprietary formulation technologies designed to
deliver drug that is retained in the ear for an extended period of time following a single local administration, which we refer to as “sustained-exposure.” One
of these technologies utilizes a thermosensitive polymer called poloxamer which transitions from a liquid to a gel at body temperature. The polymer vehicle is
combined with drug microparticles to create a suspension that is retained in the ear for an extended period of time. This prolonged residence time provides
high and sustained drug exposure.
Potential benefits of our drug delivery technologies for our product and product candidates include:
•
•
•
•
•
Single local administration.
High drug levels in the target location and minimal systemic exposure.
Eliminates the need for the patient to remain in a prone position for an extended period of time.
Simple, office-based administration by an ear, nose and throat physician (ENT).
Avoids patient compliance concerns.
We have a broad patent portfolio of approximately 92 issued patents and allowed patent applications and at least 103 pending patent applications
covering our product, product candidates and indications as well as other potential applications of our drug delivery technologies in major markets around the
world.
Competition
The biopharmaceutical market is highly competitive. Successful competitors in the biopharmaceutical market must have the ability to effectively
discover, develop, test and obtain regulatory approvals for products, as well as the ability to effectively commercialize, market and promote approved
products, including communicating the effectiveness, safety and value of products to actual and prospective customers and medical staff. Numerous
companies are engaged in the development, manufacture and marketing of biopharmaceutical products competitive with those that we are developing. Our
potential competitors may have substantially greater manufacturing, financial, research and development, personnel and marketing resources than we have.
Our competitors may also have more experience and expertise in obtaining marketing approvals from the FDA and other regulatory authorities. In addition to
product development, testing, approval and promotion, other competitive factors in the biopharmaceutical industry include industry consolidation, product
quality and price, product technology, reputation, customer service and access to technical information. As a result, our competitors may be able to develop
competing or superior technologies and processes, and compete more aggressively and sustain that competition over a longer period of time than we could.
Our technologies and products may be rendered obsolete or uneconomical by technological advances or entirely different approaches developed by one or
more of our competitors. As more companies develop new intellectual property in our market, the possibility of a competitor acquiring patent or other rights
that may limit our products or potential products increases, which could lead to litigation.
8
Any product candidates that we successfully develop and commercialize will compete with existing treatments, including unapproved and off-label
drug alternatives that are currently utilized by physicians to treat the indications for which we seek approval, as well as new treatments that may become
available in the future.
OTIPRIO
Antibiotic ear drops are currently the primary treatment option for use during TTP surgery even though no ear drop product has been approved by the
FDA for this indication. Multiple ear drops are approved and marketed for use in treating patients with AOE and AOMT. Marketed antibiotic ear drops
include CIPRODEX® Otic from Alcon, a Novartis company, and Otovel® from Arbor Pharmaceuticals, LLC. The key competitive factors affecting the
success of OTIPRIO are likely to be its efficacy, safety, tolerability, dosing regimen, route of administration, convenience and price, and the availability of
coverage and adequate reimbursement from government and other third-party payors.
OTIVIDEX
There are no drugs currently approved by the FDA for the treatment of Ménière’s disease. Current treatments commonly used for Ménière’s disease
in the United States include observance of a low-salt diet and off-label use of diuretics, oral steroids, and repeat IT injections of steroid solution. Patients who
are unresponsive to treatment may resort to surgical or chemical ablation, which can cause irreversible hearing loss. We are aware that Sound Pharmaceuticals
completed a Phase 2b clinical trial with SP-1005, Synphora AB initiated a Phase 2 clinical trial with an IT formulation of latanoprost, and Auris Medical
Holding AG is developing AM-125, a nasal formulation of betahistine, for the treatment of vertigo disorders including Ménière’s disease.
OTO-313
There are no drugs currently approved by the FDA for the treatment of tinnitus. Current treatments for tinnitus include the use of audio masking
devices, such as white noise machines, hearing aids, cognitive behavioral therapy, and the off-label administration of antidepressants, anti-anxiety
medications, and steroids. We are aware of other companies developing potential pharmaceutical treatments for tinnitus, including Auris Medical Holding
AG, which conducted a Phase 3 clinical program evaluating repeat IT injections of Keyzilen® (formerly AM-101) in patients with tinnitus. Both Phase 3
trials failed to achieve the primary endpoint. We are also aware that Autifony Therapeutics terminated a Phase 2 trial for AUT00063 in tinnitus patients
following a planned interim analysis, Merz Pharmaceuticals GmbH suspended development of oral neramexane for chronic tinnitus while its partner in Japan,
Kyorin Pharmaceutical Co., continues with a Phase 2 clinical trial for tinnitus, and Novartis AG completed a Phase 2 clinical trial for chronic tinnitus.
Hearing Loss Programs
There are no drugs currently approved by the FDA for the treatment of hearing loss. Oral steroids and repeat IT steroid injections are often used for
the treatment of sudden sensorineural hearing loss (SSNHL), which is a rapidly emergent form of hearing loss. Hearing aids are used by a subset of patients
with hearing loss and a limited number of patients with severe hearing loss are treated with cochlear implants. We are aware of a number of companies in
clinical development with potential pharmaceutical treatments for various hearing loss indications, including Auris Medical Holding AG, which has reported
negative results for a Phase 3 trial for AM-111 in SSNHL and terminated a second Phase 3 trial early, Fennec Pharmaceuticals, which has completed two
Phase 3 trials and filed a New Drug Application with the FDA for PEDMARK™ in CIHL, Metarmor, which has conducted a Phase 3 trial with D-MET in
noise-induced hearing loss (NIHL), Strekin AG, which is conducting a Phase 3 trial with STR001 in SSNHL, Sound Pharmaceuticals, which has completed a
Phase 2 trial with SPI-1005 in patients with NIHL, is enrolling a Phase 2 trial for aminoglycoside-induced hearing loss (AIHL) prevention, and has stated
plans to initiate a Phase 2 trial in CIHL, Audion Therapeutics, which has completed a Phase 2 trial with LY3056480 in SSNHL, Sensorion, which has
initiated a Phase 2 trial with SENS-401 in SSNHL and has stated plans to initiate a Phase 2 trial in CIHL, Frequency Therapeutics, which has completed a
Phase 1/2 trial with FX-322 in patients with hearing loss associated with SSNHL or NIHL and has initiated a Phase 2a trial in a similar patient population,
Otologic Pharmaceutics, which has completed a Phase 1 trial with NHPN-010, Decibel Therapeutics, which has initiated a Phase 1b trial with DB-020 in
CIHL, Spiral Therapeutics that has initiated a Phase 1 trial with LPT99 in SSNHL, and Pipeline Therapeutics that intends to initiate a Phase1/2 trial in
SSNHL.
9
Sales and Marketing
We commercialized OTIPRIO using an internal sales force beginning in the first quarter of 2016 and continued promotional support into the fourth
quarter of 2017. In November 2017, we announced the discontinuation of promotional support for OTIPRIO in order to significantly reduce operating
expenses related to the product, however, OTIPRIO continues to be available for purchase by customers. We entered into a co-promotion partnership with
Mission in August 2018 and with Glenmark in April 2019 to support the promotion of OTIPRIO for the treatment of AOE in physician offices. In July 2019,
Glenmark informed us of its early discontinuation of OTIPRIO promotional support activities due to the delay in FDA approval of its Ryaltris allergy product,
and the impact of such delay on its business operations. In September 2019, we reached a settlement with Glenmark regarding the financial and contractual
terms impacted by this decision that included committed payments by Glenmark totaling $1.0 million. In August 2019, Mission informed us of its non-
renewal of the co-promotion agreement.
We plan to evaluate whether to commercialize our product candidates on our own or in collaboration with partners in the United States and for
markets outside the United States.
Third-Party Payor Coverage and Reimbursement
Sales of pharmaceutical products depend in significant part on the availability of coverage and adequate reimbursement by third-party payors, such as
state and federal governments, including Medicare and Medicaid, and commercial insurers. Decisions regarding the extent of coverage and amount of
reimbursement to be provided for our products will most likely be made on a plan-by-plan basis.
OTIPRIO
OTIPRIO is billable as a physician-administered drug in the United States using the J Code that was assigned to the product by the Centers for
Medicare and Medicaid Services (CMS) and became effective as of January 1, 2017. The Wholesale Acquisition Cost for OTIPRIO is $283.20 per vial. A
single vial of OTIPRIO is sufficient for treating a patient during TTP surgery or for the treatment of AOE.
OTIVIDEX, OTO-313, and OTO-413
If approved by the FDA, we intend to apply to CMS for unique J Codes for OTIVIDEX, OTO-313 and OTO-413 to support reimbursement in the
physician office setting. If a J Code is granted and accepted by payors then each product is expected to be reimbursed according to its average selling price
and in addition to the fee the physician receives for performing the intratympanic injection procedure itself.
Manufacturing
We currently contract with third parties for the manufacture, testing and storage of our product and product candidates and intend to continue to do so
in the future. We do not own and have no plans to build our own clinical or commercial manufacturing capabilities. The use of contracted manufacturing is
relatively cost-efficient and has eliminated the need for our direct investment in manufacturing facilities. Because we rely on contract manufacturers, we
employ personnel with extensive technical, manufacturing, analytical and quality experience to oversee contract manufacturing and testing activities, and to
compile manufacturing and quality information for our regulatory submissions.
Manufacturing is subject to extensive regulations that impose various procedural and documentation requirements, and which govern record keeping,
manufacturing processes and controls, personnel, quality control and quality assurance, among others. Our systems and our contractors are required to be in
compliance with these regulations, and this is assessed regularly through monitoring of performance and a formal audit program. To date, our third-party
manufacturers have met our manufacturing requirements for clinical trials and our third-party manufacturer for OTIPRIO successfully passed a pre-approval
inspection conducted by the FDA. We expect third-party manufacturers to be capable of providing sufficient quantities of our product and product candidates
to meet anticipated commercial demands. We believe that there are alternate sources of raw material supply and finished goods manufacturing that can satisfy
our requirements, although we cannot be certain that transitioning to such vendors, if necessary, would not result in significant delay or material additional
costs.
10
Poloxamer 407
The basis for the formulation of our product and certain of our product candidates is P407, a thermosensitive polymer. We currently purchase P407
from a single supplier on a purchase-order basis under a supply agreement. Although P407 is available from other sources, changing suppliers could disrupt
our supply chain. We believe that we can effectively manage the risk of supply chain disruption by purchasing and storing quantities of P407 sufficient for our
clinical and commercial requirements.
OTIPRIO
OTIPRIO is a suspension containing the antibiotic ciprofloxacin and P407. The raw materials needed for the manufacture of OTIPRIO are
commercially available from multiple sources. We have qualified two sources of ciprofloxacin and have a supply agreement in place with one of the vendors.
We currently use a single third-party contract manufacturer, Siegfried Irvine, located in Irvine, California, to produce OTIPRIO, and we believe this
manufacturer can satisfy our commercial requirements as specified under a commercial supply agreement executed with this manufacturer.
OTIVIDEX
OTIVIDEX is a suspension containing the steroid dexamethasone and P407. We currently purchase dexamethasone from a single supplier on a
purchase-order basis and we do not have a long-term supply agreement. Although dexamethasone is commercially available from other sources, we do not
anticipate needing an alternative supplier. We believe that we can effectively manage the risk of supply chain disruption by purchasing and storing quantities
of dexamethasone sufficient for our clinical, and, if OTIVIDEX is approved for marketing by the applicable regulatory authorities, our commercial
requirements. We currently use two third-party contract manufacturers to produce OTIVIDEX that we believe can satisfy our clinical requirements. We are
currently evaluating our supply chain for the commercial manufacture of OTIVIDEX.
OTO-313
OTO-313 is a formulation containing gacyclidine. We currently purchase gacyclidine from a single supplier on a purchase-order basis and we do not
have a long-term supply agreement. We currently use one third-party contract manufacturer to produce OTO-313 that we believe can satisfy our clinical
requirements.
OTO-413
OTO-413 is a formulation containing BDNF. We currently purchase BDNF from a single supplier on a purchase-order basis and we do not have a
long-term supply agreement. We expect to use one third-party contract manufacturer to produce OTO-413 that we believe can satisfy our clinical
requirements.
Intellectual Property
Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our product, product candidates, novel
discoveries, product development technologies and other know-how, to operate without infringing on the proprietary rights of others and to prevent others
from infringing our proprietary rights. Our policy is to seek to protect our proprietary position by, among other methods, filing U.S. and foreign patent
applications related to our proprietary technology, inventions and improvements that are important to the development and implementation of our business.
We also rely on trademarks, trade secrets, know-how, continuing technological innovation and potential in-licensing opportunities to develop and maintain
our proprietary position.
As for the product candidates we develop and plan to commercialize, as a normal course of business, we intend to pursue composition and therapeutic
use patents, as well as novel indications for our product candidates. We also seek patent protection with respect to novel discoveries, including new active
agent, delivery vehicle and delivery target applications. We have also pursued patents with respect to our proprietary manufacturing processes. We have
sought and plan to continue to seek patent protection, either alone or jointly with our collaborators, as our collaboration agreements may dictate.
11
It is possible that our current patents, or patents which we may later acquire, may be successfully challenged or invalidated in whole or in part.
Nevertheless, we are not aware of any issued patents that we believe would prevent us from marketing OTIPRIO or our product candidates. It is also possible
that we may not obtain issued patents from our pending patent applications or other inventions we seek to protect. Due to uncertainties inherent in prosecuting
patent applications, patent applications are sometimes rejected and we subsequently abandon them. It is also possible that we may develop proprietary
products or technologies in the future that are not patentable or that the patents of others will limit or altogether preclude our ability to do business. In
addition, any patent issued to us may provide us with little or no competitive advantage, in which case we may abandon such patent or license it to another
entity. For more information, please see the section entitled “Risk Factors—Risks Related to Our Intellectual Property.”
Our patent estate includes patents and applications with claims directed to OTIPRIO, and our OTIVIDEX, OTO-313, OTO-413, and other product
candidates. Our patent estate also provides patents and applications with claims directed to a broad range of other active agents as potential future product
candidates that are delivered using our proprietary technologies. Our patent estate, on a worldwide basis, includes approximately 92 issued patents and
allowed patent applications, and at least 103 pending patent applications with claims relating to our OTIPRIO, OTIVIDEX, OTO-313, OTO-413, other
product candidates, future product candidates, manufacturing processes and alternative otic delivery technologies.
For OTIPRIO, we co-own a patent family with The Regents of the University of California (UC) that is directed to the composition and therapeutic
use of OTIPRIO. Through an exclusive license agreement, we have acquired UC’s rights in this patent family. This family includes four issued U.S. patents
and three pending U.S. applications. The latest expiry date of the U.S. patents, without extensions, is April 2030, and the first three issued U.S. patents have
been Orange Book (OB) listed for otitis media with effusion undergoing TTP surgery. The fourth issued patent has been OB listed for AOE. The fifth issued
patent is expected to be OB listable for AOMT, if approved by FDA. Any future U.S. patents issuing from the related applications and directed to OTIPRIO
are also expected to be OB listable. This family also includes issued patents or allowed applications in Australia, Canada, China, Europe, Israel, Japan, Korea,
and Mexico; and pending applications in Brazil and Thailand. Divisional patent applications have been filed in select countries of this family. In addition, we
solely own a patent family directed to certain therapeutic uses of OTIPRIO, which includes an issued U.S. patent that has been submitted for OB listing and
can extend patent protection of OTIPRIO to August 2034. Furthermore, we solely own a patent family directed to OTIPRIO and its manufacturing methods,
which includes an issued U.S. patent that has been OB listed and extends patent protection of OTIPRIO to July 2035; and another issued the U.S. patent that
has been submitted for OB listing. Outside of U.S., this patent family includes an issued patent in Japan and pending applications in Australia, Canada, China,
Europe, and Korea. Finally, we solely own a patent family directed to the packaged OTIPRIO product, and two patent families directed to AOE and AOMT.
For OTIVIDEX, we co-own a patent family with UC directed to the composition and therapeutic use of OTIVIDEX. Through an exclusive license
agreement, we have acquired UC’s rights in this patent family. This family includes seven issued U.S. patents and one pending U.S. application. The latest
expiry date of the U.S. patents, without extensions, is September 2029, and these patents and any future U.S. patent issuing from the related applications are
expected to be OB listable. This family also includes issued patents or allowed applications in Australia, Canada, Chile, China, Europe, Hong Kong, India,
Israel, Japan, Korea, Mexico, Philippines, Russia, Singapore, South Africa, Taiwan, and the United Kingdom (UK); and pending applications in Brazil and
Thailand. Divisional patent applications have been filed in select countries for this family. In addition, we solely own a patent family directed to additional
therapeutic uses of OTIVIDEX, including prevention of chemotherapeutic drug-induced ototoxicity. Finally, we solely own an issued U.S. patent directed to
manufacturing methods of OTIVIDEX. The expiry date of this U.S. patent, without extensions, is April 2030.
For OTO-313, we solely own a patent family directed to, among other things, the composition and therapeutic use of OTO-313. This family includes
one pending U.S. application and pending applications in Australia, Canada, China, Europe, Hong Kong, Israel, India, Japan, and Korea. Any future U.S. and
foreign patents issuing from those applications are expected to have an expiry date of June 2037. In addition, we have licensed from Durect a patent family
directed to the therapeutic use of OTO-313. This family includes one issued U.S. patent and one issued Japanese patent. The expiry date of the U.S. patent,
without extension, is June 2024, and the patent is expected to be OB listable.
12
For OTO-413, we co-own a patent family with UC directed to the composition and therapeutic use of OTO-413. Through an exclusive license
agreement, we have acquired UC’s rights in this patent family. Any future U.S. or foreign patents issuing from this patent family and directed to OTO-413 are
expected to have an expiry date of April 2029. In addition, we solely own two patent families directed to certain aspects of the composition and therapeutic
use of OTO-413. Any future U.S. or foreign patents issuing from those patent families and directed to OTO-413 are expected to have an expiry date of
January 2039 and January 2041, respectively.
For our future product candidates, we co-own eight other patent families with UC directed to a broad range of other active agents, including but not
limited to, anti-TNF agents, auris pressure modulators, CNS modulators, cytotoxic agents, anti-apoptotic agents, bone-remodeling modulators, free radical
modulators and ion channel modulators. As above, we have acquired, though an exclusive license, UC’s rights in those co-owned families. Furthermore, to
strengthen our protection against potential design-around, we solely own two patent families directed to alternative formulations. Finally, we have acquired
from IncuMed LLC, an affiliate of the NeuroSystec Corporation, patent families directed to formulations or devices that deliver active agents, such as the
active agent of OTO-313, into the ear for treatment of otic diseases through alternative delivery technologies. We will continue to pursue additional patent
protection as well as take appropriate measures to obtain and maintain proprietary protection for our innovative technologies.
Individual patents extend for varying periods depending on the date of filing of the patent application or the date of patent issuance and the legal term
of patents in the countries in which they are obtained. Generally, patents issued for regularly filed applications in the United States are effective for 20 years
from the earliest effective filing date. In addition, in certain instances, a patent term can be extended to recapture a portion of the U.S. Patent and Trademark
Office (USPTO) delay in issuing the patent as well as a portion of the term effectively lost as a result of the FDA regulatory review period. However, as to the
FDA component, the restoration period cannot be longer than five years and the total patent term including the restoration period must not exceed 14 years
following FDA approval. The duration of foreign patents varies in accordance with provisions of applicable local law, but typically is also 20 years from the
earliest effective filing date. In addition to the patents and allowed applications described in the preceding paragraphs, our pending patent applications related
to our product candidates, if issued, are expected to expire on dates ranging from 2029 to 2032. However, the actual protection afforded by a patent varies on
a product by product basis, from country to country and depends upon many factors, including the type of patent, the scope of its coverage, the availability of
regulatory-related extensions, the availability of legal remedies in a particular country and the validity and enforceability of the patent.
In addition to patents, we have obtained trademark registrations for the “OTIPRIO” mark in the United States, Australia, Canada, China, the
European Union (EU), Japan, Korea, and New Zealand; we have obtained trademark registrations for the “OTONOMY” mark in the United States; and we
have pending trademark applications for the “OTIVIDEX” mark in the United States, as well as a trademark registration for the “OTIVIDEX” mark in the
EU. Furthermore, we rely upon trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. We
seek to protect our proprietary information, in part, using confidentiality agreements with our commercial partners, collaborators, employees and consultants
and invention assignment agreements with our employees. We also have confidentiality agreements or invention assignment agreements with our commercial
partners and selected consultants. These agreements are designed to protect our proprietary information and, in the case of the invention assignment
agreements, to grant us ownership of technologies that are developed through a relationship with a third party. These agreements may be breached, and we
may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors.
To the extent that our commercial partners, collaborators, employees and consultants use intellectual property owned by others in their work for us, disputes
may arise as to the rights in related or resulting know-how and inventions. For more information, please see the section entitled “Risk Factors—Risks Related
to Our Intellectual Property.”
Our commercial success will also depend in part on not infringing upon the proprietary rights of third parties. It is uncertain whether the issuance of
any third-party patent would require us to alter our development or commercial strategies, or our drugs or processes, obtain licenses or cease certain activities.
Our breach of any license agreements or failure to obtain a license to proprietary rights that we may require to develop or commercialize our future products
may have a material adverse impact on us. If third parties prepare and file patent applications in the United States that also claim technology to which we
have rights, we may have to participate in interference proceedings in the USPTO, to determine priority of invention. Although it is not expected to be
relevant
13
to our product or any of our product candidates, on April 17, 2015, we filed a request for interference between one of our U.S. pending applications and a
U.S. pending application that appears to be controlled by Auris Medical AG (Auris). On July 20, 2015, we received notice from the USPTO that the Patent
Trial and Appeal Board (PTAB) declared an interference between our pending application and the Auris patent (issued as U.S. Patent No. 9,066,865 on
June 30, 2015). On January 26, 2017, the PTAB determined that all of our patent claims and all but one of the Auris patent claims are not patentable. In
addition, the PTAB determined that the written description supporting Auris’s single claim is as of Auris’s filing date of 2014 rather than the 2005 date argued
by Auris. This interference decision does not involve issued U.S. patents covering our product or product candidates. We filed a Notice of Appeal on March
27, 2017, in which we asked the Federal Circuit to reverse PTAB’s decision that our claims are not patentable and that Auris’s single claim is. On April 5,
2017, Auris filed a Notice of Cross-Appeal to ask the Federal Circuit to reverse PTAB’s decision that Auris’s other claims are not patentable. In August 2018,
the Federal Circuit Court issued a final ruling in Otonomy’s favor. We continue to monitor patent applications filed and being protected by Auris, in case we
may need to consider similar or other actions. For more information, please see the section entitled “Risk Factors—Risks Related to Our Intellectual
Property.”
License and Other Agreements
The Regents of the University of California
In November 2008, we entered into an exclusive license agreement with UC that was subsequently amended in January 2010, June 2010, and
November 2012. Under the license agreement, UC granted us an exclusive license under UC’s rights to patents and applications that are co-developed and co-
owned with us (see above regarding our patent estate) for the treatment of human otic diseases. As such, we have acquired the entire commercial rights in
those patents and applications that cover OTIPRIO, OTIVIDEX and OTO-413, and may apply to other product candidates we develop. Under the agreement,
UC reserved the right to use the patents and applications for its and other nonprofit institutions’ research and educational purposes.
Under our agreement with UC, we are obligated to diligently proceed with the development, manufacture and commercialization of licensed
products. If we do not satisfy our diligence obligations, UC may either terminate the agreement or convert our license to a non-exclusive license. In addition,
we are responsible for diligently prosecuting and maintaining the licensed patents, at our own expense; provided that if we decide to abandon a licensed
patent, UC may elect to continue prosecution and maintenance of such patent at its own expense. UC has the first right to prosecute and control any action for
infringement of the patents licensed to us under our agreement with UC; provided that if UC does not initiate an enforcement action against a potential
infringer within the time limits specified in the agreement, we have the right to do so ourselves.
Our financial obligations under the license agreement include annual license maintenance payments until we commercialize the first product covered
under the license agreement, development and regulatory milestone payments of up to $2.7 million per licensed product, of which $1.9 million has been paid
for OTIPRIO, $0.8 million has been paid for OTIVIDEX, $0.1 million has been paid for OTO-413, and $0.1 million has been paid for OTO-311 (but such
milestone payments are reduced by 75% for any orphan indication product), and a low single-digit royalty on net sales by us or our affiliates of licensed
products. In addition, for each sublicense we grant we are obligated to pay UC a fixed percentage of all royalties as well as a sliding scale percentage of non-
royalty sublicense fees received by us under such sublicense, with such percentage depending on the licensed product’s stage of development when
sublicensed to such third party. We have the right to offset a certain amount of third-party royalties, milestone fees or sublicense fees against the foregoing
financial obligations, provided such third-party royalties or fees are paid by us in consideration for intellectual property rights necessary to commercialize a
licensed product.
Unless earlier terminated, the agreement will continue in effect until expiration of the longest-lived patent licensed to us thereunder. UC may
terminate the license agreement for our uncured breach, or if a claim challenging the validity of the licensed patents is filed by or on behalf of us. We have the
right to terminate this agreement for any reason at any time upon prior notice to UC. The termination of our license agreement with UC may affect a portion
of our patent portfolio for OTIPRIO, OTIVIDEX and OTO-413, as well as certain other product candidates we may develop. For more information, please
see the section entitled “Risk Factors—Risks Related to our Intellectual Property.”
14
DURECT Corporation
In April 2013, we entered into an exclusive license agreement with Durect as a part of an asset transfer agreement between us and IncuMed LLC, an
affiliate of the NeuroSystec Corporation. Under this license agreement, Durect granted us an exclusive (even as to Durect), worldwide, royalty-bearing
license under Durect’s rights to certain patents and applications that cover our OTO-313 product candidate, as well as certain related know-how. Included
within the rights licensed from Durect is a sublicense from the Institut National de la Santé et de la Recherche Médicale (INSERM) with respect to
INSERM’s ownership interest in certain patents and patent applications owned jointly by INSERM and Durect.
We are obligated to use commercially reasonable efforts to develop and commercialize licensed products containing the active ingredient gacyclidine,
and in the event, we do not satisfy this obligation following an opportunity to cure, Durect may elect to either terminate the agreement or convert our license
to a non-exclusive license. In addition, we are responsible for prosecuting and maintaining the licensed patents, at our own expense; provided that if we
decide to abandon a licensed patent, Durect may elect to continue prosecution and maintenance of such patent at its own expense. We have the first right, but
not obligation, to prosecute and control any action for infringement of the patents licensed to us under our agreement with Durect.
We are also subject to certain financial obligations under the license agreement. We are obligated to make one-time development milestone payments
of up to $2.3 million for the first licensed product. Upon commercializing a licensed product, we are obligated to pay Durect tiered low single-digit royalties
on annual net sales by us or our affiliates or sublicensees of the licensed products, and we have the right to offset a certain amount of third-party license fees
or royalties against such royalty payments to Durect, provided such third-party fees or royalties are paid by us in connection with patent rights necessary to
sell a licensed product containing the active ingredient gacyclidine. In addition, each sublicense we grant to a third party is subject to payment to Durect of a
low double-digit percentage of all non-royalty payments we receive under such sublicense. Additionally, we are also obligated to pay INSERM, on behalf of
Durect, a low single-digit royalty payment on net sales by us or our affiliates or sublicensees upon commercialization of the licensed product. The foregoing
royalty payment obligation to Durect would continue on a product-by-product and country-by-country basis until expiration or determination of invalidity of
the last valid claim within the licensed patents that cover the licensed product, and the payment obligation to INSERM would continue so long as Durect’s
license from INSERM remains in effect.
Unless earlier terminated, the agreement will continue in effect until expiration of all our royalty payment obligations thereunder. Durect may
terminate the license agreement for our uncured material breach, and either party may terminate the agreement upon written notice in the event of insolvency
or bankruptcy of the other party. We have the right to terminate this agreement for any reason at any time upon prior notice to Durect. The termination of our
license agreement with Durect would affect a portion of our patent portfolio for OTO-313. For more information, please see the section entitled “Risk Factors
—Risks Related to our Intellectual Property.”
Asset Transfer Agreement
In April 2013, we entered into an asset transfer agreement with IncuMed, LLC, an affiliate of NeuroSystec Corporation, pursuant to which we
acquired assets and patent rights related to gacyclidine. Pursuant to the asset transfer agreement, we made a one-time payment of $0.2 million and we are
obligated to make certain one-time milestone payments in connection with the development and commercialization of products containing the active
ingredient gacyclidine, up to a maximum of $5.3 million.
Government Regulation
Government authorities in the United States (at the federal, state and local level) and in other countries extensively regulate, among other things, the
research, development, testing, quality control, manufacture, packaging, storage, recordkeeping, approval, labeling, advertising, promotion, distribution,
marketing, import and export of pharmaceutical products such as those we are developing. The processes for obtaining regulatory approvals in the United
States and in foreign countries and jurisdictions, along with subsequent compliance with applicable statutes and regulations, require the expenditure of
substantial time and financial resources. Our product candidates must be approved by the FDA before they may be legally marketed in the United States and
by the
15
appropriate foreign regulatory agency before they may be legally marketed in foreign countries. Generally, our activities in other countries will be subject to
regulation that is similar in nature and scope as that imposed in the United States, although there can be important differences. Additionally, some significant
aspects of regulation in Europe are addressed in a centralized way, but country-specific regulation remains essential in many respects.
U.S. Drug Approval Process
In the United States, the FDA regulates drugs under the federal Food, Drug, and Cosmetic Act (FDCA) and implementing regulations. The process of
obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the
expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development
process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA’s refusal to approve
pending NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial
suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. The
process required by the FDA before a drug may be marketed in the United States generally involves the following:
•
•
•
•
•
•
•
•
completion of nonclinical laboratory tests, animal studies and formulation studies in compliance with the FDA’s current good laboratory
practice (cGLP) regulations;
submission to the FDA of an IND which must become effective before clinical trials may begin;
approval by an independent institutional review board (IRB) at each clinical site before each trial may be initiated;
performance of adequate and well-controlled clinical trials in accordance with current good clinical practices (cGCP) to establish the safety
and efficacy of the proposed drug or biological product for each indication;
submission to the FDA of an NDA;
satisfactory completion of an FDA advisory committee review, if applicable;
satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance
with cGMP, and to assure that the facilities, methods and controls are adequate to preserve the drug’s identity, strength, quality and purity;
and
FDA review and approval of the NDA.
Nonclinical Studies
Nonclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess its potential
safety and efficacy. An IND sponsor must submit the results of the nonclinical tests, together with manufacturing information, analytical data and any
available clinical data or literature, among other things, to the FDA as part of an IND. Some nonclinical testing may continue even after the IND is submitted.
An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or
more proposed clinical trials and places the trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns
before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence.
Clinical Trials
Clinical trials involve the administration of the investigational new drug to patients under the supervision of qualified investigators in accordance
with cGCP requirements, which include the requirement that all research patients provide their informed consent (assent, if applicable) in writing for their
participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, the parameters
to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must
be submitted to the FDA as part of the IND. In addition, an IRB
16
at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution. Information
about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health (NIH) for public dissemination on their
ClinicalTrials.gov website.
Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:
•
•
•
Phase 1: The drug is initially introduced into healthy human patients with the target disease or condition and tested for safety, dosage
tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness.
Phase 2: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily
evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.
Phase 3: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-
controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the
overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product.
Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events
occur. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA may impose
a partial or full clinical hold or the sponsor may suspend or terminate a clinical trial or development at any time on various grounds, including a finding that
the research patients are being exposed to an unacceptable health risk.
Development, or the aspects of development, that are subject to clinical hold may not continue until the sponsor has satisfied FDA requirements for
information and has been notified that the hold is being removed. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the
clinical trial is not being conducted in accordance with the IRB’s requirements or if the drug has been associated with unexpected serious harm to patients.
The NDA Approval Process
Assuming successful completion of the required clinical testing, the results of the nonclinical studies and clinical trials, together with detailed
information relating to the product’s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA
requesting approval to market the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user
fee.
The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether
they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event,
the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing.
Once the submission is accepted for filing, the FDA begins an in-depth substantive review. Under the Prescription Drug User Fee Act (PDUFA) guidelines
that are currently in effect, the FDA has a goal of ten months from the date of the FDA’s filing of a standard non-priority NDA to review and act on the
submission.
The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and the facility in which it is manufactured,
processed, packaged or held meets standards designed to assure the product’s continued safety, quality and purity. The FDA is required to refer an application
for a novel drug to an advisory committee or explain why such referral was not made. An advisory committee is a panel of independent experts, including
clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under
what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making
decisions.
17
Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured, which is not under the control
of the product sponsor. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with
cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the
FDA will typically inspect one or more clinical sites to assure compliance with cGCP.
The FDA also may require submission of a risk evaluation and mitigation strategy (REMS) plan to mitigate any identified or suspected serious risks.
The REMS plan could include medication guides, physician communication plans, assessment plans and elements to assure safe use, such as restricted
distribution methods, patient registries or other risk minimization tools.
The testing and approval process requires substantial time, effort and financial resources, and each may take several years to complete. Data obtained
from clinical activities are not always conclusive and may be susceptible to varying interpretations, which could delay, limit or prevent regulatory approval.
The FDA may not grant approval on a timely basis, or at all.
The FDA has a Fast Track program that is intended to expedite or facilitate the process for reviewing new products that meet certain criteria.
Specifically, new products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening disease or condition and
demonstrate the potential to address unmet medical needs for the disease or condition. Fast Track designation applies to the combination of the product and
the specific indication for which it is being studied. Unique to a Fast Track product, the FDA may consider for review sections of the NDA on a rolling basis
before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept
sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the
NDA. Our Fast Track Designation for OTIVIDEX may not result in faster development or approval, if at all.
If the FDA’s evaluation of the NDA and inspection of the manufacturing facilities are favorable, the FDA may issue an approval letter, or, in some
cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final
approval of the NDA and may require additional clinical or nonclinical testing in order for FDA to reconsider the application. Even with submission of this
additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions
have been met to the FDA’s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with
specific prescribing information for specific indications.
Even if the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or
precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug’s
safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including
distribution restrictions or other risk management mechanisms, which can materially affect the potential market and profitability of the product. The FDA
may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of
changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing
requirements and FDA review and approval.
The Section 505(b)(2) NDA
For modifications to products previously approved by the FDA, an applicant may file an NDA under Section 505(b)(2) of the FDCA. This section
permits the submission of an NDA where some or all of the data required for approval comes from studies not conducted by or for the applicant and for which
the applicant has not obtained a right of reference. Under this section, an applicant may rely on the FDA’s findings of safety and effectiveness in approval of
another NDA or on studies published in the scientific literature. The applicant may be required to conduct additional studies or provide additional information
to fully demonstrate the safety and effectiveness of its modifications to the approved product.
18
Upon approval of an NDA, the FDA lists the product in a publication entitled “Approved Drug Products with Therapeutic Equivalence Evaluations,”
which is commonly known as the “Orange Book.” FDA also lists in the Orange Book patents identified by the NDA applicant as claiming the drug or an
approved method of using the drug. Any applicant who submits a Section 505(b)(2) NDA must certify to the FDA with regard to each relevant patent that
either (1) no patent information has been submitted to the FDA; (2) the patent has expired; (3) the listed patent has not expired, but will expire on a particular
date and approval is sought after patent expiration; or (4) the patent is invalid or will not be infringed upon by the manufacture, use or sale of the drug product
for which the Section 505(b)(2) NDA is submitted. The last certification is known as a Paragraph IV certification. A notice of Paragraph IV certification must
be provided to each owner of the patent that is the subject of the certification and to the holder of the approved NDA to which the Section 505(b)(2) NDA
refers. If the NDA holder submits the patent information to the FDA prior to submission of the Section 505(b)(2) application and the NDA holder or patent
owner(s) sues the Section 505(b)(2) applicant for infringement within 45 days of its receipt of the certification notice, the FDA is prevented from approving
that Section 505(b)(2) application until the earlier of 30 months from the receipt of the notice of the Paragraph IV certification, the expiration of the patent or
such shorter or longer period as may be ordered by a court. This prohibition is generally referred to as the 30-month stay. A Section 505(b)(2) applicant that is
sued for infringement may file a counterclaim to challenge the listing of the patent or information submitted to FDA about the patent. If we file a Paragraph
IV certification with any Section 505(b)(2) application, we cannot assure you that our application will not be significantly delayed as a result of costly patent
litigation.
Post-Approval Requirements
Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other
things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse
experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to
prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such
products are manufactured, as well as new application fees for supplemental applications with clinical data.
The FDA may impose a number of post-approval requirements as a condition of approval of an NDA. For example, the FDA may require post-
marketing testing, including Phase 4 clinical trials, and surveillance to further assess and monitor the product’s safety and effectiveness after
commercialization.
In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their
establishments with the FDA and state agencies, and are subject to periodic unannounced inspections by the FDA and these state agencies to determine
compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being
implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements
upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend significant time,
money and effort in the area of production and quality control to maintain cGMP compliance.
Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if
problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of
unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the
approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or
other restrictions under a REMS program. Other potential consequences include, among other things:
•
•
•
restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;
fines, warning letters or holds on post-approval clinical trials;
refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals;
19
•
•
product seizure or detention, or refusal to permit the import or export of products; or
injunctions or the imposition of civil or criminal penalties.
The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for
the approved indications and in accordance with the provisions of the approved label, although doctors may prescribe drugs for off-label purposes.
The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to
have improperly promoted off-label uses may be subject to significant liability.
In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (PDMA) which regulates the
distribution of drug and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states.
Hatch-Waxman Exclusivity
Market and data exclusivity provisions under the Federal Food, Drug, and Cosmetic Act (FFDCA) can delay the submission or the approval of
certain applications for competing products. The FFDCA provides a five-year period of non-patent data exclusivity within the United States to the first
applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug
containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may
not accept for review an Abbreviated New Drug Application (ANDA) or a Section 505(b)(2) NDA submitted by another company that references the
previously approved drug. However, an ANDA or Section 505(b)(2) NDA may be submitted after four years if it contains a certification of patent invalidity
or non-infringement. The FFDCA also provides three years of marketing exclusivity for an NDA, Section 505(b)(2) NDA or supplement to an existing NDA
or Section 505(b)(2) NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant, are deemed by
the FDA to be essential to the approval of the application, for example, for new indications, dosages, strengths or dosage forms of an existing drug. This
three-year exclusivity covers only the conditions of use associated with the new clinical investigations and, as a general matter, does not prohibit the FDA
from approving ANDAs or Section 505(b)(2) NDAs for generic versions of the original, unmodified drug product. Five-year and three-year exclusivity will
not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference
to all of the nonclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness.
New Legislation and Regulations
From time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the
testing, approval, manufacturing and marketing of products regulated by the FDA. In addition to new legislation, FDA regulations and policies are often
revised or interpreted by the agency in ways that may significantly affect our business and our products. It is impossible to predict whether further legislative
changes will be enacted or FDA regulations, guidance, policies or interpretations will be changed, or what the impact of such changes, if any, may be.
Pharmaceutical Coverage, Pricing and Reimbursement
Significant uncertainty exists as to the coverage and reimbursement status of any drug products for which we may obtain regulatory approval. Sales
of any of our product candidates, if approved, will depend, in part, on the extent to which the costs of the products will be covered by third-party payors,
including government health programs such as Medicare and Medicaid, commercial health insurers and managed care organizations. The process for
determining whether a third-party payor will provide coverage for a drug product typically is separate from the process for setting the price of a drug product
or for establishing the reimbursement rate that a payor will pay for the drug product once coverage is approved. Third-party payors may limit coverage to
specific drug products on an approved list, also known as a formulary, which might not include all of the approved drugs for a particular indication.
20
In order to secure coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive
pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA
or other comparable regulatory approvals. Whether or not we conduct such studies, our product candidates may not be considered medically necessary or
cost-effective. A third-party payor’s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved.
Further, one payor’s determination to provide coverage for a product does not assure that other payors will also provide coverage, and adequate
reimbursement, for the product. Third-party reimbursement may not be sufficient to enable us to maintain price levels high enough to realize an appropriate
return on our investment in product development.
The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of drugs have been a focus in this
effort. Third-party payors are increasingly challenging the prices charged for medical products and services, examining the medical necessity and reviewing
the cost-effectiveness of drug products and medical services and questioning safety and efficacy. If these third-party payors do not consider our products to be
cost-effective compared to other available therapies, they may not cover our products after FDA approval or, if they do, the level of payment may not be
sufficient to allow us to sell our products at a profit. The U.S. government, state legislatures and foreign governments have shown significant interest in
implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and
requirements for substitution of generic products for branded prescription drugs. Adoption of such controls and measures, and tightening of restrictive
policies in jurisdictions with existing controls and measures, could limit payments for pharmaceuticals such as OTIPRIO and our drug product candidates and
could adversely affect our net revenue and results.
Pricing and reimbursement schemes vary widely from country to country. Some countries provide that drug products may be marketed only after a
reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular
product candidate to currently available therapies. For example, the EU provides options for its member states to restrict the range of drug products for which
their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU member states may approve
a specific price for a drug product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the drug product
on the market. Other member states allow companies to fix their own prices for drug products, but monitor and control company profits. The downward
pressure on healthcare costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the
entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert competitive pressure that may reduce pricing
within a country. Any country that has price controls or reimbursement limitations for drug products may not allow favorable reimbursement and pricing
arrangements for any of our products.
The marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors
fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased and we expect will continue
to increase the pressure on drug pricing. Coverage policies, third-party reimbursement rates and drug pricing regulation may change at any time. In particular,
the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, which we collectively
refer to as the Affordable Care Act (ACA), contains provisions that have the potential to substantially change healthcare delivery and financing, including
impacting the profitability of drugs. For example, the ACA revised the methodology by which rebates owed by manufacturers to the state and federal
government for covered outpatient drugs under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate Program to utilization of covered
drugs dispensed to individuals enrolled in Medicaid managed care organizations and subjected manufacturers to new annual fees and taxes for certain branded
prescription drugs. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less
favorable coverage policies and reimbursement rates may be implemented in the future.
21
Healthcare Law and Regulation
Healthcare providers, physicians and third-party payors play a primary role in the recommendation and prescribing of any product candidates for
which we may obtain marketing approval. Our business operations and arrangements with investigators, healthcare professionals, consultants, third-party
payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws. These laws may constrain the business or financial
arrangements and relationships through which we research, manufacture, market, promote, sell and distribute our products that obtain marketing approval.
Restrictions under applicable federal and state healthcare laws, include, but are not limited to, the following:
•
•
•
•
•
•
the federal healthcare Anti-Kickback Statute prohibits, among other things, persons or entities from knowingly and willfully soliciting,
offering, receiving or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or
in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility,
item or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid;
the federal false claims laws and civil monetary penalties law impose penalties and provide for civil whistleblower or qui tam actions against
individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for
payment or approval that are false or fraudulent or making a false record or statement to avoid, decrease or conceal an obligation to pay
money to the federal government;
the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) among other things, imposes criminal liability for
knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or knowingly and willfully
falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment
for healthcare benefits, items or services;
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, also
imposes certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of
individually identifiable health information without proper written authorization;
the federal transparency requirements under the ACA requires manufacturers of drugs, devices, biologicals and medical supplies to annually
report to the Centers for Medicare & Medicaid Services (CMS) an agency within the U.S. Department of Health and Human Services (HHS)
information related to payments and other transfers of value provided to physicians and teaching hospitals and certain ownership and
investment interests held by physicians and their immediate family members; and
analogous state and foreign laws, such as state anti-kickback and false claims laws, that may apply to our business operations, including our
sales or marketing arrangements, and claims involving healthcare items or services reimbursed by governmental third-party payors, and in
some instances, also such claims reimbursed by non-governmental third-party payors, including private insurers.
Similar to the federal law, certain states also have adopted marketing and/or transparency laws relevant to manufacturers, some of which are broader
in scope. Other states impose restrictions on manufacturers’ marketing practices and require tracking and reporting of gifts, compensation, and other
remuneration to healthcare professionals and entities. State and foreign laws also govern the privacy and security of health information in some
circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. For
instance, EU data protection law, in particular the EU General Data Protection Regulation (the GDPR), which became fully applicable in May 2018, includes,
among other things, requirements for individuals’ consent, restrictions on the processing of health data, notice obligations, restrictions for the transfer of
personal data outside of the EU, security and confidentiality obligations, and significant fines in case of violation.
22
Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws will involve substantial costs. It is
possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law
involving applicable fraud and abuse or other healthcare laws. If our operations are found to be in violation of any of these laws or any other governmental
regulations that may apply to us, we may be subject to significant administrative, civil, and/or criminal penalties, damages, fines, disgorgement, individual
imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our
operations. If any of the physicians or other providers or entities with whom we expect to do business is found to be not in compliance with applicable laws,
they may be subject to administrative, civil, and/or criminal sanctions, including exclusions from government funded healthcare programs.
Foreign Regulation
In order to market any product outside of the United States, we would need to comply with numerous and varying regulatory requirements of other
countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales
and distribution of our products. The cost of establishing a regulatory compliance system for numerous varying jurisdictions can be very significant. Whether
or not we obtain FDA approval for a product, we would need to obtain the necessary approvals by the comparable foreign regulatory authorities before we
can commence clinical trials or marketing of the product in foreign countries and jurisdictions. Although many of the issues discussed above with respect to
the United States apply similarly in the context of the EU, the approval process varies between countries and jurisdictions and can involve additional product
testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer
than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or
delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.
The U.S. Foreign Corrupt Practices Act and Other Anti-Corruption Laws
We may be subject to a variety of domestic and foreign anti-corruption laws with respect to our regulatory compliance efforts and operations. The
U.S. Foreign Corrupt Practices Act, commonly known as the FCPA, is a criminal statute that prohibits an individual or business from paying, offering,
promising or authorizing the provision of money (such as a bribe or kickback) or anything else of value (such as an improper gift, hospitality, or favor),
directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision in order to assist the individual or
business in obtaining, retaining, or directing business or other advantages (such as favorable regulatory rulings). The FCPA also obligates companies with
securities listed in the United States to comply with certain accounting provisions. Those provisions require a company such as ours to (i) maintain books and
records that accurately and fairly reflect all transactions, expenses, and asset dispositions, and (ii) devise and maintain an adequate system of internal
accounting controls sufficient to provide reasonable assurances that transactions are properly authorized, executed and recorded. The FCPA is subject to broad
interpretation by the U.S. government. The past decade has seen a significant increase in enforcement activity. In addition to the FCPA, there are a number of
other federal and state anti-corruption laws to which we may be subject, including, the U.S. domestic bribery statute contained in 18 USC § 201 (which
prohibits bribing U.S. government officials) and the U.S. Travel Act (which in some instances addresses private-sector or commercial bribery both within and
outside the United States). Also, a number of the countries in which we conduct activities have their own domestic and international anti-corruption laws,
such as the UK Bribery Act 2010. There have been cases where companies have faced multi-jurisdictional liability under the FCPA and the anti-corruption
laws of other countries for the same illegal act.
We can be held liable under the FCPA and other anti-corruption laws for the illegal activities of our employees, representatives, contractors, partners,
agents, subsidiaries, or affiliates, even if we did not explicitly authorize such activity. Although we will seek to comply with anti-corruption laws, there can be
no assurance that all of our employees, representatives, contractors, partners, agents, subsidiaries or affiliates will comply with these laws at all times.
Noncompliance with these laws could subject us to whistleblower complaints, investigations, sanctions, settlements, prosecution, other enforcement actions,
disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions, suspension and/or debarment from contracting with
certain
23
governments or other persons, the loss of export privileges, reputational harm, adverse media coverage, and other collateral consequences. In addition, our
directors, officers, employees, and other representatives who engage in violations of the FCPA and certain other anti-corruption statutes may face
imprisonment, fines, and penalties. If any subpoenas or investigations are launched, or governmental or other sanctions are imposed, or if we do not prevail in
any possible civil or criminal litigation, our business, results of operations and financial condition could be materially harmed. In addition, responding to any
action will likely result in a materially significant diversion of management’s attention and resources and significant defense costs and other professional fees.
Enforcement actions and sanctions could further harm our business, results of operations, and financial condition.
Employees
As of December 31, 2019, we had 49 full-time employees. None of our employees is represented by a labor union or covered by collective bargaining
agreements, and we believe our relationship with our employees is good.
Corporate Information
We were incorporated in Delaware on May 6, 2008. Our principal executive offices are located at 4796 Executive Drive, San Diego, CA 92121. Our
telephone number is (619) 323-2200. Our website address is www.otonomy.com.
This Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any amendments to those reports filed or
furnished pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, (Exchange Act) are available (free of charge) on our
website as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC.
Information contained on, or that can be accessed through, our website or social media sites does not constitute part of this Annual Report on Form
10-K or any other report or document we file with the SEC, and any references to our website and social media sites are intended to be inactive textual
references only.
Otonomy, the Otonomy logo, OTIPRIO, OTIVIDEX and other trademarks or service marks of Otonomy are the property of Otonomy. Other service
marks, trademarks, and tradenames referred to in this Annual Report are the property of their respective owners. Except as set forth above and solely for
convenience, the trademarks and tradenames in this Annual Report are generally referred to without the ® and ™ symbols, but such references should not be
construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto.
ITEM 1A.
RISK FACTORS
Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as all other information
included in this Annual Report on Form 10-K, including our financial statements, the notes thereto and the section titled “Management’s Discussion and
Analysis of Financial Condition and Results of Operations.” If any of the following risks actually occurs, our business, financial condition, operating results,
prospects and ability to accomplish our strategic objectives could be materially harmed. As a result, the trading price of our common stock could decline and
you could lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also
impair our business operations and the market price of our common stock.
24
Risks Related to Our Financial Condition and Capital Requirements
We have a limited operating history and have incurred significant losses since our inception, and we anticipate that we will continue to incur losses for
the foreseeable future, which makes it difficult to assess our future viability.
We are a commercial-stage biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects. We
are not profitable and have incurred losses in each year since we commenced operations in 2008. In addition, we have limited experience and have not yet
demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving
fields, particularly in the biopharmaceutical industry. Drug development is a highly speculative undertaking and involves a substantial degree of risk. To date,
we have obtained U.S. regulatory approval and launched a single product, OTIPRIO, but have not yet generated significant revenue. We continue to incur
significant research and development expenses related to our clinical trials and product development activities and other selling, general and administrative
expenses. We have recorded net losses of $44.7 million, $50.4 million and $90.1 million for the years ended December 31, 2019, 2018 and 2017, respectively.
As of December 31, 2019, we had an accumulated deficit of $459.9 million.
We have not yet generated significant product revenue and may never become profitable.
We expect to continue to incur significant losses for the foreseeable future. Our ability to achieve significant revenue and profitability is dependent on
our ability to complete the development of our product candidates, obtain necessary regulatory approvals and successfully commercialize our products. We
may never succeed in these activities and may never generate revenue that is significant or large enough to achieve profitability. We launched OTIPRIO in
March 2016, but we have not generated significant revenue from sales of OTIPRIO, and in November 2017, we announced the discontinuation of our
promotional support for OTIPRIO in TTP surgery. In August 2018, we announced the initiation of a partnership with Mission, and in May 2019, we
announced the initiation of a partnership with Glenmark, both for the promotion of OTIPRIO to certain end users involved in the treatment of patients for
AOE. In July 2019, we were notified by Glenmark of its early discontinuation of OTIPRIO promotional support activities due to the delay in FDA approval
of its Ryaltris allergy product, and the impact of such delay on its business operations. In August 2019, Mission informed us of its non-renewal of the co-
promotion agreement. We may seek a new promotional partner for OTIPRIO, however there are no assurances that we can find a new promotional partner or
that the terms and timing of any such arrangements would be acceptable to us. Such partnerships may not generate significant revenue, may not be successful,
and may be terminated. In addition, we currently have limited sales and marketing capabilities. If we are unable to enter into arrangements on acceptable
terms or at all, or if such arrangements are not successful, we may not be able to successfully commercialize our products or generate product revenue. Any
failure or delay in entering promotional partnerships or developing our internal sales, marketing and distribution capabilities could adversely impact the
commercialization of our products. If we are not successful in commercializing our products, either on our own or through partnering with one or more third
parties, our future product revenue may suffer and we could incur significant additional losses. Even if we achieve profitability in the future, we may not be
able to sustain or increase profitability on a quarterly or annual basis. Our prior losses and expected future losses have had and will continue to have an
adverse effect on our stockholders’ equity and working capital and any failure to become and remain profitable may adversely affect the market price of our
common stock, our ability to raise capital, and our viability.
We may require additional financing to obtain regulatory approval for OTIVIDEX, OTO-313, OTO-413 and any other product candidates, and a failure
to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our commercialization
efforts, product development, or other operations.
Since our inception, most of our resources have been dedicated to the development of OTIPRIO and our product candidates, OTIVIDEX, OTO-311 (now
OTO-313) and OTO-413. In particular, conducting clinical trials for OTIVIDEX, OTO-313 and OTO-413 will require substantial funds. We have funded our
operations primarily through the sale and issuance of common stock, convertible preferred stock and convertible notes. As of December 31, 2019, we had cash,
cash equivalents and short-term investments of $60.7 million and long-term debt of $15.0 million, net of debt discounts. We believe that we will continue to
expend substantial resources for the foreseeable future for the continued development of OTIVIDEX, OTO-313, OTO-413 and any other product candidates we
may choose to
25
pursue. These expenditures will include costs associated with marketing and selling any products approved for sale, manufacturing, preparing regulatory
submissions, and conducting nonclinical studies and clinical trials. We cannot estimate with reasonable certainty the actual amounts necessary to successfully
complete the development and commercialization of our product candidates.
Our future capital requirements depend on many factors, including:
•
•
•
•
•
•
•
•
•
•
•
•
•
the revenue generated by OTIPRIO and our product candidates, if approved;
the timing of, and the costs involved in, nonclinical and clinical development and obtaining regulatory approvals for OTIVIDEX, OTO-313,
OTO-413 or any other product candidates;
the cost of manufacturing OTIPRIO and our product candidates;
the cost of commercialization activities for OTIPRIO and any of our product candidates that may be approved for sale, if any, including
marketing, sales and distribution costs;
the number and characteristics of any other product candidates we develop or acquire;
our ability to establish and maintain strategic collaborations, licensing, development or commercialization arrangements and the terms and
timing of such arrangements, including whether we are able to timely find a new promotional partner for OTIPRIO;
the degree and rate of market acceptance of OTIPRIO and any other approved products;
the emergence, approval, availability, perceived advantages, relative cost, relative safety and relative efficacy of other products or treatments;
the expenses needed to attract and retain skilled personnel;
the costs associated with being a public company;
the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims and other intellectual property rights,
including litigation costs and the outcome of such litigation;
the extent to which we are required to pay milestone or other payments under our in-license agreements and the timing of such payments; and
the cost of litigation, including any product liability or other lawsuits related to our products.
Additional capital may not be available when we need it, on terms that are acceptable to us or at all. If adequate funds are not available to us on a
timely basis, we may be required to delay, limit, reduce or terminate our sales and marketing, manufacturing or distribution capabilities or other activities that
may be necessary to commercialize our product or product candidates, nonclinical studies, clinical trials or other development activities.
If we raise additional capital through marketing and distribution arrangements or other collaborations, strategic alliances or licensing arrangements
with third parties, we may have to relinquish certain valuable rights to our product or product candidates, technologies, future revenue streams or research
programs or grant licenses on terms that may not be favorable to us. In addition, we have a sales agreement in place with Cowen and Company, LLC (Cowen)
to sell up to $40.0 million worth of shares of our common stock, from time to time, through an “at the market” equity offering program under which Cowen
will act as sales agent or principal. As of December 31, 2019, $40.0 million worth of shares of our common stock remained available for sale under the “at the
market” equity offering program. If we raise additional capital through our “at the market” equity offering program, or other public or private equity
offerings, the ownership interest of our existing stockholders will be diluted and the terms of any new equity securities may have preferential rights over our
common stock. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions,
such as incurring additional debt or making capital expenditures or specified financial ratios, any of which could restrict our ability to commercialize our
product, develop and commercialize our product candidates or operate as a business.
26
Risks Related to Our Product and Product Candidates
We are dependent upon the clinical, regulatory and commercial success of OTIVIDEX for Ménière’s disease.
We have invested substantial resources in the development of OTIVIDEX. We have completed two Phase 3 trials for OTIVIDEX in Ménière’s
disease patients. The AVERTS-2 trial, conducted in Europe, achieved its primary endpoint while the AVERTS-1 trial, conducted in the United States, did not.
Based on a Type C meeting with the FDA, we believe that one additional successful pivotal trial is sufficient to support the U.S. registration of OTIVIDEX in
Ménière’s disease, and we are currently enrolling such trial.
OTIVIDEX is subject to the risks associated with completing such pivotal trial and any future clinical trials required for registration, including risks
associated with:
•
•
•
•
•
the successful and timely implementation, enrollment and completion of such clinical trials of OTIVIDEX;
the use and adequacy of patient reported outcomes in such clinical trials;
our ability to demonstrate with substantial clinical evidence the safety and efficacy of OTIVIDEX in such clinical trials;
the successful implementation and completion of any additional clinical safety studies or any additional non-clinical studies that may be
required by the FDA; and
the ability to submit an NDA for regulatory approval to the FDA.
If we are able to successfully complete the clinical trials required for OTIVIDEX registration, its success will still remain subject to the risks
associated with obtaining regulatory approval from the FDA and being manufactured and commercialized, including risks associated with:
•
•
•
•
•
•
•
•
•
•
•
•
the successful completion of all non-clinical studies required to support regulatory approval by the FDA;
the timing of review, as the FDA’s grant of Fast Track designation for OTIVIDEX does not guarantee priority review;
the FDA’s acceptance of our NDA submission for OTIVIDEX;
the successful and timely receipt of necessary marketing approval from the FDA to allow us to begin commercializing OTIVIDEX in the
United States;
the ability to manufacture commercial supplies of OTIVIDEX in compliance with cGMP;
our success in selling OTIVIDEX and achieving broad market acceptance;
our success in educating physicians and patients about the benefits, administration and use of OTIVIDEX;
the availability, perceived advantages, relative cost, relative safety and relative efficacy of other products or treatments for Ménière’s disease;
patient demand for the treatment of Ménière’s disease;
the availability of coverage and adequate reimbursement for OTIVIDEX;
our ability to enforce our intellectual property rights in and to OTIVIDEX; and
a continued acceptable safety profile of OTIVIDEX following approval.
Many of these clinical, regulatory and commercial matters are beyond our control and are subject to other risks described elsewhere in this “Risk
Factors” section. Accordingly, we cannot assure you that we will be able to advance OTIVIDEX through final clinical development, or obtain regulatory
approval of, manufacture, commercialize or generate significant revenue from OTIVIDEX. If we cannot do so, or are significantly delayed in doing so, our
business will be materially harmed.
27
In addition to OTIVIDEX, our long-term prospects depend in part upon advancing additional product candidates, such as OTO-313 and OTO-413,
through clinical development to regulatory approval and commercialization.
Although we are focused upon continued development, regulatory approval and commercialization of OTIVIDEX, the development of OTO-313,
OTO-413 and other product candidates for the treatment of inner ear disorders is a key element of our long-term strategy. These programs are currently most
subject to the risks associated with nonclinical and clinical development, including the risks associated with:
•
•
•
•
•
•
generating sufficient data to support the initiation or continuation of clinical trials;
obtaining regulatory approval to commence clinical trials;
contracting with the necessary parties to conduct clinical trials;
enrolling sufficient numbers of subjects or patients in clinical trials;
the timely manufacture of sufficient quantities of the product candidate for use in clinical trials; and
adverse events in the clinical trials.
Even if we successfully advance OTO-313 or OTO-413 through clinical development, or advance other product candidates from our hearing loss
programs or any other future product candidate into clinical development, their success will be subject to all the clinical, regulatory and commercial risks
described elsewhere in this “Risk Factors” section. Accordingly, we cannot assure you that we will ever be able to develop, obtain regulatory approval of,
commercialize or generate significant revenue from OTO-313, OTO-413, any other product candidate from our hearing loss programs or any other future
product candidate.
Risks Related to Our Business and Strategy
OTIPRIO and our product candidates, OTIVIDEX, OTO-313, OTO-413 or any future product candidates that obtain regulatory approval, may fail to
achieve the broad degree of market acceptance and use necessary for commercial success.
OTIPRIO and our product candidates, if approved, may not achieve market acceptance among physicians and patients, and may not be commercially
successful. For OTIPRIO, treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery is currently addressed with the off-
label use of antibiotic ear drops, but antibiotic ear drops are approved for the AOE indication. We launched OTIPRIO in March 2016, but we have not
generated significant revenue from sales of OTIPRIO, and in November 2017, we announced the discontinuation of our promotional support for OTIPRIO in
TTP surgery. In August 2018, we announced the initiation of a partnership with Mission, and in May 2019, we announced the initiation of a partnership with
Glenmark, both for the promotion of OTIPRIO to certain end users involved in the treatment of patients for AOE. In July 2019, we were notified by
Glenmark of its early discontinuation of OTIPRIO promotional support activities due to the delay in FDA approval of its Ryaltris allergy product, and the
impact of such delay on its business operations. In August 2019, Mission informed us of its non-renewal of the co-promotion agreement.
28
There are currently no FDA-approved drug treatments for the indications we are pursuing for our product candidates. Our proposed initial indication
for OTIVIDEX is the treatment of vertigo associated with Ménière’s disease. Currently, Ménière’s disease patients are routinely prescribed a low-salt diet and
off-label use of diuretics. Physicians may also prescribe the off-label use of antihistamines, anticholinergics, phenothiazines and benzodiazepines as well as
corticosteroids. Our proposed indication for OTO-313 is the treatment of tinnitus. Currently, physicians may attempt to treat tinnitus symptoms with the off-
label use of steroids, anxiolytics, antidepressants, and antipsychotics. Our target indication for OTO-413 is the treatment of speech-in-noise hearing
difficulties. A subset of patients with this condition are currently treated with hearing aids. The commercial success of OTIPRIO and our product candidates,
if approved, will depend significantly on the adoption and use of the resulting product by physicians for approved indications. The decision to elect treatment
with OTIPRIO for middle ear effusion in pediatric patients requiring TTP surgery and AOE, or to elect to utilize OTIVIDEX for Ménière’s disease, OTO-313
for tinnitus or OTO-413 for speech-in-noise hearing difficulties, rather than other products or treatments, may be influenced by a number of factors,
including:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
the cost, safety and effectiveness of our products as compared to other products or treatments;
physician willingness to adopt our product in lieu of other products or treatments;
ability to gain utilization in facilities responsible for purchasing our products;
the extent to which physicians recommend our products to their patients;
patient or caregiver sentiment about the benefits and risks of our products;
proper training and administration of our products by physicians and medical staff, such that their patients do not experience excessive
discomfort during treatment or adverse side effects;
the procedural risks of IT injection;
overcoming any biases physicians or patients may have in favor of other products or treatments;
patient preference for non-injectable treatments;
patient or caregiver satisfaction with the results and administration of our product and overall treatment experience, including relative
convenience and ease of administration;
the effectiveness of our sales and marketing efforts;
demand for the treatment of the relevant diseases or disorders;
product labeling or product insert requirements of the FDA or other regulatory authorities;
the prevalence and severity of any adverse events;
the revenue and profitability that our products will offer a physician as compared to other products or treatments;
the availability of coverage and adequate reimbursement by third-party payors and government authorities and perceptions regarding such
availability; and
general patient or caregiver confidence, which may be impacted by economic and political conditions.
If our product candidates, if approved for use, fail to achieve the broad degree of market acceptance necessary for commercial success, our operating
results and financial condition will be adversely affected. In addition, even if any of our products gain acceptance, the markets for treatment of patients with
our target indications may not be as significant as we estimate.
29
Clinical drug development involves a lengthy and expensive process with an uncertain outcome, results of earlier studies and trials may not be predictive
of future trial results, and our clinical trials may fail to adequately demonstrate the safety and efficacy of our product candidates.
Clinical testing is expensive, can take many years to complete and its outcome is inherently uncertain. A failure of one or more of our clinical trials
can occur at any time during the clinical trial process. The results of nonclinical studies and early clinical trials of our product candidates may not be
predictive of the results of later-stage clinical trials. There is a high failure rate for drugs proceeding through clinical trials, and product candidates in later
stages of clinical trials may fail to show the required safety and efficacy despite having progressed through nonclinical studies and initial clinical trials. For
instance, our AVERTS-2 Phase 3 trial for OTIVIDEX in Ménière’s disease patients, conducted in Europe, achieved its primary endpoint, while our AVERTS-
1 Phase 3 trial, conducted in the United States, did not. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced
clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier clinical trials, and we cannot be certain that we
will not face similar setbacks. Even if our clinical trials are completed, the results may not be sufficient to obtain regulatory approval for our product
candidates or support the indications which we are pursuing.
We have in the past experienced delays in our clinical trials and we may in the future. We do not know whether future clinical trials, if any, will begin
on time, need to be redesigned, enroll an adequate number of patients on time or be completed on schedule, if at all. Clinical trials can be delayed, suspended
or terminated for a variety of reasons, including failure to:
•
•
•
•
•
•
•
•
•
•
•
•
•
generate sufficient nonclinical, toxicology, or other in vivo or in vitro data to support the initiation or continuation of clinical trials;
obtain regulatory approval, or feedback on trial design, to commence a clinical trial;
identify, recruit and train suitable clinical investigators;
reach agreement on acceptable terms with prospective contract research organizations (CROs), and clinical trial sites;
obtain and maintain institutional review board (IRB) approval at each clinical trial site;
identify, recruit and enroll suitable patients to participate in a clinical trial;
have a sufficient number of patients complete a clinical trial or return for post-treatment follow-up;
ensure clinical investigators observe trial protocol and comply with Good Clinical Practices (GCP) or continue to participate in a clinical
trial;
address any patient safety concerns that arise during the course of a clinical trial;
address any conflicts with new or existing laws or regulations;
add a sufficient number of clinical trial sites;
timely manufacture sufficient quantities of product candidate for use in clinical trials; or
have sufficient capital to fund a clinical trial.
Patient enrollment is a significant factor in the timing of clinical trials. We may not be able to initiate or continue clinical trials for our product
candidates on a timely basis if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials. Patient enrollment is
affected by many factors, including the size and nature of the patient population, the proximity of and access by patients to clinical sites, the eligibility criteria
for the clinical trial, the design of the clinical trial, competing clinical trials and clinicians’ and patients’ or caregivers’ perceptions as to the potential
advantages of the drug candidate being studied in relation to other available therapies, including any new drugs or treatments that may be approved for the
indications we are investigating.
We could also encounter delays if a clinical trial is suspended or terminated by us, by the data safety monitoring board for such clinical trial or by the
FDA or any other regulatory authority, or if the IRBs of the
30
institutions in which such clinical trials are being conducted suspend or terminate the participation of their clinical investigators and sites subject to their
review. Such authorities may suspend or terminate a clinical trial due to a number of factors, including failure to conduct the clinical trial in accordance with
regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in
the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in
governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.
For example, OTIVIDEX was previously subject to Full Clinical Hold that was removed in July 2013 and then subject to Partial Clinical Hold that
was removed in June 2014. The removal of Full Clinical Hold allowed us to initiate the Phase 2b clinical trial. As a result of OTIVIDEX being placed on Full
Clinical Hold, OTIPRIO was also placed on Full Clinical Hold. The OTIPRIO Full Clinical Hold was removed in November 2012. We cannot assure you that
our product candidates will not be subject to new clinical holds or significant delay in the future.
If we experience delays in the initiation or completion of any clinical trial of our product candidates for any reason, or if any clinical trial is
terminated, the commercial prospects of our product candidates may be harmed, and our ability to generate product revenues from any of these product
candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product candidate development and
approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly harm our business,
financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may
also ultimately lead to the denial of regulatory approval of our product candidates.
We may be unable to obtain regulatory approval for our product candidates other than OTIPRIO. The denial or delay of any such approval would delay
commercialization and have a material adverse effect on our potential to generate revenue, our business and our results of operations.
The research, development, testing, manufacturing, labeling, packaging, approval, promotion, advertising, storage, recordkeeping, marketing,
distribution, post-approval monitoring and reporting, and export and import of drug products are subject to extensive regulation by the FDA and by foreign
regulatory authorities in other countries. These regulations differ from country to country. To gain approval to market our product candidates, we must
provide clinical data that demonstrates with substantial evidence the safety and efficacy of the product for the intended indication. Other than OTIPRIO in the
United States, we have not yet obtained regulatory approval to market any of our other product candidates in the United States or any other country. Our
business depends upon obtaining these regulatory approvals.
The FDA can delay, limit or deny approval of our product candidates for many reasons, including:
•
•
•
•
•
•
•
•
our inability to satisfactorily demonstrate that the product candidates are safe and effective for the requested indication;
the FDA’s disagreement with our trial protocol or the interpretation of data from nonclinical studies or clinical trials;
the population studied in the clinical trial may not be sufficiently broad or representative to assess safety in the full population for which we
seek approval;
our inability to demonstrate that clinical or other benefits of our product candidates outweigh any safety or other perceived risks;
the FDA’s determination that additional nonclinical or clinical trials are required;
the FDA’s non-approval of the formulation, labeling or the specifications of our product candidates;
the FDA’s failure to accept the manufacturing processes or facilities of third-party manufacturers with which we contract, or our inability to
manufacture our product candidates pursuant to cGMP; or
the potential for approval policies or regulations of the FDA to significantly change in a manner rendering our clinical data insufficient for
approval.
31
Even if we eventually complete clinical testing and receive approval of any regulatory filing for our product candidates, the FDA may grant approval
contingent on the performance of costly additional post-approval clinical trials. The FDA may also approve our product candidates for a more limited
indication or a narrower patient population than we originally requested, and the FDA may not approve the labeling that we believe is necessary or desirable
for the successful commercialization of our product candidates. To the extent we seek regulatory approval in foreign countries, we may face challenges
similar to those described above with regulatory authorities in applicable jurisdictions. Any delay in obtaining, or inability to obtain, applicable regulatory
approval for any of our product candidates would delay or prevent commercialization of our product candidates and would materially adversely impact our
business, results of operations and prospects.
Use of our product or product candidates could be associated with undesirable side effects or adverse events that could halt their clinical development,
delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.
Our product or product candidates could be associated with side effects or adverse events which can vary in severity and frequency. Side effects or
adverse events associated with the use of our product or product candidates may be observed at any time, including in clinical trials or once a product is
commercialized, and any such side effects or adverse events may negatively affect our ability to obtain regulatory approval for our product candidates or
market our product or product candidates, if approved. Side effects such as toxicity or other safety issues associated with the use of our product or product
candidates could require us to perform additional studies or halt development or sale of our product or product candidates or expose us to product liability
lawsuits which will harm our business. We may be required by regulatory agencies to conduct additional nonclinical or clinical trials regarding the safety and
efficacy of our product or product candidates which we have not planned or anticipated. We cannot assure you that we will resolve any issues related to any
product-related adverse events to the satisfaction of the FDA or any regulatory agency in a timely manner or ever, which could harm our business, prospects
and financial condition.
Some patients in our clinical trials have reported adverse events after being treated with OTIPRIO and OTIVIDEX. If we are successful in
commercializing our product or product candidates, the FDA and other foreign regulatory agency regulations will require that we promptly report certain
information about adverse medical events if those products may have caused or contributed to those adverse events. The timing of our obligation to report
would be triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events we become
aware of within the prescribed timeframe. We may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is not
reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our product or product candidates. If we
fail to comply with our reporting obligations, the FDA or other foreign regulatory agencies could take action including criminal prosecution, the imposition of
civil monetary penalties, seizure of our products, or delay in approval or clearance of future products.
OTIPRIO and our product candidates, if approved, will face significant competition in the biopharmaceutical industry, and our failure to effectively
compete with competitor drugs, including off-label drug use, and future competitors may prevent us from achieving significant market penetration and
expansion.
The biopharmaceutical industry is intensely competitive and subject to rapid and significant technological change. If approved, our products must
compete with off-label drug use by physicians to treat the indications for which we seek approval, such as, in the case of OTIPRIO, the current use of
inexpensive generic antibiotic ear drops to treat middle ear effusion in patients requiring TTP surgery. We are also aware that other companies, such as Arbor
Pharmaceuticals, LLC, Audion Therapeutics, Auris Medical Holding AG, Autifony Therapeutics Ltd., Decibel Therapeutics, Inc., Fennec Pharmaceuticals
Inc., Frequency Therapeutics, KYORIN Pharmaceutical Co. Ltd., Laboratorios SALVAT S.A., Novartis AG, Novus Therapeutics, Inc., Otologic
Pharmaceutics Inc., Pipeline Therapeutics, Sensorion SA, Sound Pharmaceuticals Inc., Spiral Therapeutics, Strekin AG and Synphora AB, are
commercializing products or conducting clinical trials for potential products for the treatment of various otic indications, including ear infections, tinnitus,
Ménière’s disease and hearing loss. Many companies in the biopharmaceutical industry have greater resources to discover, obtain patents, develop, test and
obtain regulatory approvals for products, as well as commercialize, market and promote approved products, including communicating the effectiveness,
safety and value of products to actual and prospective customers and medical staff. These
32
companies may develop new drugs to treat the diseases and disorders we target or seek to have existing drugs approved for use for new indications that treat
the diseases and disorders we target. Mergers and acquisitions in the biopharmaceutical industry may result in even more resources being concentrated in
potential competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of
capital for investment in this industry. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, products that are more
effective, easier to administer or less costly than our product or product candidates.
We rely on third parties to conduct many of our nonclinical studies and all our clinical trials. If these third parties do not successfully carry out their
contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for, or commercialize, our product candidates.
We do not have the ability to independently conduct many of our nonclinical studies or any of our clinical trials. We rely on medical institutions,
clinical investigators, contract laboratories, and other third parties, such as CROs, to conduct clinical trials on our product candidates. Third parties play a
significant role in the conduct of our clinical trials and the subsequent collection and analysis of data. These third parties are not our employees, and except
for remedies available to us under our agreements, we have limited ability to control the amount or timing of resources that any such third party will devote to
our clinical trials. If our CROs or any other third parties upon which we rely for administration and conduct of our clinical trials do not successfully carry out
their contractual duties or obligations, comply with applicable laws, including with respect to data privacy, or meet expected deadlines, if they need to be
replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory
requirements, unauthorized system or data access, or for other reasons, or if they otherwise perform in a substandard manner, our clinical trials may be
extended, delayed, suspended or terminated, and we may not be able to complete development of, obtain regulatory approval for, or successfully
commercialize our product candidates.
We and the third parties upon whom we rely are required to comply with GCP, which are regulations and guidelines enforced by regulatory
authorities around the world for products in clinical development. Regulatory authorities enforce these GCP regulations through periodic inspections of
clinical trial sponsors, principal investigators and clinical trial sites. If we or our third parties fail to comply with applicable GCP regulations, the clinical data
generated in our clinical trials may be deemed unreliable and our submission of marketing applications may be delayed, or the regulatory authorities may
require us to perform additional clinical trials before reviewing or approving our marketing applications. We cannot assure you that, upon inspection, a
regulatory authority will determine that any of our clinical trials comply or complied with applicable GCP regulations.
In addition, our clinical trials must be conducted with drug supply produced under cGMP regulations, which are enforced by regulatory authorities.
Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our
business may be impacted if our CROs, clinical investigators or other third parties violate federal or state fraud and abuse or false claims laws and regulations
or healthcare privacy and security laws. In order for our clinical trials to be carried out effectively and efficiently, it is imperative that our CROs and other
third parties communicate and coordinate with one another. Moreover, our CROs and other third parties may also have relationships with other commercial
entities, some of which may compete with us. Our CROs and other third parties may terminate their agreements with us upon as few as 30 days’ notice under
certain circumstances. If our CROs or other third parties conducting our clinical trials do not perform their contractual duties or obligations, experience work
stoppages, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the clinical data they
obtain is compromised due to the failure to adhere to our clinical trial protocols or GCPs, or for any other reason, we may need to conduct additional clinical
trials or enter into new arrangements with alternative CROs, clinical investigators or other third parties. We may be unable to enter into arrangements with
alternative CROs, clinical investigators or other third parties on commercially reasonable terms, or at all. Switching or adding CROs, clinical investigators or
other third parties can involve substantial cost and require extensive management time and focus. In addition, there is a natural transition period when a new
CRO commences work. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines. Although
we carefully manage our relationship with our CROs, clinical investigators and other third parties, there can be no assurance that we will not encounter such
challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, prospects, financial condition or
results of operations
33
We rely completely on third parties to manufacture our nonclinical, clinical drug supplies and commercial supplies of OTIPRIO and any other approved
products.
We outsource the manufacture of OTIPRIO and our product candidates. We do not currently have the infrastructure or internal capability to
manufacture supplies of OTIPRIO or our product candidates for use in development and commercialization. If we were to experience an unexpected loss of
supply of OTIPRIO or our product candidates for any reason, whether as a result of manufacturing, supply or storage issues or otherwise, our business would
be harmed, and we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical
trials. Although we generally do not begin a clinical trial unless we believe we have a sufficient supply of a product candidate to complete the clinical trial,
we may be required to manufacture additional supplies of our product candidates to the extent our estimates of the amounts required prove inaccurate, we
suffer unexpected losses of product candidate supplies, or to the extent that we are required to have fresh product candidate supplies manufactured to satisfy
regulatory requirements or specifications. Any significant delay or discontinuation in the supply of OTIPRIO or a product candidate, or the raw material
components thereof, due to the need to replace a contract manufacturer or other third-party manufacturer, could considerably harm our business and ability to
generate revenue and delay completion of our clinical trials, product testing and potential regulatory approval of our product candidates.
Reliance on third-party manufacturers entails additional risks, including reliance on the third party for regulatory compliance and quality assurance,
the possible breach of the manufacturing agreement by the third party, and the possible termination or nonrenewal of the agreement by the third party at a
time that is costly or inconvenient for us. The facilities used by our third-party manufacturers must be accepted by the FDA pursuant to inspections that will
be conducted before approval and after we submit our NDA to the FDA. We do not control the implementation of the manufacturing process of, and are
completely dependent on, our third-party manufacturers for compliance with the regulatory requirements, for manufacture of both active drug substances and
finished drug products. If our third-party manufacturers cannot successfully manufacture material that conforms to applicable specifications in our regulatory
applications and the strict regulatory requirements of the FDA or foreign regulatory authorities, we will not be able to secure and/or maintain regulatory
acceptance of our contract manufacturing facilities. In addition, we have no control over the ability of our contract manufacturers or other third-party
manufacturers to maintain adequate quality control, quality assurance and qualified personnel. The failure of our third-party manufacturers to comply with
applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of
approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely
affect supplies of OTIPRIO or our product candidates or any other product candidates or products that we may develop. In addition, if the FDA does not
accept these facilities for the manufacture of our product or our product candidates or if it withdraws any such acceptance in the future, we will need to find
alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates,
if approved. Any failure or refusal to supply the components for our product or our product candidates could delay, prevent or impair our clinical
development or commercialization efforts. If our contract manufacturers were to breach or terminate their manufacturing arrangements with us, the
development or commercialization of the affected product or product candidates could be delayed, which could have an adverse effect on our business. Any
change in our manufacturers could be costly because the commercial terms of any new arrangement could be less favorable and because the expenses relating
to the transfer of necessary technology and processes could be significant.
We may encounter issues with manufacturing as we commercialize OTIPRIO or our product candidates, if approved.
We have limited experience manufacturing OTIPRIO for commercial use, and our product candidates have never been manufactured for commercial
use. There are risks associated with manufacturing for commercial use including, among others, potential problems with forecasting and cost overruns,
process reproducibility, storage availability, stability issues, lot consistency and timely availability of materials. We cannot assure you that our contract
manufacturers will be able to manufacture any approved product to specifications acceptable to the FDA or foreign regulatory authorities, or to produce it in
sufficient quantities to meet the market demand. We have in the past manufactured, and may in the future manufacture, batches of OTIPRIO that do not meet
the appropriate specifications and cannot be used. We may also manufacture OTIPRIO or any approved product that remains unused due to obsolescence,
expiry or quantities in excess of expected demand. If our contract manufacturers are unable to successfully produce sufficient quantities of any approved
product for commercialization, our commercial efforts would be impaired, which would have an adverse effect on our business, financial condition, results of
operations and growth prospects.
34
We depend on a small number of suppliers for the raw materials necessary to produce OTIPRIO and our product candidates. The loss of these suppliers,
or their failure to supply us with these raw materials, would materially and adversely affect our business.
We depend on the availability of key raw materials, including poloxamer for OTIPRIO and our product candidates, ciprofloxacin for OTIPRIO,
dexamethasone for OTIVIDEX, gacyclidine for OTO-313 and BDNF for OTO-413, from a small number of third-party suppliers. Because there are a limited
number of suppliers for the raw materials that we use to manufacture our product and product candidates, we may need to engage alternate suppliers to
prevent a possible disruption of the manufacture of the materials necessary to produce OTIPRIO for required commercial supplies or our product candidates
for our clinical trials. We do not have any control over the availability of raw materials. If we or our manufacturers are unable to purchase these raw materials
on acceptable terms, at sufficient quality levels, or in adequate quantities, if at all, commercial sales of OTIPRIO and the development of OTIVIDEX, OTO-
313, OTO-413 or any future product candidates, would be delayed or there would be a shortage in supply, which would impair our ability to meet our
development objectives for our product candidates or generate revenues from the sale of any approved products.
Our ability to market OTIPRIO is limited to its approved indications, and our product candidates, if approved, will be limited to certain indications. If we
want to expand the indications for which we may market our products, we will need to obtain additional regulatory approvals, which may not be granted.
OTIPRIO is currently approved for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery and for the
treatment of AOE and is in development for AOMT. We are developing OTIVIDEX for the treatment of vertigo associated with Ménière’s disease, OTO-313
for the treatment of tinnitus and OTO-413 for the treatment of speech-in-noise hearing difficulties. The FDA and other applicable regulatory agencies will
restrict our ability to market and advertise our products to the scope of the approved label for the applicable product and for no other indications, which could
limit physician and patient adoption. We may attempt to develop new treatment indications for our product or product candidates in the future, but we cannot
predict when or if we will receive the regulatory approvals required to promote our product or product candidates for new treatment indications. Failure to
receive such approvals prevents us from promoting and commercializing the new treatment indications. In addition, we would be required to conduct
additional clinical trials or studies to support approvals for additional indications, which would be time consuming and expensive, and may produce results
that do not support regulatory approvals. If we do not obtain additional regulatory approvals, our ability to expand our business will be limited.
If our product candidates are approved for marketing, and we are found to have improperly promoted off-label uses, or if physicians misuse our products,
we may become subject to prohibitions on the sale or marketing of our products, significant sanctions and product liability claims, and our image and
reputation within the industry and marketplace could be harmed.
The FDA and other regulatory agencies strictly regulate the marketing and promotional claims that are made about drug products. In particular, a
product may not be promoted for uses or indications that are not approved by the FDA or such other regulatory agencies as reflected in the product’s
approved labeling. For example, OTIPRIO is approved for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery
and for the treatment of AOE, and we cannot promote the use of our product in a manner that is inconsistent with the approved label. Although physicians are
able to, in their independent medical judgment, use OTIPRIO on their patients in an off-label manner, such as for the treatment of other otic indications, if we
are found to have promoted such off-label uses, we may receive warning letters and become subject to significant liability, which would materially harm our
business. The federal government has levied large administrative, civil and criminal fines against companies for alleged improper promotion and has enjoined
several companies from engaging in off-label promotion. If we become the target of such an investigation or prosecution based on our marketing and
promotional practices, we could face similar sanctions, which would materially harm our business. In addition, management’s attention could be diverted
from our business operations, significant legal expenses could be incurred, and our reputation could be damaged. The federal government and regulatory
authorities have also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or
curtailed. If we are deemed by the federal government or regulatory authorities to have engaged in the promotion of our products for off-label use, we could
be subject to prohibitions on the sale or marketing of our products or significant fines and penalties, and the imposition of these sanctions could also affect our
reputation with physicians, patients and caregivers, and our position within the industry.
35
Physicians may also misuse our products or use improper techniques, potentially leading to adverse results, side effects or injury, which may lead to
product liability claims and costly litigation. Product liability claims could divert management’s attention from our core business, be expensive to defend, and
result in sizable damage awards against us that may not be covered by insurance. We currently carry product liability insurance with policy limits that we
believe are customary for similarly situated companies and adequate to provide us with coverage for foreseeable risks. Although we maintain such insurance,
any claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance
or that is in excess of the limits of our insurance coverage. Furthermore, the use of our products for conditions other than those approved by the FDA may not
effectively treat such conditions, which could harm our reputation in the marketplace among physicians and patients.
We have limited sales and marketing experience and may be unable to successfully commercialize our products or generate product revenue.
We have limited experience in the marketing and sale of pharmaceutical products, and there are significant risks involved in managing a sales and
marketing organization, including our ability to hire, retain, adequately compensate and incentivize qualified individuals, generate sufficient sales leads,
provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. For example, we
discontinued promotional support for OTIPRIO and, as a result, no longer have a sales force. If we decide not to promote our product candidates ourselves, if
approved, we may consider promotional partnership arrangements. For instance, in August 2018, we announced the initiation of a partnership with Mission,
and in May 2019, we announced the initiation of a partnership with Glenmark, both for the promotion of OTIPRIO to certain end users involved in the
treatment of patients for AOE. In July 2019, we were notified by Glenmark of its early discontinuation of OTIPRIO promotional support activities due to the
delay in FDA approval of its Ryaltris allergy product, and the impact of such delay on its business operations. In August 2019, Mission informed us of its
non-renewal of the co-promotion agreement. We have not generated significant revenue from sales of OTIPRIO to date. We may seek a new promotional
partner for OTIPRIO, however there are no assurances that we can find a new promotional partner or that the terms and timing of any such arrangements
would be acceptable to us. Such partnerships may not generate significant revenue, may not be successful, and may be terminated. If we are unable to enter
into such arrangements on acceptable terms or at all, or if such arrangements are not successful, we may not be able to successfully commercialize our
products or generate product revenue. Any failure or delay in entering promotional partnerships or developing our internal sales, marketing and distribution
capabilities would adversely impact the commercialization of our products. If we are not successful in commercializing our products, either on our own or
through partnering with one or more third parties, our future product revenue will suffer and we would incur significant additional losses.
To expand our development and commercial support capabilities in the future, we may need to increase the size of our organization, and we may
experience difficulties in managing this growth.
As we advance our product candidates through the development process and commercialize our product and product candidates, if approved, we may
need to expand our development, regulatory, quality, managerial, sales and marketing, operational, finance and other resources to manage our operations and
clinical trials, continue our development activities and commercialize our product candidates, if approved. If our operations expand, we expect that we will
need to manage additional relationships with various manufacturers and collaborative partners, suppliers and other organizations.
Due to our limited financial resources and our limited experience in managing a company with such growth, we may not be able to effectively
manage the expansion of our operations or recruit, train and retain additional qualified personnel. For example, in December 2016, we moved into our current
headquarters location in San Diego, California. The physical expansion of our operations has led, and may continue to lead, to significant costs. Any inability
to manage growth could delay the execution of our development and strategic objectives, or disrupt our operations, which could materially impact our
business, revenue and operating results.
36
Coverage and reimbursement decisions by third-party payors may have an adverse effect on pricing and market acceptance. Recent legislative and
regulatory activity may exert downward pressure on potential pricing and reimbursement for our products, if approved, that could materially affect the
opportunity to commercialize.
There is significant uncertainty related to the third-party coverage and reimbursement of newly approved drugs. Patients who are provided medical
treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Therefore, market
acceptance and sales of our products, if approved, in both domestic and international markets will depend significantly on the availability of adequate
coverage and reimbursement from third-party or government payors for any of our products and may be affected by existing and future healthcare reform
measures. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs they will
cover and establish payment levels. CMS has established a unique J Code for OTIPRIO that replaces a previously assigned C Code. We also intend to apply
for a unique J Code for OTIVIDEX, OTO-313 and OTO-413. We cannot assure you that J Codes will be issued for OTIVIDEX, OTO-313 and OTO-413, if
approved. We also cannot assure you that third-party payors will provide reimbursement according to a J Code. If a J Code is not issued or a J Code is issued
but not reimbursed by third-party payors, then the cost of these drugs may be absorbed by healthcare providers or charged to patients. If this is the case, our
expectations of the pricing we expect to achieve for OTIPRIO, and OTIVIDEX, OTO-313 and OTO-413, if approved, and the related potential revenue, may
be significantly diminished. We cannot be certain that coverage and adequate reimbursement will be available for OTIPRIO or any other products, if
approved, or that such coverage and reimbursement will be authorized in a timely fashion, even if a unique J Code is assigned for such products. Also, we
cannot be certain that reimbursement policies will not reduce the demand for, or the price paid for, OTIPRIO or any of our product candidates, if approved. If
reimbursement is not available or is available on a limited basis for any of our products, if approved, we may not be able to successfully commercialize any
such products. Reimbursement by a third-party or government payor may depend upon a number of factors, including, without limitation, the third-party or
government payor’s determination that use of a product is:
•
•
•
•
•
a covered benefit under its health plan;
safe, effective and medically necessary;
appropriate for the specific patient;
cost-effective; and
neither experimental nor investigational.
Obtaining coverage and reimbursement approval for a product from a government or other third-party payor is a time consuming and costly process
that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our products to the payor. We may not be able to
provide data sufficient to gain acceptance with respect to coverage and reimbursement or to have pricing set at a satisfactory level. If reimbursement of our
products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels such as may result where alternative or generic treatments are
available, we may be unable to achieve or sustain profitability.
Assuming we obtain coverage for a given product, the resulting reimbursement payment rates might not be adequate or may require co-payments that
patients find unacceptably high. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant
portion of the cost of our products.
In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and
reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly
process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and
adequate reimbursement will be obtained. In some foreign countries, particularly in Europe, the pricing of prescription pharmaceuticals is subject to
governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval
for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct additional clinical trials that compare the cost-
effectiveness of our products to other available therapies. If reimbursement of any of our products, if approved, is unavailable or limited in scope or amount in
a particular country, or if pricing is set at unsatisfactory levels, we may be unable to achieve or sustain profitability of our products in such country.
37
The United States and several other jurisdictions are considering, or have already enacted, a number of legislative and regulatory proposals to change
the healthcare system in ways that could affect our ability to sell any of our products profitably, if approved. Among policy-makers and payors in the United
States and elsewhere, there has been significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs,
improving quality and/or expanding access to healthcare. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has
been significantly affected by major legislative initiatives. There have been, and likely will continue to be, legislative and regulatory proposals at the federal
and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict if or how these or
future initiatives may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors
of healthcare services to contain or reduce costs of healthcare may adversely affect:
•
•
•
•
•
the demand for any of our products, if approved;
the ability to set a price that we believe is fair for any of our products, if approved;
our ability to generate revenues and achieve or maintain profitability;
the level of taxes that we are required to pay; and
the availability of capital.
In March 2010, the Affordable Care Act (ACA) became law in the United States. One goal of ACA is to reduce the cost of healthcare and
substantially change the way healthcare is financed by both governmental and private insurers. While we cannot fully predict what impact on federal
reimbursement policies this legislation will have in general or on our business specifically, ACA may result in downward pressure on pharmaceutical
reimbursement, which could negatively affect our ability to generate revenue, achieve market acceptance of our product or future approved products, attain
profitability, or commercialize our product or any future approved products. Provisions of ACA relevant to the pharmaceutical industry include the following:
•
•
•
•
•
•
•
an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned
among these entities according to their market share in certain government healthcare programs, not including orphan drug sales;
an increase in the rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of the average manufacturer
price for most branded and generic drugs, respectively;
a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts on
negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer’s
outpatient drugs to be covered under Medicare Part D;
extension of manufacturers’ Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care
organizations;
expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional
individuals and by adding new mandatory eligibility categories for certain individuals with income at or below 133% of the Federal Poverty
Level, thereby potentially increasing manufacturers’ Medicaid rebate liability;
expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;
new requirements to report annually certain financial arrangements with physicians and teaching hospitals, as defined in ACA and its
implementing regulations, including reporting any payment or “transfer of value” provided to physicians and teaching hospitals and any
ownership and investment interests held by physicians and their immediate family members during the preceding calendar year;
38
•
•
expansion of healthcare fraud and abuse laws, including the federal False Claims Act and the federal Anti-Kickback Statute, new government
investigative powers and enhanced penalties for noncompliance; and
a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research,
along with funding for such research.
Recent changes in the U.S. government could lead to repeal of or changes in some or all the ACA and complying with any new legislation or
reversing changes implemented under the ACA could be time-intensive and expensive, resulting in a material adverse effect on our business. Healthcare
reform measures that may be adopted in the future may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage
criteria, new payment methodologies and additional downward pressure on the price that we receive for our product or future approved products. Any such
reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The
implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, achieve market acceptance of
our product or future approved products, attain profitability, or commercialize future approved products. Until the ACA or other healthcare reform measures
are fully implemented or there is more certainty concerning the future of the ACA or such healthcare reform measures, it will be difficult to predict its full
impact and influence on our business.
If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products.
We face an inherent risk of product liability as a result of the clinical testing of our product candidates and face an even greater risk now that
OTIPRIO has been commercialized and as other product candidates get approved, if at all. For example, we may be sued if any product we develop allegedly
causes or is perceived to cause injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product
liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict
liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against
product liability claims, we may incur substantial liabilities or be required to limit commercialization of our products. Even a successful defense would
require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:
•
•
•
•
•
•
•
•
•
•
decreased demand for our products;
injury to our reputation and significant negative media attention;
withdrawal of clinical trial participants or cancellation of clinical trials;
costs to defend the related litigation;
a diversion of management’s time and our resources;
substantial monetary awards to clinical trial participants or patients;
regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions;
exhaustion of any available insurance and our capital resources;
loss of revenue; and
the inability to commercialize any products we develop.
Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost and scope of coverage to protect against potential
product liability claims could prevent or inhibit the commercialization of our products. We currently carry product liability insurance with policy limits that
we believe are customary for similarly situated companies and adequate to provide us with coverage for foreseeable risks. Although we maintain such
insurance, any claim that may be brought against us could result in a court judgment or settlement in an amount
39
that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. If we determine that it is prudent to
increase our product liability coverage in the future, we may be unable to obtain such increased coverage on acceptable terms, or at all. Our insurance policies
also have various exclusions and deductibles, and we may be subject to a product liability claim for which we have no coverage. We will have to pay any
amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have,
or be able to obtain, sufficient capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or
in sufficient amounts to protect us against losses.
If we fail to attract and retain senior management and key scientific personnel, we may be unable to successfully develop and commercialize our product
candidates.
Our success depends, in part, on our continued ability to attract, retain and motivate highly qualified management, commercial, clinical and scientific
personnel. We believe that our future success is highly dependent upon the contributions of our senior management, particularly our President and Chief
Executive Officer, as well as our senior scientists and other members of our senior management team. The loss of services of any of these individuals, who all
have at-will employment arrangements with us, could delay or prevent the successful development of our product pipeline, completion of our planned clinical
trials or the commercialization of our product candidates, if approved.
We could experience difficulties in attracting, hiring and retaining qualified employees. For example, competition for qualified personnel in the
biotechnology and pharmaceuticals field is intense due to the limited number of individuals who possess the skills and experience required by our industry.
We will need to hire additional personnel as we expand our clinical development and commercial activities. We may not be able to attract and retain quality
personnel on acceptable terms, or at all, which may cause our business and operating results to suffer.
If we are not successful in discovering, developing, acquiring and commercializing additional product candidates, our ability to expand our business and
achieve our strategic objectives would be impaired.
Although a substantial amount of our efforts are focused on the development and regulatory approval of our current product candidates, a key
element of our strategy is to identify, develop and commercialize additional product candidates for the treatment of inner ear disorders. We are seeking to do
so through our internal research programs and may explore strategic collaborations with third parties for the development or acquisition of new product
candidates or products. Research programs to identify new product candidates require substantial technical, financial and human resources, whether or not
any product candidates are ultimately identified or successfully developed.
Our internal computer systems, or those of our CROs or other contractors or consultants, or our partners, may fail or suffer security breaches, which
could result in a material disruption of our drug development programs.
We rely on information technology systems to keep financial records, maintain laboratory and corporate records, communicate with staff and external
parties and operate other critical functions. Despite the implementation of security measures, our internal computer systems and those of our third-party
logistics vendor, CROs and other contractors and consultants, and our partners, are vulnerable to damage from computer viruses, unauthorized access, natural
disasters, terrorism, war and telecommunication and electrical failures. To our knowledge, we have not experienced a material system failure, accident or
security breach to date, and if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our
commercialization activities or drug development programs. For example, the loss of clinical trial data from completed or future clinical trials could result in
delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security
breach (whether to our systems or to our CROs or other contractors, consultants, or partners) were to result in a loss of, or damage to, our data or applications,
or inappropriate disclosure of confidential, proprietary, or other protected information, we could incur liability and the development and commercialization of
our product candidates could be delayed.
40
Changes in financial accounting standards or practices may cause adverse, unexpected financial reporting fluctuations and affect our reported operating
results.
Generally accepted accounting principles in the United States are subject to interpretation by the Financial Accounting Standards Board, the SEC and
various bodies formed to promulgate and interpret appropriate accounting principles. A change in accounting standards or practices can have a significant
effect on our reported results and may even affect our reporting of transactions completed before the change is effective. New accounting pronouncements
and varying interpretations of accounting pronouncements have occurred and may occur in the future. Changes to existing rules or the questioning of current
practices may adversely affect our reported financial results or the way we conduct our business.
Our employees, independent contractors, clinical investigators, CROs, consultants and vendors may engage in misconduct or other improper activities,
including noncompliance with regulatory standards and requirements and insider trading.
We are exposed to the risk that our employees, independent contractors, clinical investigators, CROs, consultants and vendors may engage in
fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct or disclosure of
unauthorized activities to us that violates: (i) FDA regulations, including those laws requiring the reporting of true, complete and accurate information to the
FDA, (ii) manufacturing standards, (iii) federal, state and foreign healthcare fraud and abuse laws, (iv) privacy protection laws or (v) laws that require the
reporting of financial information or data accurately. Specifically, research, sales, marketing, education and other business arrangements in the healthcare
industry are subject to extensive laws intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws may restrict or
prohibit a wide range of pricing, discounting, education, marketing and promotion, sales commission, customer incentive programs and other business
arrangements. Activities subject to these laws also involve the improper use of information obtained in the course of clinical trials, which could result in
regulatory sanctions and serious harm to our reputation. We have adopted a code of business conduct and ethics, as well as various compliance policies and
procedures, but it is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and
prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other
actions or lawsuits stemming from a failure to be in compliance with such laws. If any such actions are instituted against us, even if we are successful in
defending ourselves or asserting our rights, those actions could have a significant impact on our business. Violations of such laws subject us to numerous
penalties, including, but not limited to, the imposition of civil, criminal and administrative penalties, damages, monetary fines, disgorgement, individual
imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm,
diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our
results of operations.
We or the third parties upon whom we depend may be adversely affected by earthquakes, wildfires or other natural disasters, and our business continuity
and disaster recovery plans may not adequately protect us from a serious disaster.
Our corporate headquarters are located in San Diego, which in the past has experienced severe earthquakes. We do not carry earthquake insurance.
The San Diego area has also experienced serious wildfires. If a natural disaster or other event occurred that prevented us from using all or a significant portion
of our headquarters, that damaged critical infrastructure, such as product development and research efforts for our current product candidates and finance
records, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of
time. The disaster recovery and business continuity plans we have in place currently are limited and may not be adequate in the event of a serious disaster or
similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which, particularly
when taken together with our lack of earthquake insurance, could have a material adverse effect on our business.
41
Furthermore, integral parties in our supply chain and distribution chain are geographically concentrated and operating from single sites, increasing
their vulnerability to natural disasters or other sudden, unforeseen and severe adverse events. If such an event were to affect our supply chain, it could have a
material adverse effect on our business.
Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations.
Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. A severe or
prolonged economic downturn may cause extreme volatility and disruptions in the capital and credit markets and could result in a variety of risks to our
business and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers,
possibly resulting in supply disruption, or cause our customers and third-party payors to delay making payments for our services.
Recent events, including the UK’s 2016 vote in favor of exiting the EU, or “Brexit,” and the UK’s withdrawal, and similar geopolitical developments
or the perception that any of them could occur, may lead to worldwide economic and legal uncertainty, including significant volatility in global stock markets
and currency exchange rates, and increasingly divergent laws and regulations.
Any of the foregoing could harm our business, and we cannot anticipate all the ways in which the current economic climate and financial market
conditions could adversely impact our business.
Our business is subject to economic, political, regulatory, operational and other risks associated with international operations.
Our business is subject to risks associated with conducting business internationally. Some of our suppliers and collaborative relationships are located
outside the United States, and we conduct some of our clinical trials outside the United States. Accordingly, our ability to operate our business and our future
results could be harmed by a variety of factors, including:
•
•
•
•
•
•
•
•
•
•
•
•
•
economic weakness, including inflation, or political instability in non-U.S. economies and markets;
differing and changing regulatory requirements in non-U.S. countries;
challenges enforcing our contractual and intellectual property rights, especially in non-U.S. countries that may not respect and protect
intellectual property rights to the same extent as the United States;
difficulties in compliance with non-U.S. laws and regulations;
changes in non-U.S. regulations and customs, tariffs and trade barriers;
changes in currency exchange rates and non-U.S. currency controls;
changes in a country’s or region’s political or economic environment;
trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or non-U.S. governments;
negative consequences from changes in tax laws;
compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
workforce uncertainty and labor unrest;
difficulties associated with staffing and managing international operations;
potential liability under the FCPA, UK Bribery Act or comparable non-U.S. laws; and
42
•
business interruptions resulting from (i) geopolitical actions, including annexation, war and terrorism, (ii) natural disasters, including
earthquakes, typhoons, floods and fires or (iii) outbreaks of health epidemics and pandemics.
Risks Related to Our Intellectual Property
If our efforts to protect the intellectual property related to our product and product candidates are not adequate, we may not be able to compete effectively
in our market.
We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our
product, product candidates and technology. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable
competitors to quickly duplicate or surpass our technological achievements, eroding our competitive position in the market.
The patent application process, also known as patent prosecution, is expensive and time-consuming, and we and our current or future licensors and
licensees may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also
possible that we or our current licensors, or any future licensors or licensees, will fail to identify patentable aspects of inventions made in the course of
development and commercialization activities before it is too late to obtain patent protection on them. Therefore, it is possible that certain patentable aspects
of our inventions may not be protected in a manner consistent with the best interests of our business. Defects of form in the preparation or filing of our patents
or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, etc., although we are unaware of
any such defects that we believe are of material import. If there are material defects in the form or preparation of our patents or patent applications, such
patents or applications may be invalid and unenforceable. If we or our current licensors, or any future licensors or licensees, fail to file patent applications, or
maintain, enforce or protect our patents, such patent rights may be reduced or eliminated. If our current licensors, or any future licensors or licensees, are not
fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. Any of
these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.
The strength of patents in the pharmaceutical field involves complex legal and scientific questions and can be uncertain. This uncertainty includes
changes to the patent laws through either legislative action to change statutory patent law or court action that may reinterpret existing law or rules in ways
affecting the scope or validity of issued patents. The patent applications that we own or in-license may fail to result in issued patents in the United States or
foreign countries with claims that cover our product or product candidates. Even if patents do successfully issue from the patent applications that we own or
in-license, third parties may challenge the validity, enforceability or scope of such patents, which may result in such patents being narrowed, invalidated or
held unenforceable. For example, patents granted by the European Patent Office may be challenged, also known as opposed, by any person within nine
months from the publication of their grant. Any successful challenge to our patents could deprive us of exclusive rights necessary for the successful
commercialization of our product or product candidates. Furthermore, even if they are unchallenged, our patents may not adequately protect our product or
product candidates, provide exclusivity for our product or product candidates, or prevent others from designing around our patents. If the breadth or strength
of protection provided by the patents we hold or pursue with respect to our product or product candidates is challenged, it could dissuade companies from
collaborating with us to develop, or threaten our ability to commercialize our product or product candidates.
Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after its effective filing date. Various
extensions may be available; however, the life of a patent, and the protection it affords, is limited. Without patent protection for our product or product
candidates, we may be open to competition from generic versions of our product or product candidates. Further, if we encounter delays in our development
efforts, including our clinical trials, the period of time during which we could market our product or product candidates under patent protection would be
reduced.
Most of our patents and patent applications are entitled to effective filing dates prior to March 16, 2013. For U.S. patent applications for which patent
claims are entitled to a priority date before March 16, 2013, an interference proceeding can be provoked by a third party, for example a competitor, or
instituted by the U.S. Patent and
43
Trademark Office (USPTO) to determine who was the first to invent any of the subject matter covered by those patent claims. An unfavorable outcome could
require us either to cease using the related technology or to attempt to license rights from the prevailing party. Our business could be harmed if the prevailing
party does not offer us a license on commercially reasonable terms. Our participation in an interference proceeding may fail and, even if successful, may
result in substantial costs and distract our management.
In addition to the protection afforded by patents, we also rely on trade secret protection to protect proprietary know-how that may not be patentable or
that we elect not to patent, processes for which patents may be difficult to obtain or enforce, and any other elements of our product and product candidates,
and our product development processes (such as manufacturing and formulation technologies) that involve proprietary know-how, information or technology
that is not covered by patents. However, trade secrets can be difficult to protect. If the steps taken to maintain our trade secrets are deemed inadequate, we
may have insufficient recourse against third parties for misappropriating any trade secrets. Misappropriation or unauthorized disclosure of our trade secrets
could significantly affect our competitive position and may have a material adverse effect on our business. Furthermore, trade secret protection does not
prevent competitors from independently developing substantially equivalent information and techniques, and we cannot guarantee that our competitors will
not independently develop substantially equivalent information and techniques. The FDA, as part of its Transparency Initiative, is currently considering
whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other
proprietary information, and it is not clear at the present time how the FDA’s disclosure policies may change in the future, if at all.
In an effort to protect our trade secrets and other confidential information, we require our employees, consultants, advisors, and any other third parties
that have access to our proprietary know-how, information or technology, for example, third parties involved in the formulation and manufacture of our
product and product candidates, and third parties involved in our clinical trials, to execute confidentiality agreements upon the commencement of their
relationships with us. These agreements require that all confidential information developed by such employees, consultants, advisors, etc., or made known to
them by us during the course of our relationship with them be kept confidential and not disclosed to third parties. However, we cannot be certain that our
trade secrets and other confidential proprietary information will not be disclosed despite having such confidentiality agreements. Adequate remedies may not
exist in the event of unauthorized use or disclosure of our trade secrets. In addition, in some situations, these confidentiality agreements may conflict with, or
be subject to, the rights of third parties with whom our employees, consultants, or advisors have previous employment or consulting relationships. To the
extent that our employees, consultants or advisors use any intellectual property owned by third parties in their work for us, disputes may arise as to the rights
in any related or resulting know-how and inventions. If we are unable to prevent unauthorized material disclosure of our trade secrets to third parties, we may
not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results and
financial condition.
Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.
As is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly on obtaining and enforcing
patents. Obtaining and enforcing patents in the pharmaceutical industry involves both technological and legal complexity, and therefore is costly, time-
consuming and inherently uncertain. In addition, the United States has recently enacted and is currently implementing wide-ranging patent reform legislation.
Further, recent U.S. Supreme Court rulings have either narrowed the scope of patent protection available in certain circumstances or weakened the rights of
patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events
has created uncertainty with respect to the value of patents, once obtained.
For our U.S. patent and patent applications containing a claim not entitled to priority before March 16, 2013, there is a greater level of uncertainty in
the patent law. In September 2011, the Leahy-Smith America Invents Act, or the American Invents Act (AIA), was signed into law. The AIA includes a
number of significant changes to U.S. patent law, including provisions that affect the way patent applications will be prosecuted and may also affect patent
litigation. It is not clear what other, if any, impact the AIA will have on the operation of our business. Moreover, the AIA and its implementation could
increase the uncertainties and costs surrounding the prosecution of our patent
44
applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.
An important change introduced by the AIA is that, as of March 16, 2013, the United States transitioned to a “first-to-file” system for deciding which
party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a
patent application in the USPTO after March 16, 2013 but before us could therefore be awarded a patent covering an invention of ours even if we had made
the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent
application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the
prior art allow our technology to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a
period of time after filing, we cannot be certain that we were the first to either (i) file any patent application related to our product or product candidates or
(ii) invent any of the inventions claimed in our patents or patent applications.
Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and provided
opportunities for third parties to challenge any issued patent in the USPTO. This applies to all our U.S. patents, even those issued before March 16, 2013.
Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal court necessary to invalidate a
patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same
evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO
procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party in a district court action.
Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in
unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and any patents that we might obtain in the future.
Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements
imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.
The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other
similar provisions during the patent prosecution process. Periodic maintenance fees and various other governmental fees on any issued patent and/or pending
patent applications are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of a patent or patent application. We have
systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees. While an inadvertent lapse
may sometimes be cured by payment of a late fee or by other means in accordance with the applicable rules, there are many situations in which
noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant
jurisdiction. If we fail to maintain the patents and patent applications directed to our product or product candidates, our competitors might be able to enter the
market earlier than should otherwise have been the case, which would have a material adverse effect on our business.
45
We may not be able to protect our intellectual property rights throughout the world.
Filing and prosecuting patent applications and defending patents on our product and product candidates in all countries throughout the world would
be prohibitively expensive. The requirements for patentability may differ in certain countries, particularly developing countries. For example, China has a
heightened requirement for patentability, and specifically requires a detailed description of medical uses of a claimed drug. In addition, the laws of some
foreign countries do not protect intellectual property rights to the same extent as laws in the United States. Consequently, we may not be able to prevent third
parties from practicing our inventions in all countries outside the United States. Competitors may use our technologies in jurisdictions where we have not
obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection,
but enforcement on infringing activities is inadequate. These products may compete with our products, and our patents or other intellectual property rights
may not be effective or sufficient to prevent them from competing.
Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal
systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection,
particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products
in violation of our proprietary rights generally in those countries. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial
costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our
patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and
the damages or other remedies awarded, if any, may not be commercially meaningful. In addition, certain countries in Europe and certain other countries,
including India and China, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries,
we may have limited remedies if our patents are infringed or if we are compelled to grant a license to our patents to a third party, which could materially
diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our intellectual property rights
around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license. Finally, our ability to
protect and enforce our intellectual property rights may be adversely affected by unforeseen changes in foreign intellectual property laws.
Third-party claims alleging intellectual property infringement may adversely affect our business.
Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties, for example, patents and
proprietary rights of competitors. Our research, development and commercialization activities, including the commercialization of OTIPRIO, may be subject
to claims that we infringe or otherwise violate patents owned or controlled by third parties, including our competitors. There are also patent applications,
owned by third parties including competitors, that have been filed but not issued that, if issued as patents, may be asserted against us. Numerous U.S. and
foreign issued patents and pending patent applications, exist in the otic field in which we are developing our product candidates. As the biotechnology and
pharmaceutical industries expand and more patents are issued, the risk increases that our activities related to our product or product candidates may give rise
to claims of infringement of the patent rights of third parties. We cannot assure you that our product or product candidates will not infringe existing or future
patents owned by third parties. We may not be aware of patents that have already issued and that a third party, for example a competitor in the otic market,
might assert are infringed by our product or product candidates. It is also possible that patents owned by third parties of which we are aware, but which we do
not believe are relevant to our product or product candidates, could be found to be infringed by our product or product candidates.
Third parties making claims against us for infringement or misappropriation of their intellectual property rights may seek and obtain injunctive or
other equitable relief, which could effectively block our ability to further develop our product candidates and commercialize our product and product
candidates, if approved. Further, if a patent infringement suit were brought against us, we could be forced to stop or delay research, development,
manufacturing or sales of the product or product candidate that is the subject of the suit. Regardless of the merits of any third-party claims, our defense
against such claims, or other related actions we may take, could cause us to incur substantial expenses, and would be a substantial diversion of employee
resources from our business. In the event of
46
a successful claim of infringement against us by a third party, we may have to (i) pay substantial damages, including treble damages and attorneys’ fees if we
are found to have willfully infringed the third party’s patents; (ii) obtain one or more licenses from the third party; (iii) pay royalties to the third party; and/or
(iv) redesign any infringing products. Redesigning any infringing products may be impossible or require substantial time and monetary expenditure. Further,
we cannot predict whether any required license would be available at all or whether it would be available on commercially reasonable terms. In the event that
we could not obtain a license, we may be unable to further develop our product candidates and commercialize our product and product candidates, if
approved, which could harm our business significantly. Even if we are able to obtain a license, the license would likely obligate us to pay license fees or
royalties or both, and the rights granted to us might be nonexclusive, which could result in our competitors gaining access to the same intellectual property.
Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or
threatened patent infringement claims, we are unable to enter into licenses on acceptable terms.
Engaging in litigation is very expensive, particularly for a company of our size, and time-consuming. Some of our competitors may be able to sustain
the costs of litigation or administrative proceedings more effectively than we can because of greater financial resources. Patent litigation and other
proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other
proceedings could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could have a material adverse effect on our
business, financial condition or results of operations.
We may become involved in lawsuits to protect or enforce our patents or other intellectual property or the patents of our licensors, which could be
expensive and time consuming.
Third parties may infringe or misappropriate our intellectual property, including our existing patents, patents that may issue to us in the future, or the
patents of our licensors to which we have a license. As a result, we may be required to file infringement claims to stop third-party infringement or
unauthorized use. Further, we may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in
countries where the laws may not protect those rights as fully as in the United States.
Generic drug manufacturers may develop, seek approval for, and launch generic versions of our products. If we file an infringement action against
such a generic drug manufacturer, that company may challenge the scope, validity or enforceability of our or our licensors’ patents, requiring us and/or our
licensors to engage in complex, lengthy and costly litigation or other proceedings. For example, if we or one of our licensors initiated legal proceedings
against a third party to enforce a patent covering our product or product candidates, the defendant could counterclaim that the patent covering our product or
product candidates is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or
unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent.
In addition, within and outside of the United States, there has been a substantial amount of litigation and administrative proceedings, including
interference and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in various foreign jurisdictions, regarding
patent and other intellectual property rights in the pharmaceutical industry. Recently, the AIA introduced new procedures including inter partes review and
post grant review. The implementation of these procedures brings uncertainty to the possibility of challenges to our patents in the future, including challenges
to those patents perceived by our competitors as blocking entry into the market for their products, and the outcome of such challenges.
Such litigation and administrative proceedings could result in revocation of our patents or amendment of our patents such that they do not cover our
product or product candidates. They may also put our pending patent applications at risk of not issuing or issuing with limited and potentially inadequate
scope to cover our product and product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to
the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during
prosecution. Additionally, it is also possible that prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim,
may, nonetheless, ultimately be found by a court of law or an administrative panel to affect the validity or enforceability of a claim, for example if a priority
claim is found to be improper. If a defendant were to prevail on a legal assertion of invalidity and/or
47
unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product and product candidates. Such a loss of patent protection
could have a material adverse impact on our business.
Enforcing our or our licensors’ intellectual property rights through litigation is very expensive, particularly for a company of our size, and time-
consuming. Some of our competitors may be able to sustain the costs of litigation more effectively than we can because of greater financial resources. Patent
litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation
or other proceedings could impair our ability to compete in the marketplace. The occurrence of any of the foregoing could have a material adverse effect on
our business, financial condition or results of operations.
Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative proceedings,
there is a risk that some of our confidential information could be compromised by disclosure. In addition, during the course of litigation or administrative
proceedings, there could be public announcements of the results of hearings, motions or other interim proceedings or developments or public access to related
documents. If investors perceive these results to be negative, the market price for our common stock could be significantly harmed.
Although not involving issued U.S. patents covering our product or any of our product candidates, on April 17, 2015, we filed a request for
interference between one of our U.S. pending applications and a U.S. pending application controlled by Auris Medical Holding AG (Auris). On July 20,
2015, we received notice from the USPTO that the Patent Trial and Appeal Board (PTAB) declared an interference between our pending application and the
Auris patent (issued as U.S. Patent No. 9,066,865 on June 30, 2015). On January 26, 2017, the PTAB determined that all of Otonomy’s patent claims and all
but one of the Auris patent claims were not patentable. We filed a Notice of Appeal on March 27, 2017, in which we asked the Federal Circuit to reverse
PTAB’s decision that our claims are not patentable and that Auris’s single claim is. On August 1, 2018, the Federal Circuit agreed with us that the PTAB had
erred in its rulings for Auris. The court reversed the PTAB’s decision against Otonomy and remanded the case for the PTAB to enter judgment for Otonomy.
On March 11, 2019, the PTAB entered the judgment for Otonomy and cancelled the Auris patent.
If we fail to comply with our obligations in any of the agreements under which we license intellectual property rights from third parties or otherwise
experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.
We are a party to a number of license agreements under which we are granted intellectual property rights that are crucial to our business. A portion of
our patent portfolio for our product and certain product candidates was co-developed and is co-owned with UC which licensed its rights to us through an
exclusive worldwide license agreement. Under our existing license agreement with UC, we are subject to various obligations, including development and
commercialization diligence obligations, and patent prosecution and maintenance obligations, as well as financial obligations such as potential development
milestone payments, sublicensing income payments, and royalty payments. If we fail to comply with any of these obligations or otherwise breach other terms
of our license agreement, and fail to cure such breach, UC may have the right to terminate the license or, in the instance where we fail to meet our diligence
obligations, UC may instead elect to change our exclusive license to a non-exclusive license. The loss of the license from UC would affect a significant
portion of the patent portfolio for OTIPRIO and OTIVIDEX, as well as certain other product candidates we may develop. While we could still proceed with
development and, if approved, commercialization of OTIPRIO, OTIVIDEX and other product candidates as co-owner of the licensed patents, third parties,
such as our competitors, could enter into the market by obtaining a license from UC under UC’s rights to such patents.
In addition, a portion of our patent portfolio for our OTO-313 product candidate is exclusively in-licensed from Durect, which license includes a
sublicense to patents jointly owned by Durect and INSERM. Under our existing license agreement with Durect, we are subject to various obligations,
including development and commercialization diligence obligations and pre-commercial launch progress reporting obligations, as well as financial
obligations such as potential development milestone payments, sublicensing income payments, and royalty payments to both Durect and INSERM. If we fail
to comply with the diligence obligations or otherwise materially breach our license agreement and fail to remedy such failure or cure such breach, Durect may
have the right to terminate the license or, in the instance of our failure to meet the diligence obligations, Durect may instead elect to
48
convert our exclusive license to a non-exclusive license. In particular, the loss of the license from Durect would affect a portion of the patent portfolio for
OTO-313, which would adversely affect our ability to proceed with any development or potential commercialization of OTO-313 and could subject us to
claims of patent infringement by Durect if OTO-313 is covered by the licensed patents.
Licensing of intellectual property rights is of critical importance to our business and involves complex legal, business and scientific issues. Disputes
may arise between us and our licensors regarding intellectual property rights subject to a license agreement, including:
•
•
•
the scope of rights granted under the license agreement and other interpretation-related issues;
our right to sublicense intellectual property rights to third parties under collaborative development relationships; and
our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our
product and product candidates, and what activities satisfy those diligence obligations.
While we would expect to exercise all rights and remedies available to us, including seeking to cure any breach by us, and otherwise seek to preserve
our rights under the patents licensed to us, we may not be able to do so in a timely manner, at an acceptable cost or at all. Generally, the loss of any one of our
current licenses, or any other license we may acquire in the future, could materially harm our business, prospects, financial condition and results of
operations.
We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of
third parties.
We have received confidential and proprietary information from third parties. In addition, we employ individuals, consultants and independent
contractors who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees,
consultants or independent contractors have inadvertently or otherwise improperly used or disclosed confidential information of these third parties or their
former employers. Further, we may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants,
independent contractors or others who are involved in developing our product candidates. We may also be subject to claims that former employees,
consultants, independent contractors, collaborators or other third parties have an ownership interest in our patents or other intellectual property. Litigation
may be necessary to defend against these and other claims challenging our right to and use of confidential and proprietary information. If we fail in defending
any such claims, in addition to paying monetary damages, we may lose our rights therein. Such an outcome could have a material adverse effect on our
business. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and
employees.
Risks Related to Government Regulation
Our business and products are subject to extensive government regulation.
We are subject to extensive, complex, costly and evolving regulation by federal and state governmental authorities in the United States, principally by
the FDA, the U.S. Drug Enforcement Administration (DEA), the Centers for Disease Control and Prevention (CDC), the U.S. Department of Health and
Human Services, and its various agencies, and also from state and foreign regulatory authorities. Failure to comply with all applicable regulatory
requirements, including those promulgated under the Federal Food, Drug, and Cosmetic Act (FFDCA), the Public Health Service Act, and the Controlled
Substances Act, among others, may subject us to operating restrictions and criminal prosecution, monetary penalties and other disciplinary actions, including,
sanctions, warning letters, product seizures, recalls, fines, injunctions, suspension, revocation of approvals, disgorgement, contractual damages, and/or
exclusion from future participation in the Medicare and Medicaid programs. After our products receive regulatory approval or clearance, we, and our direct
and indirect suppliers, remain subject to the periodic inspection of our plants and facilities, review of production processes, and testing of our products to
confirm that we are in compliance with all applicable regulations. Adverse findings during regulatory inspections
49
may result in the implementation of Risk Evaluation and Mitigation Strategies (REMS), programs, completion of government mandated clinical trials, and
government enforcement action relating to labeling, advertising, marketing and promotion, as well as regulations governing cGMPs.
The regulatory approval process is highly uncertain and we may not obtain regulatory approval for the commercialization of OTIVIDEX, OTO-313,
OTO-413 or any other product candidates.
The research, testing, manufacturing, labeling, approval, selling, import, export, marketing and distribution of drug products are subject to extensive
regulation by the FDA and other regulatory authorities in the United States and other countries, which regulations differ from country to country. We are not
permitted to market our product candidates in the United States until we receive approval of an NDA from the FDA. Obtaining regulatory approval of a
product can be a lengthy, expensive and uncertain process. In addition, failure to comply with FDA and other applicable United States and foreign regulatory
requirements may subject us to administrative or judicially imposed sanctions or other actions, including:
•
•
•
•
•
•
•
•
warning letters and adverse publicity;
civil and criminal penalties;
injunctions;
withdrawal of approved products;
product seizure or detention;
product recalls;
total or partial suspension of production; and
refusal to approve pending NDAs or supplements to approved NDAs.
Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we must demonstrate with substantial evidence from
well-controlled nonclinical studies and clinical trials, and to the satisfaction of the FDA or other foreign regulatory agencies, that such product candidates are
safe and effective for their intended uses. Results from nonclinical studies and clinical trials can be interpreted in different ways, and insufficient or adverse
results from nonclinical studies can affect the ability to conduct clinical trials. For example, following completion of a Phase 1b clinical trial, the OTIVIDEX
program was put on Full Clinical Hold due to adverse findings in a nonclinical study evaluating the safety of repeated doses of OTIVIDEX. OTIVIDEX was
subsequently removed from Full Clinical Hold in July 2013, allowing for initiation of the Phase 2b single-dose clinical trial, and placed on Partial Clinical
Hold prohibiting the initiation of multiple-dose clinical trials in the United States pending the submission and review of additional nonclinical data. We
submitted additional nonclinical data to the FDA and OTIVIDEX was removed from Partial Clinical Hold in June 2014. As a result of OTIVIDEX being
placed on Full Clinical Hold, OTIPRIO was also placed on Full Clinical Hold. The OTIPRIO Full Clinical Hold was removed in November 2012. We cannot
assure you that our product candidates will not be subject to new clinical holds in the future.
Even if we believe the nonclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the
FDA and other regulatory authorities. Administering product candidates to humans may produce undesirable side effects, which could interrupt, delay or halt
clinical trials and result in the FDA or other regulatory authorities denying approval of a product candidate for any or all targeted indications.
50
Regulatory approval is not guaranteed, and the approval process is expensive and may take several years. The FDA also has substantial discretion in
the approval process. Despite the time and expense expended, failure can occur at any stage, and we could encounter problems that cause us to abandon or
repeat clinical trials, or perform additional nonclinical studies and clinical trials. The number of nonclinical studies and clinical trials that will be required for
FDA approval varies depending on the product candidate, the disease or condition that the product candidate is designed to address and the regulations
applicable to any particular product candidate. The FDA can delay, limit or deny approval of a product candidate for many reasons, including the following:
•
•
•
•
a product candidate may not be deemed safe, effective, pure or potent;
FDA officials may not find the data from nonclinical studies and clinical trials sufficient;
the FDA might not accept or approve our third-party manufacturers’ processes or facilities; or
the FDA may change its approval policies or adopt new regulations.
If OTIVIDEX, OTO-313, OTO-413 or any other product candidates fail to demonstrate safety and efficacy in clinical trials or do not gain regulatory
approval, our business and results of operations will be materially and adversely harmed.
For our product, and if we receive regulatory approval for any of our product candidates, we will be subject to ongoing regulatory obligations and
continued regulatory review, which may result in significant additional expense, or the limiting or withdrawal of regulatory approval and subject us to
penalties if we fail to comply with applicable regulatory requirements.
If and when regulatory approval has been granted, our product candidates or any approved product will be subject to continual regulatory review by
the FDA and/or non-U.S. regulatory authorities. Additionally, our product and any product candidates, if approved, will be subject to extensive and ongoing
regulatory requirements, including labeling and other restrictions and market withdrawal, and we may be subject to penalties if we fail to comply with
regulatory requirements or experience unanticipated problems with our products. Any regulatory approvals that we receive for our product candidates may
also be subject to limitations on the approved indications for which the product may be marketed or to the conditions of approval, or contain requirements for
potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product. In addition, for
our product, and if the applicable regulatory agency approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse
event reporting, storage, advertising, promotion and recordkeeping for the product will be subject to extensive and ongoing regulatory requirements. These
requirements include prompt submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with
cGMP and GCP for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with our product or our product
candidates, including adverse events of unanticipated severity or frequency, or problems with our third-party manufacturers’ processes, or failure to comply
with regulatory requirements, may result in, among other things:
•
•
•
•
•
restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product
recalls;
fines, warning letters or holds on clinical trials;
refusal by the FDA to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of
product approvals;
product seizure or detention, or refusal to permit the import or export of products; and
injunctions or the imposition of civil or criminal penalties.
Our ongoing regulatory requirements may also change from time to time, potentially harming or making costlier our commercialization efforts. We
cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United
States or other countries. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if
51
we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain
profitability, which would adversely affect our business.
Our relationships with healthcare professionals, clinical investigators, CROs and third-party payors in connection with our current and future business
activities may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, government price reporting, and
health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face penalties.
We are subject to various U.S. federal and state health care laws, including those intended to prevent healthcare fraud and abuse.
The federal Anti-Kickback Statute prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or
paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the
referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole
or in part, under a federal healthcare program such as Medicare, and Medicaid Remuneration has been broadly defined to include anything of value,
including, but not limited to, cash, improper discounts, and free or reduced price items and services. Many states have similar laws that apply to their state
health care programs as well as private payors.
Federal false claims laws, including the federal False Claims Act (FCA), and civil monetary penalties law impose penalties against individuals or
entities for, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false or
fraudulent or making a false record or statement to avoid, decrease or conceal an obligation to pay money to the federal government. The FCA has been used
to, among other things, prosecute persons and entities submitting claims for payment that are inaccurate or fraudulent, that are for services not provided as
claimed, or for services that are not medically necessary. The FCA includes a whistleblower provision that allows individuals to bring actions on behalf of the
federal government and share a portion of the recovery of successful claims. Many states also have similar laws that apply to their state health care programs
as well as private payors.
Additionally, state and federal authorities have aggressively targeted medical technology companies for, among other things, alleged violations of
these anti-fraud statutes, based on, for example, improper research or consulting contracts with doctors, certain marketing arrangements that rely on volume-
based pricing, off-label marketing schemes, and other improper promotional practices.
The federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), among other things, imposes criminal liability for knowingly and
willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or knowingly and willfully falsifying, concealing or
covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services.
Additionally, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH Act), and their
implementing regulations, also imposes certain obligations, including mandatory contractual terms, on certain types of people and entities, with respect to
safeguarding the privacy, security and transmission of individually identifiable health information without proper written authorization. Similarly, the
collection and use of health data in the EU is governed by the GDPR, which became fully applicable in May 2018. The GDPR extends the geographical scope
of EU Data protection law to non-EU entities under certain conditions, tightens existing EU data protection principles and creates new obligations for
companies and new rights for individuals. The GDPR is new and guidance, interpretation and application under the GDPR are still developing. Failure to
comply with the GDPR may result in substantial fines and other administrative penalties. The GDPR may increase our responsibility and liability in relation
to personal data that we control and/or process and we may be required to put in place additional mechanisms ensuring compliance with the GDPR. This may
be onerous and if our efforts to comply with GDPR or other applicable EU laws and regulations are not successful, it could adversely affect our business in
the EU.
52
Since the approval of OTIPRIO, our operations have been subject to the federal transparency requirements under the ACA, which requires certain
manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid, or the Children’s Health
Insurance Program, with specific exceptions, to annually report to CMS information related to payments and other transfers of value provided to physicians
and teaching hospitals and certain ownership and investment interests held by physicians and their immediate family members.
If any of our business activities, including but not limited to our relationships with healthcare providers or payors, violate any of the aforementioned
laws, we may be subject to administrative, civil and/or criminal penalties, damages, monetary fines, disgorgement, individual imprisonment, possible
exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and
future earnings and curtailment or restructuring of our operations.
In addition, the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries
from making improper payments to non-U.S. officials for the purpose of obtaining or retaining business. We cannot assure you that our internal control
policies and procedures will protect us from reckless or negligent acts committed by our employees, future distributors, partners, collaborators or agents.
Violations of these laws, or allegations of such violations, could result in fines, penalties or prosecution and have a negative impact on our business, results of
operations and reputation.
Legislative or regulatory healthcare reforms in the United States or abroad may make it more difficult and costly for us to obtain regulatory clearance or
approval of our product candidates or any future product candidates and to produce, market, and distribute our products after clearance or approval is
obtained.
From time to time, legislation is drafted and introduced in Congress in the United States or by governments in foreign jurisdictions that could
significantly change the statutory provisions governing the regulatory clearance or approval, manufacture, and marketing of regulated products or the
reimbursement thereof. In addition, FDA or foreign regulatory agency regulations and guidance are often revised or reinterpreted by the FDA or the
applicable foreign regulatory agency in ways that may significantly affect our business and our product and product candidates. Any new regulations or
revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of our product candidates or any future product
candidates. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted
may have on our business in the future. Such changes could, among other things, require:
•
•
•
changes to manufacturing methods;
recall, replacement, or discontinuance of one or more of our products; and
additional recordkeeping.
Each of these would likely entail substantial time and cost and could materially harm our business and our financial results. In addition, delays in
receipt of or failure to receive regulatory clearances or approvals for any future products would harm our business, financial condition, and results of
operations.
If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could
have a material adverse effect on the success of our business.
We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling,
use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including
chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these
materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our
use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant
costs associated with civil or criminal fines and penalties.
53
We maintain workers’ compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the
use of hazardous materials or other work-related injuries with policy limits that we believe are customary for similarly situated companies and adequate to
provide us with coverage for foreseeable risks. Although we maintain such insurance, this insurance may not provide adequate coverage against potential
liabilities. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These
current or future laws and regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also
may result in substantial fines, penalties or other sanctions.
We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and
regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal
liability and other serious consequences for violations which can harm our business.
We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations,
various economic and trade sanctions regulations administered by the Office of Foreign Assets Control of the U.S. Department of the Treasury, the U.S.
Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. § 201, the U.S. Travel Act, the USA PATRIOT
Act, the UK Bribery Act 2010, and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. U.S.
economic sanctions and export control laws and regulations prohibit the shipment of certain products and services to countries, governments, and persons
targeted by U.S. sanctions. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, contractors, and other partners
from authorizing, promising, offering, or providing, directly or indirectly, improper payments or anything else of value to recipients in the public or private
sector.
We may engage third parties for clinical trials outside of the United States, to sell our products abroad once we enter a commercialization phase,
and/or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals. We also have direct or indirect interactions with officials and
employees of government agencies or government-affiliated hospitals, universities, and other organizations. We can be held liable for any unauthorized
exports and reexports of our products and for the corrupt or other illegal activities of our employees, agents, contractors, and other partners, even if we do not
explicitly authorize or have actual knowledge of such activities. Any violation of the laws and regulations described above may result in substantial civil and
criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation,
reputational harm, and other consequences.
Risks Related to Ownership of Our Common Stock
The market price of our common stock has been and may continue to be volatile, and you could lose all or part of your investment.
Our stock is currently traded on The Nasdaq Global Select Market, but we can provide no assurance that we will be able to maintain an active trading
market on The Nasdaq Global Select Market or any other exchange in the future. Moreover, the trading price of our common stock may fluctuate
substantially.
The stock market in general and the market for pharmaceutical companies in particular have experienced extreme volatility that has often been
unrelated to the operating performance of particular companies. The market price of our common stock following our initial public offering has been and is
likely to continue to be highly volatile and could be subject to wide fluctuations in response to various factors, some of which are beyond our control,
including:
•
•
•
•
regulatory or legal developments;
results from or delays in clinical trials of our product candidates or product candidates of companies that are perceived to be similar to us;
announcements of regulatory approval or disapproval of our product candidates;
commercialization of our products;
54
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
FDA or other regulatory actions affecting us or our industry;
introductions and announcements of new products by us, any commercialization partners or our competitors, and the timing of these
introductions and announcements;
our financial results or those of companies that are perceived to be similar to us;
changes in the structure of healthcare payment systems;
announcements by us or our competitors of significant acquisitions, licenses, strategic partnerships, joint ventures or capital commitments;
market conditions in the pharmaceutical and biopharmaceutical sectors and issuance of securities analysts’ reports or recommendations;
actual or anticipated quarterly variations in our results of operations or those of our competitors;
changes in financial estimates or guidance, including our ability to meet our revenue, operating profit or loss and cash balance estimates or
guidance;
sales of substantial amounts of our stock by insiders and large stockholders, or the expectation that such sales might occur;
general economic, industry and market conditions;
additions or departures of key personnel;
intellectual property, product liability or other litigation against us;
expiration or termination of our potential relationships with strategic partners;
limited trading volume of our common stock; and
the other factors described in this “Risk Factors” section.
If securities or industry analysts do not continue to publish research or publish unfavorable research about our business, our stock price and trading
volume could decline.
The trading market for our common stock will be influenced in part on the research and reports that equity research analysts publish about us and our
business. Although certain equity research analysts currently cover us, we do not have any control of the analysts or the content and opinions included in their
reports or whether any such analysts will continue to, or whether new analysts will, cover us for any given period of time. The price of our common stock
could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research
analyst ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which in turn could cause our stock
price or trading volume to decline.
Sales of substantial amounts of our common stock in the public markets, or the perception that such sales might occur, could cause the market price of
our common stock to drop significantly, even if our business is doing well.
Sales of a substantial number of shares of our common stock in the public market could occur at any time. If our stockholders sell, or the market
perceives that our stockholders intend to sell, substantial amounts of our common stock in the public market, the market price of our common stock could
decline significantly.
As of December 31, 2019, certain holders of approximately 4,192,638 shares of our common stock, including shares issuable upon the exercise of
outstanding options, are entitled to certain rights with respect to the registration of their shares under the Securities Act. Registration of these shares under the
Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by our affiliates as
defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the market price of our
common stock.
55
If we sell shares of our common stock in future financings, stockholders may experience immediate dilution and, as a result, the market price of our
common stock may decline.
We may from time to time issue additional shares of common stock at a discount from the current trading price of our common stock. As a result, our
stockholders would experience immediate dilution upon the purchase of any shares of our common stock sold at such discount. In addition, as opportunities
present themselves, we may enter into financing or similar arrangements in the future, including the issuance of debt securities, preferred stock or common stock.
In September 2018, our shelf registration statement on Form S-3 (File No. 333-227269) was declared effective by the SEC, pursuant to which we may offer debt
securities, preferred stock, common stock and certain other securities from time to time. On August 1, 2019, we filed a prospectus supplement in connection with
an “at-the-market” offering under our Sales Agreement with Cowen, under which we may sell shares of common stock for up to an aggregate of $40.0 million. If
in the future we issue additional shares of common stock or securities convertible into common stock, our common stockholders would experience additional
dilution and, as a result, the market price of our common stock may decline.
Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may
reduce the amount of money available to us.
Our amended and restated certificate of incorporation and amended and restated bylaws provide that we will indemnify our directors and officers, in
each case to the fullest extent permitted by Delaware law.
In addition, as permitted by Section 145 of the Delaware General Corporation Law, our amended and restated bylaws and our indemnification
agreements that we have entered into with our directors and officers provide that:
•
•
•
•
•
•
We will indemnify our directors and officers for serving us in those capacities, or for serving other business enterprises at our request, to the
fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good
faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any
criminal proceeding, had no reasonable cause to believe such person’s conduct was unlawful.
We may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law.
We are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such
directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification.
We are not obligated pursuant to our amended and restated bylaws to indemnify a person with respect to proceedings initiated by that person
against us or our other indemnitees, except with respect to proceedings authorized by our board of directors or brought to enforce a right to
indemnification.
The rights conferred in our amended and restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with
our directors, officers, employees and agents and to obtain insurance to indemnify such persons.
We may not retroactively amend our amended and restated bylaw provisions to reduce our indemnification obligations to directors, officers,
employees and agents.
To the extent that a claim for indemnification is brought by any of our directors or officers, it would reduce the amount of funds available for use in
our business.
56
Concentration of ownership of our common stock among our existing principal stockholders may effectively limit the voting power of other stockholders.
As of December 31, 2019, our executive officers, directors and current beneficial owners of 5% or more of our common stock, in aggregate,
beneficially owned approximately 32.7% of our outstanding common stock. Accordingly, these stockholders, acting together, may significantly influence all
matters requiring stockholder approval, including the election and removal of directors and any merger or other significant corporate transactions. These
stockholders may therefore delay or prevent a change of control, even if such a change of control would benefit our other stockholders. The significant
concentration of stock ownership may adversely affect the market price of our common stock due to investors’ perception that conflicts of interest may exist
or arise.
Anti-takeover provisions in our corporate charter documents and under Delaware law could make an acquisition of us more difficult, which could
discourage takeover attempts and lead to management entrenchment, and the market price of our common stock may be lower as a result.
Certain provisions in our certificate of incorporation and bylaws may make it difficult for a third party to acquire, or attempt to acquire, control of our
company, even if a change in control was considered favorable by you and other stockholders. For example, our board of directors has the authority to issue
up to 10,000,000 shares of preferred stock. Our board of directors can fix the price, rights, preferences, privileges, and restrictions of the preferred stock
without any further vote or action by our stockholders. The issuance of shares of preferred stock may delay or prevent a change in control transaction. As a
result, the market price of our common stock and the voting and other rights of our stockholders may be adversely affected. An issuance of shares of preferred
stock may result in the loss of voting control to other stockholders.
Our charter documents contain other provisions that could have an anti-takeover effect, including provisions that:
•
•
•
•
•
•
•
•
•
•
•
establish that our board of directors is divided into three classes, Class I, Class II and Class III, with each class serving staggered three-year
terms;
provide that vacancies on our board of directors may be filled only by a majority of directors then in office, even though less than a quorum;
provide that our directors may only be removed for cause;
eliminate cumulative voting in the election of directors;
authorize our board of directors to issues shares of preferred stock and determine the price and other terms of those shares, including
preferences and voting rights, without stockholder approval;
provide our board of directors with the exclusive right to elect a director to fill a vacancy or newly created directorship;
permit stockholders to only take actions at a duly called annual or special meeting and not by written consent;
prohibit stockholders from calling a special meeting of stockholders;
require that stockholders give advance notice to nominate directors or submit proposals for consideration at stockholder meetings;
authorize our board of directors, by a majority vote, to amend the bylaws; and
require the affirmative vote of at least 66 2/3% or more of the outstanding shares of common stock to amend many of the provisions
described above.
57
In addition, we are subject to the anti-takeover provisions of Section 203 of the Delaware General Corporation Law, which limits the ability of
stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us. Finally, our amended and restated certificate of
incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our
stockholders. These provisions could discourage potential acquisition proposals and could delay or prevent a change in control transaction. They could also
have the effect of discouraging others from making tender offers for our common stock, including transactions that may be in your best interests. These
provisions may also prevent changes in our management or limit the price that certain investors are willing to pay for our stock.
We may be subject to securities litigation, which is expensive and could divert management attention.
The market price of our common stock has been and will likely continue to be volatile, and in the past companies that have experienced volatility in
the market price of their stock have been subject to securities class action litigation. We may be the target of this type of litigation in the future. Securities
litigation against us could result in substantial costs and divert our management’s attention from other business concerns, which could seriously harm our
business.
Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be your sole
source of gains.
We have not declared or paid cash dividends on our common stock to date. We currently intend to retain our future earnings, if any, to fund the
development and growth of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable
future.
Our ability to use our net operating loss carryforwards and certain other tax attributes to offset future taxable income may be subject to certain
limitations.
As of December 31, 2019, we had U.S. federal and state net operating loss carryforwards (NOLs) of approximately $337.4 million and $131.7
million, respectively. Of the federal NOLs, approximately $96.8 million were generated after January 1, 2018, and therefore do not expire. Federal net
operating losses that occur after January 1, 2018 are subject to a taxable income limitation of 80%. The remaining federal and state NOLs will expire in
various years beginning in 2030, if not utilized. As of December 31, 2019, we had federal and California research and development tax credit carryforwards
of approximately $10.9 million and $5.0 million, respectively. The federal research and development tax credit carryforwards expire in various years
beginning in 2030, if not utilized. The California research credit will carry forward indefinitely. Under Sections 382 and 383 of the Internal Revenue Code of
1986, as amended (Code) if a corporation undergoes an “ownership change,” the corporation’s ability to use its pre-change federal NOLs and other pre-
change tax attributes, such as research tax credits, to offset its future post-change income and taxes may be limited. In general, an “ownership change” occurs
if there is a cumulative change in our ownership by “5% shareholders” that exceeds 50 percentage points over a rolling three-year period. Similar rules may
apply under state tax laws. We believe we have experienced certain ownership changes in the past and have reduced our deferred tax assets related to NOLs
and research and development tax credit carryforwards accordingly. In the event that it is determined that we have in the past experienced additional
ownership changes, or if we experience one or more ownership changes as a result of future transactions in our stock, then we may be further limited in our
ability to use our NOLs and other tax assets to reduce taxes owed on the net taxable income that we earn in the event that we attain profitability. Any such
limitations on the ability to use our NOLs and other tax assets could adversely impact our business, financial condition and operating results in the event that
we attain profitability.
58
The comprehensive tax reform bill could adversely affect our business and financial condition.
On December 22, 2017, President Trump signed into law new legislation that significantly revises the Code. The newly enacted federal income tax
law, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a
flat rate of 21%, limitation of the tax deduction for interest expense to 30% of adjusted earnings (except for certain small businesses), limitation of the
deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks, immediate deductions for certain
new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits. Our net deferred
tax assets and liabilities were revalued at the newly-enacted U.S. corporate rate. We do not expect this to have a material impact on our financials because we
currently maintain a full valuation allowance on our U.S. net deferred tax assets. We have reflected reasonable estimates of the effects of certain aspects of
this legislation in our financial statements. In addition, it is uncertain if and to what extent various states will conform to the newly enacted federal tax law.
We have incurred and will continue to incur costs as a result of operating as a public company, and our management has been and will continue to be
required to devote substantial time to new compliance initiatives and corporate governance practices, including maintaining an effective system of
internal control over financial reporting.
As a public company listed in the United States, we incur and will continue to incur significant legal, accounting and other expenses. In addition,
changing laws, regulations and standards relating to corporate governance and public disclosure, including the Sarbanes-Oxley Act of 2002 (the Sarbanes-Oxley
Act) and regulations implemented by the SEC, and The Nasdaq Stock Market (Nasdaq) may increase legal and financial compliance costs and make some
activities more time consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may
evolve over time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and
standards, and this investment may result in increased general and administrative expenses and a diversion of management’s time and attention from revenue-
generating activities to compliance activities. If, notwithstanding our efforts to comply with new laws, regulations and standards, we fail to comply, regulatory
authorities may initiate legal proceedings against us and our business may be harmed.
As a public company in the United States, we are required, pursuant to the Sarbanes-Oxley Act, to maintain effective disclosure controls and procedures
and internal control over financial reporting. We are also required to provide an annual management report on the effectiveness of our disclosure controls and
procedures over financial reporting.
In addition, our independent registered public accounting firm is required to audit the effectiveness of our internal control over financial reporting
pursuant to Section 404(b) of the Sarbanes-Oxley Act annually. Our independent registered public accounting firm may issue a report that is adverse in the event
it is not satisfied with the level at which our controls are documented, designed or operating. Moreover, our testing, or the subsequent testing by our independent
registered public accounting firm, may reveal material weaknesses or significant deficiencies. If material weaknesses are identified or we are not able to comply
with the requirements of Section 404 in a timely manner, our reported financial results could be materially misstated or could subsequently require restatement,
we could receive an adverse opinion regarding our internal control over financial reporting from our independent registered public accounting firm, we could be
subject to investigations or sanctions by regulatory authorities and we could incur substantial expenses.
Our current controls, and any new controls that we develop may become inadequate because of changes in conditions in our business or the degree of
compliance with these policies or procedures may deteriorate and significant deficiencies or material weaknesses in our internal control over financial reporting
may be discovered. We may err in the design or operation of our controls, and all internal control systems, no matter how well designed and operated, may
provide only reasonable assurance that the objectives of the control system are met. Because there are inherent limitations in all control systems, there can be no
absolute assurance that all control issues have been or will be detected. Any failure to develop or maintain effective controls or any difficulties encountered in
their implementation could harm our results of operations or cause us to fail to meet our reporting obligations and may result in a restatement
59
of our financial statements for prior periods. Any failure to implement and maintain effective internal control over financial reporting also could adversely affect
the results of periodic management evaluations and annual independent registered public accounting firm attestation reports regarding the effectiveness of our
internal control over financial reporting that are required to be included in our periodic reports that will be filed with the SEC. Ineffective disclosure controls and
procedures and internal control over financial reporting could also cause investors to lose confidence in our reported financial information and operating results,
which could result in a negative market reaction and effect on the trading price of our common stock. In addition, if we are unable to continue to meet these
requirements, we may not be able to remain listed on Nasdaq.
We are a “smaller reporting company,” and the reduced disclosure requirements applicable to smaller reporting companies could make our common
stock less attractive to investors.
We are a “smaller reporting company,” as defined in in Rule 12b-2 of the Exchange Act. For as long as we remain a “smaller reporting company,” we
are permitted and intend to continue to rely on exemptions from certain disclosure requirements that are applicable to other public companies that are not
“smaller reporting companies.” These exemptions include:
•
•
being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim financial statements,
with correspondingly reduced “Management’s discussion and analysis of financial condition and results of operations” disclosure; and
reduced disclosure obligations regarding executive compensation.
We cannot predict whether investors will find our common stock less attractive as a result of our reliance on these exemptions. If some investors find
our common stock less attractive as a result, there may be a less active trading market for our common stock and the market price of our common stock may
be reduced or more volatile.
We have broad discretion in the use of the net proceeds from our public offerings, including our “at the market” offering, and may not use them
effectively.
We have broad discretion as to how to spend and invest the proceeds from our public offerings, including our “at-the-market” offering with Cowen,
and we may spend or invest these proceeds in a way with which our stockholders disagree. Accordingly, investors will need to rely on our judgment with
respect to the use of these proceeds and these uses may not yield a favorable return to our stockholders. In addition, until the net proceeds are used, they may
be placed in investments that do not produce significant income or that may lose value.
Item 1B. UNRESOLVED STAFF COMMENTS
None.
Item 2. PROPERTIES
Our corporate headquarters are located in San Diego, California, where we lease and occupy approximately 62,000 square feet of space, which we
believe is adequate to meet our existing needs. The current term of our lease on this facility expires in September 2027. We have an option to extend this lease
by an additional five years.
Item 3. LEGAL PROCEEDINGS
From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a
party to any legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome,
litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.
Item 4. MINE SAFETY DISCLOSURE
Not applicable.
60
Item 5. MARKET FOR REGISTRANT’S COMMON EQUITY RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF
EQUITY SECURITIES
Market Information for Common Stock
Our common stock began trading on The NASDAQ Global Select Market under the symbol “OTIC” on August 13, 2014. Prior to that date, there was
PART II
no public trading market for our common stock.
Holders of Record
On February 21, 2020, the closing sale price of our common stock on The NASDAQ Global Select Market was $3.55. As of February 21, 2020, there
were approximately 21 holders of record of our common stock. The actual number of stockholders is greater than this number of holders of record and
includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record
also does not include stockholders whose shares may be held in trust or by other entities.
Dividend Policy
We have never declared or paid cash dividends on our common stock. We currently intend to retain all available funds and any future earnings for use
in the operation of our business and do not anticipate paying any dividends on our common stock in the foreseeable future. Any future determination to
declare dividends will be made at the discretion of our board of directors and will depend on, among other factors, our financial condition, operating results,
capital requirements, general business conditions and other factors that our board of directors may deem relevant.
Recent Sale of Unregistered Securities
There were no sales of unregistered securities during the period covered by this Annual Report on Form 10-K, other than those previously reported in
a Quarterly Report on Form 10-Q or in a Current Report on Form 8-K.
Use of Proceeds
None.
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
None.
Item 6. SELECTED FINANCIAL DATA
As a “smaller reporting company” as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended, we are not required to provide the
information required by this item.
61
Item 7. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
You should read the following discussion and analysis of our financial condition and results of operations together with the financial statements and
related notes included elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements based upon current expectations
that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various
factors, including those discussed in the section entitled “Risk Factors” and in other parts of this Annual Report on Form 10-K.
Overview
We are a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. We pioneered the application of drug
delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered
by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière’s disease,
hearing loss and tinnitus.
OTIVIDEX is a steroid in development for the treatment of Ménière’s disease. Two Phase 3 trials in Ménière’s disease patients were completed in the
second half of 2017. The AVERTS-2 trial, conducted in Europe, achieved its primary endpoint (p value = 0.029), while the AVERTS-1 trial, conducted in the
United States, did not (p value = 0.62). Based on a Type C meeting with the FDA, we believe that one additional successful pivotal trial is sufficient to
support the U.S. registration of OTIVIDEX in Ménière’s disease. We are enrolling patients in a Phase 3 trial for Ménière’s disease with results expected by
the end of the third quarter of 2020.
OTO-313 is a sustained-exposure formulation of gacyclidine, a potent and selective NMDA receptor antagonist, in development for the treatment of
tinnitus. We are enrolling patients in a Phase 1/2 clinical trial for OTO-313 for the treatment of tinnitus with results expected by the end of the second quarter
of 2020.
OTO-413 is a sustained exposure formulation of BDNF in development for the repair of cochlear synaptopathy, an underlying pathology in age-
related and noise-induced hearing loss that manifests as speech-in-noise hearing difficulty. We are enrolling patients in a Phase 1/2 clinical trial for OTO-413
for the treatment of hearing loss with results expected in the second half of 2020.
We also have preclinical stage programs addressing prevention of cisplatin-induced hearing loss (OTO-510) and hair cell regeneration for severe
hearing loss (OTO-6XX).
In October 2019, we entered into a strategic collaboration with AGTC to co-develop and co-commercialize an AAV-based gene therapy to restore
hearing in patients with congenital hearing loss caused by a mutation in the GJB2 gene.
In addition, we developed, received FDA approval for and commercially launched OTIPRIO for use during TTP surgery in pediatric patients.
OTIPRIO was also approved by the FDA for the treatment of AOE. We entered into a co-promotion agreement with Mission in August 2018 and with
Glenmark in April 2019 to support the promotion of OTIPRIO for the treatment of AOE in physician offices. In July 2019, Glenmark informed us of its early
discontinuation of OTIPRIO promotional support activities due to the delay in FDA approval of its Ryaltris allergy product, and the impact of such delay on
its business operations. In September 2019, we reached a settlement with Glenmark regarding the financial and contractual terms impacted by this decision
that included committed payments by Glenmark totaling $1.0 million. In August 2019, Mission informed us of its non-renewal of the co-promotion
agreement.
62
We have a limited operating history. Since our inception in 2008, we have devoted substantially all our efforts to developing and commercializing
OTIPRIO, developing our current product candidates, and providing general and administrative support for these operations. As of December 31, 2019, we
had cash, cash equivalents and short-term investments of $60.7 million and long-term debt of $15.0 million, net of debt discounts.
We have never been profitable, and as of December 31, 2019, we had an accumulated deficit of $459.9 million. Our net losses were $44.7 million,
$50.4 million and $90.1 million for the years ended December 31, 2019 2018 and 2017, respectively. Substantially all our net losses have resulted from
research and development expenses related to our clinical trials and product development activities, commercialization expenses to launch OTIPRIO in the
U.S. market, and other general and administrative expenses.
We expect to continue to incur significant expenses and operating losses for the foreseeable future as we continue to develop, seek regulatory
approval, and, if approved, commercialize our product candidates. In the near term, we anticipate our expenses will continue to be substantial as we:
•
•
•
•
•
•
•
conduct clinical development of OTIVIDEX, OTO-313 and OTO-413;
conduct nonclinical development of OTO-510, OTO-6XX and the GJB2 gene therapy program;
contract to manufacture our product candidates;
evaluate opportunities for development of additional product candidates;
maintain and expand our intellectual property portfolio;
hire additional staff as necessary to execute our product development plan; and
operate as a public company.
We will require additional financing to complete the development of and, if approved, commercialize, OTIVIDEX, OTO-313, OTO-413 and any other
product candidates. We believe we will continue to expend substantial resources for the foreseeable future for the development of OTIVIDEX, OTO-313, OTO-
413 and any other product candidates we may choose to pursue. These expenditures will include costs associated with marketing and selling any products
approved for sale, manufacturing, preparing regulatory submissions, and conducting nonclinical studies and clinical trials. The amount and timing of our future
funding requirements will depend on many factors, including the pace and results of our clinical development efforts, the timing and nature of the regulatory
approval process for our product candidates, and the revenue generated by OTIPRIO and our other product candidates, if approved. When additional financing is
required, we anticipate we will seek funding through public or private equity or debt financings or other sources, such as potential collaboration arrangements. We
may not be able to raise capital on terms acceptable to us, or at all. Our failure to raise capital as and when needed could have a negative impact on our financial
condition and our ability to pursue our business strategies. We believe our existing cash and cash equivalents and short-term investments will be sufficient to fund
our currently planned operations for a period of at least twelve months from the date of this Annual Report on Form 10-K.
In November 2008, we entered into an exclusive license agreement with the Regents of the University of California (UC). Under the license
agreement, UC granted us an exclusive license under their rights to patents and applications that are co-developed and co-owned with us for the treatment of
human otic diseases. Our financial obligations under the license agreement include development and regulatory milestone payments of up to $2.7 million per
licensed product, of which $1.9 million has been paid for OTIPRIO, $0.8 million has been paid for OTIVIDEX, $0.1 million has been paid for OTO-413, and
$0.1 million has been paid for OTO-311 (but such milestone payments are reduced by 75% for any orphan indication product), and a low single-digit royalty
on net sales by us or our affiliates of licensed products. In addition, for each sublicense we grant we are obligated to pay UC a fixed percentage of all royalties
as well as a sliding-scale percentage of non-royalty sublicense fees received by us under such sublicense, with such percentage depending on the licensed
product’s stage of development when sublicensed to such third party. We have the right to offset a certain amount of third-party royalties, milestone fees or
sublicense fees against the foregoing financial obligations, provided such third-party royalties or fees are paid by us in consideration for intellectual property
rights necessary to commercialize a licensed product.
63
In April 2013, we entered into an exclusive license agreement with DURECT Corporation (Durect), as part of an asset transfer agreement between us
and IncuMed LLC, an affiliate of the NeuroSystec Corporation. Under this license agreement, Durect granted us an exclusive, worldwide, royalty-bearing
license under Durect’s rights to certain patents and applications covering our OTO-313 product candidate, as well as certain related know-how. Under this
license agreement and the asset transfer agreement, we are obligated to make one-time milestone payments of up to $7.5 million for the first licensed product.
Upon commercializing a licensed product, we are obligated to pay Durect tiered, low single-digit royalties on annual net sales by us or our affiliates or
sublicensees of the licensed products, and we have the right to offset a certain amount of third-party license fees or royalties against such royalty payments to
Durect. In addition, each sublicense we grant to a third party is subject to payment to Durect of a low double-digit percentage of all non-royalty payments we
receive under such sublicense. Additionally, we are also obligated to pay the Institut National de la Santé et de la Recherche Médicale (INSERM), on behalf
of Durect, for a low single-digit royalty payment on net sales by us or our affiliates or sublicensees upon commercialization of the licensed product. The
foregoing royalty payment obligation to Durect would continue on a product-by-product and country-by-country basis until expiration or determination of
invalidity of the last valid claim within the licensed patents that cover the licensed product, and the payment obligation to INSERM would continue so long as
Durect’s license from INSERM remains in effect.
Financial Operations Overview
Revenue
In December 2015, OTIPRIO was approved by the FDA for the treatment of pediatric patients with bilateral otitis media with effusion undergoing
TTP surgery. In March 2016, we began sales of OTIPRIO in the United States to our network of specialty distributors who fill orders received from hospitals
and ambulatory surgery centers who are the primary end user customers of OTIPRIO for use during TTP surgery. We also entered into co-promotion
partnerships to support the promotion of OTIPRIO for the treatment of AOE in physician offices. In July 2019, we were notified by Glenmark of its early
discontinuation of OTIPRIO promotional support activities due to the delay in FDA approval of its Ryaltris allergy product, and the impact of such delay on
its business operations. In August 2019, Mission informed us of its non-renewal of the co-promotion agreement.
We recognize revenue on sales of OTIPRIO upon delivery to our distributors. Product sales are recorded net of estimated chargebacks, government
rebates and distributor fees.
Prior to March 2016 we had not generated revenue. We do not expect to generate any revenue from any of our product candidates unless and until we
obtain regulatory approval and commercialize our products or enter into collaborative agreements with third parties.
Operating Expenses
Cost of product sales
Cost of product sales consists primarily of direct and indirect costs related to the manufacturing of OTIPRIO, including third party manufacturing
costs, allocation of overhead costs and royalty payments based on OTIPRIO sales. In 2017, OTIPRIO inventory values were written down due to the
discontinuation of promotional support for the product indicating our expectation that the useful life and ability to recover inventory costs have decreased.
Similarly, OTIPRIO manufacturing equipment was impaired in 2017. These expenses were recorded in cost of product sales on the statement of operations.
Research and development expenses
Our research and development expenses primarily consist of costs associated with the nonclinical and clinical development of our product candidates
and the development of OTIPRIO for additional indications.
64
Our research and development expenses include:
•
•
•
•
•
•
employee-related expenses, including salaries, benefits, travel and stock-based compensation expense;
external development expenses incurred under arrangements with third parties, such as fees paid to CROs in connection with nonclinical
studies and clinical trials, costs of acquiring and evaluating clinical trial data such as investigator grants, patient screening fees, laboratory
work and statistical compilation and analysis, and fees paid to consultants and our scientific advisory board;
costs to acquire, develop and manufacture clinical trial materials, including fees paid to contract manufacturers;
payments related to licensed product candidates and technologies;
costs related to compliance with drug development regulatory requirements; and
facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities,
depreciation of leasehold improvements and equipment, and laboratory and other supplies.
We expense our internal and third-party research and development expenses as incurred.
The following table summarizes our research and development expenses (in thousands) for OTIPRIO and our product candidates:
Third-party development costs:
OTIPRIO
OTIVIDEX
OTO-313
OTO-413
Total third-party development costs
Other unallocated internal research and development
costs
Total research and development costs
2019
Years Ended December 31,
2018
2017
$
— $
7,709
2,951
4,557
15,217
137 $
5,160
2,262
5,264
12,823
17,588
32,805 $
19,021
31,844 $
$
2,300
15,705
414
926
19,345
23,356
42,701
We expect our research and development expenses to continue to be substantial for the foreseeable future as we advance our product candidates
through their respective development programs. The process of conducting nonclinical studies and clinical trials necessary to obtain regulatory approval is
costly and time consuming. We may never succeed in achieving regulatory approval for our product candidates. The probability of success will be affected by
numerous factors, including nonclinical data, clinical data, competition, manufacturing capability and commercial viability. We are responsible for all of the
research and development costs for our programs.
Completion dates and completion costs can vary significantly for each of our clinical development programs and are difficult to predict. We therefore
cannot estimate with any degree of certainty the costs we will incur in connection with development of our product candidates. We anticipate that we will make
determinations as to which programs and product candidates to pursue and how much funding to direct to each program and product candidate on an ongoing basis
in response to the results of ongoing and future clinical trials, regulatory developments, and our ongoing assessments as to each current or future product candidate’s
commercial potential. We may need to raise substantial additional capital in the future to complete the development of and, if approved, commercialize, our product
candidates. We may enter into collaborative agreements in the future in order to conduct clinical trials and gain regulatory approval of our product candidates,
particularly in markets outside of the United States. We cannot forecast which programs or product candidates may be subject to future collaborations, when such
arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and overall capital requirements.
65
The costs of clinical trials may vary significantly over the life of a program owing to the following:
•
•
•
•
•
•
•
•
•
•
•
per patient trial costs;
the number of sites included in the trials;
the countries in which the trials are conducted;
the length of time required to enroll eligible patients;
the number of patients that participate in the trials;
the number of doses that patients receive;
the drop-out or discontinuation rates of patients;
potential additional safety monitoring or other studies requested by regulatory agencies;
the duration of patient follow-up;
the phase of development of the product candidate; and
the efficacy and safety profile of the product candidate.
Selling, general and administrative expenses
Our selling, general and administrative expenses consist primarily of employee-related expenses, including salaries, benefits, travel and stock-based
compensation expense, as well as other related costs for our employees and consultants in executive, administrative, finance and human resource functions.
Other selling, general and administrative expenses include facility-related costs not otherwise included in research and development, costs associated with
prosecuting and maintaining our patent portfolio and corporate legal expenses, costs required for public company activities and infrastructure necessary for
the general conduct of our business, and OTIPRIO product support expenses and profit-sharing fees payable to our co-promotion partners, which are reduced
by payments received from them.
We expect our selling, general and administrative expenses to be substantial as we support development of our product candidates, and as we incur
ongoing expenses related to audit, legal, regulatory, and tax-related services associated with maintaining compliance with stock exchange listing and SEC
requirements, directors’ and officers’ liability insurance premiums, and investor relations-related expenses.
Other Income (Expense)
Other income (expense) primarily consists of interest income earned on cash and cash equivalents and short-term investments and interest expense
related to our long-term debt and finance leases.
Critical Accounting Policies and Significant Judgments and Estimates
Our financial statements are prepared in accordance with generally accepted accounting principles in the United States of America. The preparation
of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses and the
disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and assumptions, including those
related to net product sales, accrued expenses and stock-based compensation. We base our estimates on our historical experience, known trends and events,
and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the
carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different
assumptions or conditions.
While our significant accounting policies are described in more detail in Note 2 to our financial statements appearing elsewhere in this Annual Report
on Form 10-K, we believe that the following accounting policies are most critical to the judgments and estimates used in the preparation of our financial
statements.
66
Leases
Right-of-use (ROU) assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the
lease term at commencement date. The discount rate implicit within our leases is generally not determinable, therefore, we use a collateralized incremental
borrowing rate based on the information available at commencement date, including lease term, in determining the present value of future payments. We
estimated our collateralized incremental borrowing rate at January 1, 2019 to be 10.0% based on the remaining term of our operating leases and available
interest rates. The below table summarizes the differences in our ROU assets and operating lease liabilities had we utilized an incremental borrowing rate of
9.0% or 11.0% on January 1, 2019 (in thousands, except percentages). Neither change in estimate would have a material impact on our statements of
operations, comprehensive loss and cash flows.
Interest rate increase from 10.0% to 11.0%
Right-of-use assets
Operating lease liabilities
Interest rate decrease from 10.0% to 9.0%
Right-of-use assets
Operating lease liabilities
Stock-based Compensation
Actual
$ Change
Revised
Estimate
% Change
$
$
16,715 $
19,754
(752) $
(752)
15,963
19,002
16,715 $
19,754
795 $
795
17,510
20,549
-4.5%
-3.8%
4.8%
4.0%
We recognize non-cash expense for the fair value of all stock options and other share-based awards. We use the Black-Scholes-Merton option
valuation model to calculate the fair value of stock options, using the single-option award approach and straight-line attribution method. For options granted
to employees and directors, we recognize the resulting fair value as expense on a straight-line basis over the vesting period of each respective stock option,
generally four years.
We have granted stock options that vest upon achievement of certain performance criteria, or Performance Awards. For performance-based awards to
employees, (i) the fair value of the award is determined on the grant date, (ii) we assess the probability of the individual performance milestones under the
award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management
believes the performance criteria is probable of being met.
In January 2018, we completed an option exchange program (Option Exchange) which allowed eligible employees to exchange certain outstanding
stock options (Eligible Options), whether vested or unvested, with an exercise price greater than $12.00 per share, for new stock options. These new options
vest over one to three years, subject to the terms of the Option Exchange and expire eight years from the date of grant. We determined this Option Exchange
was an option modification. The exchange of these stock options was treated as a modification for accounting purposes. The difference in the fair value of the
canceled options immediately prior to the cancellation and the fair value of the modified options resulted in incremental value, of approximately $0.6 million,
which was calculated using the Black-Scholes-Merton option pricing model. Total stock-based compensation expense to be recognized over the requisite
service period is equal to the remaining unrecognized expense for the exchanged option, as of the exchange date, plus the incremental value of the
modification to the award.
Clinical Trial Expense Accruals
As part of the process of preparing our financial statements, we estimate expenses resulting from our obligations under contracts with vendors, CROs
and consultants and under clinical site agreements in connection with conducting clinical trials. The financial terms of these contracts vary and may result in
payment flows that do not match the periods over which materials or services are provided under such contracts.
67
Our objective is to reflect the appropriate trial expenses in our financial statements by recording those expenses in the period in which services are
performed and efforts are expended. We account for these expenses according to the progress of the trial as measured by patient progression and the timing of
various aspects of the trial. We determine accrual estimates through financial models taking into account discussion with applicable personnel and outside
service providers as to the progress of trials. During the course of a clinical trial, we adjust the clinical expense recognition if actual results differ from our
estimates. We make estimates of accrued expenses as of each balance sheet date based on the facts and circumstances known at that time. Our clinical trial
accruals are dependent upon accurate reporting by CROs and other third-party vendors. Although we do not expect our estimates to differ materially from
amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may
vary and may result in reporting amounts that are too high or too low for any particular period. For the years ended December 31, 2019, 2018 and 2017 there
were no material adjustments to our prior period estimates of accrued expenses for clinical trials.
Recent Accounting Pronouncements
See Note 2 to our financial statements included in Part II, Item 8, “Financial Statements,” of this Annual Report on Form 10-K for a description of
recent accounting pronouncements applicable to our business.
Other Information
Net Operating Loss and Research and Development Tax Credit Carryforwards
As of December 31, 2019, we had federal and state NOLs of $337.4 million and $131.7 million, respectively. Of the federal NOLs, approximately
$96.8 million were generated after January 1, 2018, and therefore do not expire. Federal net operating losses that occur after January 1, 2018 are subject to a
taxable income limitation of 80%. Our remaining federal and state NOLs will begin to expire in 2030, unless we utilize them beforehand. As of December 31,
2019, we also had federal and California research and development tax credit carryforwards of $10.9 million and $5.0 million, respectively. The federal
research and development tax credit carryforwards will begin expiring in 2030 unless we utilize them beforehand. The California research tax credit will carry
forward indefinitely.
Pursuant to the Code, Sections 382 and 383, our annual use of our NOLs and research and development tax credit carryforwards may be limited in
the event that a cumulative change in ownership of more than 50% occurs within a three-year period. We have determined that we have experienced
ownership changes in the past. We have reduced our deferred tax assets related to our NOLs and federal research and development tax credit carryforwards
that we expect to expire unused as a result of these ownership changes. We have excluded these tax attributes from our deferred tax assets with a
corresponding reduction of the valuation allowance with no net effect on our income tax expense or our effective tax rate. The California research tax credits
were not limited because these credits carry forward indefinitely. Future ownership changes as a result of shifts in our stock ownership may further limit our
ability to utilize our remaining NOLs and research and development tax credit carryforwards.
As of December 31, 2019, we had a full valuation allowance against our net deferred tax assets.
Reduced Reporting Requirements
Section 107 of the JOBS Act provides that an “emerging growth company” can take advantage of the extended transition period provided in
Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay
the adoption of certain accounting standards until those standards would otherwise apply to private companies. Until December 31, 2019, when we ceased
being an “emerging growth company,” we elected not to avail ourselves of this extended transition period and, as a result, we adopted new or revised
accounting standards on the relevant dates on which adoption of such standards was required for other public companies.
68
Subject to certain conditions set forth in the JOBS Act, as we are no longer an “emerging growth company,” we are subject to certain additional
requirements, including without limitation, (i) providing an auditor’s attestation report on our system of internal controls over financial reporting pursuant to
Section 404(b) of the Sarbanes-Oxley Act and (ii) complying with any requirement that may be adopted by the Public Company Accounting Oversight Board
regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements,
known as the auditor discussion and analysis.
Results of Operations
Comparison of the Years Ended December 31, 2019 and 2018
The following table sets forth the significant components of our results of operations for the years ended December 31, 2019 and 2018 (in thousands):
Research and development
Selling, general and administrative
Years Ended December 31,
2018
2019
32,805
11,690
31,844
20,008
Change
961
(8,318)
Research and development expenses. The increase of $1.0 million in research and development expenses resulted from a number of activities
including: (i) a $2.5 million increase in OTIVIDEX clinical trial and development costs related to the Phase 3 trial initiated in the third quarter of 2018; (ii) a
$0.7 million increase in OTO-313 clinical trial and development costs related to the Phase 1/2 trial initiated in the second quarter of 2019; and (iii) an increase
of $0.5 million in other research and development costs, including professional services. These increases were partially offset by: (i) a decrease of $0.7
million in clinical trial and development costs for our OTO-413 hearing loss program; and (ii) $2.0 million net decrease in personnel costs, including stock-
based compensation expense associated with the Option Exchange in 2018.
Selling, general and administrative expenses. The decrease of $8.3 million in selling, general and administrative expenses was a result of a $5.3
million reduction in personnel costs, primarily due to a decrease in stock-based compensation expense associated with the Option Exchange in 2018, and a
$3.0 million decrease in outside service expense as a result of OTIPRIO cost reimbursement recognized from our co-promotion partners in 2019.
Comparison of the Years Ended December 31, 2018 and 2017
The following table sets forth the significant components of our results of operations for the years ended December 31, 2018 and 2017 (in thousands):
Research and development
Selling, general and administrative
Years Ended December 31,
2017
2018
31,844
20,008
42,701
46,838
Change
(10,857)
(26,830)
Research and development expenses. The decrease of $10.9 million in research and development expenses resulted from decreased spending for a
number of activities including: (i) a net $10.5 million decrease in OTIVIDEX clinical trial and development costs due to the completion and early termination
of our OTIVIDEX clinical trials in 2017, which was partially offset by an increase in clinical trial costs from the OTIVIDEX Phase 3 trial initiated in the third
quarter of 2018; (ii) a $2.2 million decrease in OTIPRIO related expenses mainly due to costs incurred in 2017 related to filing our OTIPRIO supplemental
New Drug Application for AOE; (iii) a decrease of $2.6 million in other research and development costs, including professional services; and (iv) a $1.7
million decrease in personnel costs, including stock-based compensation expense, due to a reduction in headcount. These decreases were partially offset by:
(i) an increase of $4.3 million in research costs for our OTO-413 hearing loss program; and (ii) a $1.8 million increase in research costs for our OTO-313
tinnitus program.
69
Selling, general and administrative expenses. The decrease of $26.8 million in selling, general and administrative expenses was primarily related to
reduced personnel costs, including stock-based compensation expense, of approximately $18.1 million, resulting primarily from reductions in commercial
headcount during 2017 and 2018, and a $8.7 million decrease in outside services and other operating expenses for OTIPRIO promotional support.
Liquidity and Capital Resources
We have incurred significant losses and negative cash flows from operations since our inception. As of December 31, 2019, we had an accumulated
deficit of $459.9 million and we expect to continue to incur significant losses for the foreseeable future. We expect our research and development and selling,
general and administrative expenses to continue to be substantial for the foreseeable future and, as a result, we will need additional capital to fund our
operations, which we may obtain through one or more public or private equity or debt financings, or other sources such as potential collaboration
arrangements.
As of December 31, 2019, we had cash, cash equivalents and short-term investments of $60.7 million. We have principally financed our operations
through sales and issuances of our equity securities, debt financing as well as private placements of redeemable convertible preferred stock and convertible
notes.
The following table sets forth a summary of the primary sources and uses of cash for the years ended December 31, 2019, 2018 and 2017 (in
thousands):
Net cash (used in) provided by:
Operating activities
Investing activities
Financing activities
Net (decrease) increase in cash, cash equivalents
and restricted cash
2019
Years Ended December 31,
2018
2017
$
(36,925) $
28,296
195
(38,434) $
37,984
15,165
(75,307)
68,998
1,070
$
(8,434) $
14,715 $
(5,239)
Operating activities. The primary uses of cash were to fund increased levels of development activities for our product candidates and to support the
commercialization of OTIPRIO. We expect to continue the use of cash for development of our product candidates for the foreseeable future.
Net cash used in operating activities was $36.9 million in 2019 compared to $38.4 million in 2018. The decrease in the utilization of cash was
primarily due to a decrease in operating losses compared to the prior year. Net cash used in operating activities was $38.4 million in 2018 compared to $75.3
million in 2017. The $36.9 million decrease in the utilization of cash was primarily due to a decrease in operating losses compared to the prior year.
Investing activities. The primary source of cash from investing activities was from maturities of short-term investments and the primary use of cash
from investing activities was for purchases of short-term investments and capital expenditures.
Net cash provided by investing activities was $28.3 million in 2019 compared to net cash provided of $38.0 million in 2018 and net cash provided
of $69.0 million in 2017. The decrease in net cash provided by investing activities in 2019 compared to 2018 was primarily due to net maturities of short-term
investments used to fund operations. The decrease in net cash provided by investing activities in 2018 compared to 2017 was primarily due to net maturities
of short-term investments used to fund operations.
Financing activities. The primary source of net cash provided by financing activities were net proceeds from debt and net proceeds from the sale of
our common stock.
70
Net cash provided by financing activities was $0.2 million in 2019 compared to $15.2 million in 2018 and $1.1 million in 2017. Net cash provided by
financing activities in 2019 consisted of $0.2 million in net proceeds for shares issued for stock option exercises and under our employee stock purchase plan.
Net cash provided by financing activities in 2018 consisted primarily of net proceeds of $14.8 million from a loan and $0.4 million in net proceeds for shares
issued for stock option exercises and under our employee stock purchase plan. Net cash provided by financing activities in 2017 consisted of $1.1 million in
net proceeds for shares issued for stock option exercises and under our employee stock purchase plan.
At the Market Offering Program
In August 2019, we entered into a sales agreement (Sales Agreement) with Cowen to sell shares of our common stock having aggregate sales
proceeds of up to $40.0 million, from time to time, through an “at the market” equity offering program under which Cowen will act as sales agent or
principal. Under the Sales Agreement, we set the parameters for the sale of shares, including the number or dollar value of shares to be issued, the time period
during which sales are requested to be made, limitation on the number of shares that may be sold in any one trading day and any minimum price below which
sales may not be made. The Sales Agreement provides that Cowen will be entitled to compensation for its services that will equal 3.0% of the gross sales
price per share of all shares sold through Cowen under the Sales Agreement. The Sales Agreement shall automatically terminate upon the issuance and sale of
placement shares equaling sales proceeds of $40.0 million and may be terminated earlier by either us or Cowen upon five days’ notice. We have no obligation
to sell any shares under the Sales Agreement and may at any time suspend solicitation and offers under the Sales Agreement. Through December 31, 2019,
we have not sold any shares under the Sales Agreement.
Long-Term Debt
Oxford Loan
On December 31, 2018 (the Closing Date), we entered into a Loan and Security Agreement with Oxford Finance LLC (the Loan Agreement). The
Loan Agreement provides for a $15.0 million secured term loan credit facility (the Term Loan). The proceeds of the Term Loan may be used for working
capital and general corporate purposes. We have the right to prepay the Term Loan in whole or in part at any time, subject to a prepayment fee of 3.00% if
prepaid on or prior to the first anniversary of the Closing Date, 2.00% if prepaid after the first anniversary of the Closing Date and on or prior to the second
anniversary of the Closing Date, and 1.00% thereafter. Amounts prepaid or repaid under the Term Loan may not be reborrowed. The Term Loan was fully
funded on the Closing Date and matures on December 1, 2023 (the Maturity Date). We paid a facility fee of 0.75% and customary closing fees on the Closing
Date.
The Term Loan bears interest at a floating rate equal to the greater of 5.25% and the prime rate as reported in the Wall Street Journal from time to
time, plus 3.75% (9.0% as of December 31, 2019, the minimum interest rate). Interest on the Term Loan is payable monthly in arrears. We are permitted to
make interest-only payments on the Term Loan for the twenty-four (24) months following the Closing Date followed by consecutive equal monthly payments
of principal and interest in arrears through the Maturity Date. The interest-only period can be extended by an additional twelve (12) months subject to the
achievement of a certain clinical trial milestone. The outstanding principal amount of the Term Loan, together with accrued and unpaid interest, is due on
December 1, 2023. The net outstanding Term Loan balance was $15.0 million as of December 31, 2019.
Upon repayment or acceleration of the Term Loan, a final payment fee equal to 4.00% of the aggregate original principal amount of the Term Loan is
payable (the Final Payment). The Final Payment of $0.6 million, as well as the initial facility fee and all other direct fees and costs associated with the Loan
Agreement, was recognized as a debt discount. The debt discount will be amortized to interest expense over the term of the Loan Agreement using the
effective interest method.
Our obligations under the Loan Agreement are secured by substantially all of our assets, excluding intellectual property and subject to certain other
exceptions and limitations.
71
The Loan Agreement contains customary affirmative covenants, including covenants regarding compliance with applicable laws and regulations,
reporting requirements, payment of taxes and other obligations, and maintenance of insurance. Further, subject to certain exceptions, the Loan Agreement
contains customary negative covenants limiting our ability to, among other things, sell assets, allow a change of control to occur (if the Term Loan is not
repaid), make acquisitions, incur debt, grant liens, make investments, pay dividends or repurchase stock. Upon the occurrence and during the continuance of
an event of default, the lenders may declare all outstanding principal and accrued and unpaid interest under the Loan Agreement immediately due and
payable, increase the applicable rate of interest by 5.00%, and exercise the other rights and remedies provided for under the Loan Agreement and related loan
documents. The events of default under the Loan Agreement include payment defaults, breaches of covenants or representations and warranties, material
adverse changes, certain bankruptcy events, cross defaults with certain other indebtedness, and judgment defaults.
Funding Requirements
We expect to continue to incur significant losses for the foreseeable future as we: (i) develop and seek regulatory approvals for our product candidates
OTIVIDEX, OTO-313 and OTO-413; and (ii) work to develop additional product candidates through research and development programs. We are subject to
all the risks incident in the development of new therapeutic products, and we may encounter unforeseen expenses, difficulties, complications, delays and other
unknown factors that may adversely affect our business.
We believe that our existing cash and cash equivalents and short-term investments along with the outstanding debt from Oxford Finance LLC will be
sufficient to fund our currently planned operations for a period of at least 12 months from the date of this Annual Report on Form 10‑K.
We will require additional financing to complete the development of and, if approved, commercialize OTIVIDEX, OTO-313, OTO-413 and any other
product candidates. When additional financing is required, we anticipate that we will seek funding through public or private equity or debt financings or other
sources, such as potential collaboration arrangements. We may not be able to raise capital on terms acceptable to us, or at all. If we are unable to raise
additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or
commercialization of one or more of our product candidates. If we raise additional funds through the issuance of additional debt or equity securities, it could
result in dilution to our existing stockholders, increased fixed payment obligations and the existence of securities with rights that may be senior to those of our
common stock. If we incur indebtedness, we could become subject to covenants that would restrict our operations and potentially impair our competitiveness,
such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating
restrictions that could adversely impact our ability to conduct our business. Any collaboration agreements we enter into may provide capital in the near-term
but limit our potential cash flow and revenue in the future. Any of the foregoing could significantly harm our business, financial condition and prospects.
Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement
and involves risks and uncertainties, and actual results could vary as a result of a number of factors. We have based this estimate on assumptions that may
prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. The amount and timing of future funding
requirements, both near- and long-term, will depend on many factors, including:
•
•
•
•
the revenue generated by OTIPRIO and our product candidates, if approved;
the costs related to manufacturing commercial supplies of OTIPRIO;
the timing and costs of completing the remaining clinical development and obtaining regulatory approval for OTIVIDEX in Ménière’s
disease;
the design, initiation, progress, size, timing, costs and results of nonclinical studies and clinical trials for our other product candidates,
including OTO-313 and OTO-413;
72
•
•
•
•
•
•
•
•
•
•
•
the outcome, timing and cost of regulatory approvals by the FDA and comparable foreign regulatory authorities, including the potential for
the FDA or comparable foreign regulatory authorities to require that we perform more studies than, or evaluate clinical endpoints other than,
those that we currently expect;
the timing and costs associated with manufacturing our product candidates for clinical trials, nonclinical studies and for commercial sale;
the cost of building and maintaining sales, marketing and distribution capabilities for any products for which we may receive regulatory
approval and commercialize, including related facilities expansion costs;
the number and characteristics of product candidates that we pursue;
the potential acquisition and in-licensing of other technologies, products or assets;
the extent to which we are required to pay milestone or other payments under our in-license agreements and the timing of such payments;
the cost of preparing, filing, prosecuting, maintaining, defending and enforcing any patent claims and other intellectual property rights,
including litigation costs and the outcome of such litigation;
our need to expand our development activities, including our need and ability to hire and adequately compensate additional employees;
the costs associated with being a public company;
the effect of competing technological and market developments; and
the cost of litigation, including potential patent litigation.
If we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, financial
condition and results of operations could be materially adversely affected.
Off-Balance Sheet Arrangements
During the periods presented we did not have, nor do we currently have, any off-balance sheet arrangements as defined under the applicable rules of
the SEC.
Item 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
As a “smaller reporting company” as defined in Rule 12b-2 of the Securities Exchange Act of 1934, as amended, we are not required to provide the
information required by this item.
73
Item 8. FINANCIAL STATEMENTS
Otonomy, Inc.
Index to Financial Statements
Report of Independent Registered Public Accounting Firm
Balance Sheets
Statements of Operations
Statements of Comprehensive Loss
Statements of Stockholders’ Equity
Statements of Cash Flows
Notes to Financial Statements
74
Page
75
76
77
78
79
80
81
Report of Independent Registered Public Accounting Firm
The Board of Directors and Stockholders of Otonomy, Inc.
Opinion on the Financial Statements
We have audited the accompanying balance sheets of Otonomy, Inc. (the “Company”) as of December 31, 2019 and 2018, the related statements of
operations and comprehensive loss, stockholders’ equity, and cash flows, for each of the three years in the period ended December 31, 2019 and the related
notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial
position of the Company at December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended
December 31, 2019, in conformity with U.S. generally accepted accounting principles.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the
Company’s internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control—Integrated Framework issued
by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February 27, 2020 expressed an
unqualified opinion thereon.
Adoption of ASU No. 2016-02
As discussed in Note 2 to the financial statements, the Company changed its method of accounting for leases in 2019 due to the adoption of
Accounting Standards Update (ASU) No. 2016-02, Leases (Topic 842), and the related amendments.
Basis for Opinion
These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s
financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the
Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the
PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing
procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to
those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also
included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the
financial statements. We believe that our audits provide a reasonable basis for our opinion.
/s/ Ernst & Young LLP
We have served as the Company’s auditor since 2010.
San Diego, California
February 27, 2020
75
Otonomy, Inc.
Balance Sheets
(in thousands, except share and per share data)
Assets
Current assets:
Cash and cash equivalents
Short-term investments
Accounts receivable, net
Prepaid and other current assets
Total current assets
Restricted cash
Property and equipment, net
Right-of-use assets
Other long-term assets
Total assets
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable
Accrued expenses
Accrued compensation
Leases, current
Deferred rent, current
Total current liabilities
Long-term debt, net
Leases, net of current
Deferred rent, net of current
Total liabilities
Commitments and Contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000,000 shares authorized at
December 31, 2019 and 2018; no shares issued or outstanding at
December 31, 2019 and 2018
Common stock, $0.001 par value; 200,000,000 shares authorized at
December 31, 2019 and 2018; 30,814,211 and 30,685,412 shares issued
and outstanding at December 31, 2019 and 2018, respectively
Additional paid-in capital
Accumulated other comprehensive income (loss)
Accumulated deficit
Total stockholders’ equity
Total liabilities and stockholders’ equity
See accompanying notes.
76
December 31,
2019
2018
$
$
$
25,194
35,476
48
2,432
63,150
701
3,702
15,465
—
83,018
1,161
5,442
2,593
3,302
—
12,498
14,967
15,320
—
42,785
33,633
63,651
108
2,677
100,069
696
3,996
—
231
104,992
1,029
3,788
2,635
—
38
7,490
14,764
—
3,001
25,255
—
—
31
500,084
11
(459,893)
40,233
83,018
$
31
494,947
(23)
(415,218)
79,737
104,992
$
$
$
$
Otonomy, Inc.
Statements of Operations
(in thousands, except share and per share data)
Product sales, net
Costs and operating expenses:
Cost of product sales
Research and development
Selling, general and administrative
Total costs and operating expenses
Loss from operations
Other income (expense):
Interest income
Interest expense
Total other income, net
Net loss
Net loss per share, basic and diluted
2019
Years Ended December 31,
2018
2017
$
600
$
745
$
1,236
912
32,805
11,690
45,407
(44,807)
1,723
(1,591)
132
(44,675)
946
31,844
20,008
52,798
(52,053)
1,689
(4)
1,685
(50,368)
$
(1.45) $
(1.65) $
3,098
42,701
46,838
92,637
(91,401)
1,271
—
1,271
(90,130)
(2.97)
Weighted-average shares used to compute net loss per share, basic
and diluted
30,726,786
30,610,244
30,304,158
See accompanying notes.
77
Otonomy, Inc.
Statements of Comprehensive Loss
(in thousands)
Net loss
Other comprehensive loss:
Unrealized gain (loss) on available-for-sale securities
Comprehensive loss
2019
Years Ended December 31,
2018
2017
(44,675) $
(50,368) $
(90,130)
34
(44,641) $
77
(50,291) $
(59)
(90,189)
$
$
See accompanying notes.
78
Otonomy, Inc.
Statements of Stockholders’ Equity
(in thousands, except share data)
Balance at December 31, 2016
30,255,339
$
30
$
467,468
$
(41 )
$
(274,720 )
$
192,737
Common Stock
Shares
Amount
Additional
Paid-in
Capital
Accumulated
Other
Comprehensive
Loss
Accumulated
Deficit
Total
Stockholders’
Equity
Issuance of common stock upon exercise
of stock options
Issuance of common stock under
employee stock purchase plan
Issuance of common stock upon exercise
of warrants
Stock-based compensation expense
Net loss
Unrealized loss on available-for-sale securities
Balance at December 31, 2017
Issuance of common stock upon exercise
of stock options
Issuance of common stock under
employee stock purchase plan
Stock-based compensation expense
Net loss
Unrealized gain on available-for-sale securities
Balance at December 31, 2018
Issuance of common stock upon exercise
of stock options
Issuance of common stock under
employee stock purchase plan
Stock-based compensation expense
Net loss
Unrealized gain on available-for-sale securities
Balance at December 31, 2019
191,106
80,072
32,209
—
—
—
30,558,726
18,800
107,886
—
—
—
30,685,412
2,912
125,887
—
—
—
30,814,211
$
1
—
—
—
—
—
31
—
—
—
—
—
31
—
—
—
—
—
31
$
447
622
—
13,661
—
—
482,198
32
303
12,414
—
—
494,947
5
242
4,890
—
—
500,084
$
—
—
—
—
—
(59 )
(100 )
—
—
—
—
77
(23 )
—
—
—
—
34
11
$
—
—
—
—
(90,130 )
—
(364,850 )
—
—
—
(50,368 )
—
(415,218 )
—
—
—
(44,675 )
—
(459,893 )
$
448
622
—
13,661
(90,130 )
(59 )
117,279
32
303
12,414
(50,368 )
77
79,737
5
242
4,890
(44,675 )
34
40,233
See accompanying notes.
79
Otonomy, Inc.,
Statements of Cash Flows
(in thousands)
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating
activities:
Depreciation
Stock-based compensation
Reserve for excess and obsolete inventory
(Accretion of discounts) amortization of premiums on short-term investments
Amortization of debt discount
Impairment of property, plant and equipment
Deferred rent
Changes in operating assets and liabilities:
Accounts receivable, net
Prepaid and other assets
Accounts payable
Accrued expenses
Accrued compensation
Right-of-use assets and lease liabilities, net
Net cash used in operating activities
Cash flows from investing activities:
Purchases of short-term investments
Maturities of short-term investments
Purchases of property and equipment
Net cash provided by investing activities
Cash flows from financing activities:
Proceeds from issuance of long-term debt, net of cash issuance costs
Proceeds from issuance of common stock
Proceeds from exercise of stock options
Payments of debt issuance costs
Net cash provided by financing activities
Net change in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Cash and cash equivalents at end of period
Restricted cash at end of period
Cash, cash equivalents and restricted cash at end of period
Supplemental cash flow information:
Cash paid for interest
Supplemental disclosure of non-cash investing and financing activities:
Purchase of property and equipment in accounts payable and
accrued expenses
Debt issuance costs in accounts payable and accrued expenses
Debt issuance costs
Years Ended December 31,
2019
2018
2017
$
(44,675) $
(50,368) $
(90,130)
1,149
4,890
—
(787)
189
—
—
60
476
127
1,656
(42)
32
(36,925)
(85,004)
114,000
(700)
28,296
—
242
5
(52)
195
(8,434)
34,329
25,895
$
25,194
701
25,895
$
$
1,186
12,414
—
(506)
—
—
103
(1)
(492)
68
(166)
(672)
—
(38,434)
(104,270)
142,750
(496)
37,984
14,830
303
32
—
15,165
14,715
19,614
34,329
33,633
696
34,329
$
$
$
1,289
13,661
1,546
358
—
400
2,272
(16)
2,761
(398)
(5,518)
(1,532)
—
(75,307)
(129,308)
199,565
(1,259)
68,998
—
448
622
—
1,070
(5,239)
24,853
19,614
18,456
1,158
19,614
1,394
$
4
$
—
76
—
—
$
$
$
7
66
771
$
$
$
132
—
—
$
$
$
$
$
$
$
See accompanying notes.
80
Otonomy, Inc.,
Notes to Financial Statements
1. Description of Business and Basis of Presentation
Description of Business
Otonomy, Inc. (Otonomy or the Company) was incorporated in the state of Delaware on May 6, 2008. Otonomy is a biopharmaceutical company
dedicated to the development of innovative therapeutics for neurotology. The Company pioneered the application of drug delivery technology to the ear in
order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is
being utilized to develop a pipeline of products addressing important unmet medical needs including Ménière’s disease, hearing loss and tinnitus.
OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone that has completed two Phase 3 trials for the treatment of Ménière’s
disease, with a third Phase 3 trial currently enrolling patients. OTO-313 is a sustained-exposure formulation of the potent and selective N-Methyl-D-Aspartate
(NMDA) receptor antagonist gacyclidine that is currently enrolling tinnitus patients in a Phase 1/2 clinical trial. OTO-413 is a sustained-exposure formulation
of brain-derived neurotrophic factor (BDNF) for the repair of cochlear synaptopathy, an underlying cause of hearing loss, that is currently enrolling hearing
loss patients in a Phase 1/2 clinical trial. Otonomy also has preclinical stage programs addressing prevention of cisplatin-induced hearing loss (OTO-510) and
hair cell regeneration for severe hearing loss (OTO-6XX). In October 2019, the Company entered into a collaboration with Applied Genetic Technologies
Corporation (AGTC), to co-develop and co-commercialize a gene therapy to restore hearing in patients with congenital hearing loss.
In addition, the Company developed, received United States Food and Drug Administration (FDA) approval and commercially launched OTIPRIO
for use during tympanostomy tube placement (TTP) surgery in pediatric patients. OTIPRIO was also approved by the FDA for the treatment of acute otitis
externa (AOE).
Basis of Presentation
The financial statements have been prepared assuming the Company will continue as a going concern, which contemplates the realization of assets
and the satisfaction of liabilities in the normal course of business. The Company has incurred operating losses and negative cash flows from operating
activities since inception. As of December 31, 2019, the Company had cash, cash equivalents and short-term investments of $60.7 million and an accumulated
deficit of $459.9 million. The Company anticipates that it will continue to incur net losses into the foreseeable future as it: (i) develops and seeks regulatory
approvals for OTIVIDEX and its other product candidates; and (ii) works to develop additional product candidates through research and development
programs. When additional financing is required, the Company anticipates that it will seek additional funding through future debt and/or equity financings or
other sources, such as potential collaboration agreements. If the Company is not able to secure adequate additional funding, if or when necessary, the
Company may be forced to make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail
planned programs. Any of these actions could materially harm the Company’s business, results of operations, and future prospects.
2. Summary of Significant Accounting Policies
Use of Estimates
The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP).
The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts
of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of product sales and
expense during the reporting period. Although these estimates are based on the Company’s knowledge of current events and anticipated actions it may
undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.
81
Segment Reporting
Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by
the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations and
manages its business in one operating segment.
Concentrations of Credit Risk
Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and
short-term investments. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not
experienced any losses in such accounts and believes it is not exposed to significant risk on its cash balances due to the financial position of the depository
institution in which those deposits are held. Additionally, the Company established guidelines regarding approved investments and maturities of investments,
which are designed to maintain safety and liquidity.
Cash, Cash Equivalents and Restricted Cash
Cash and cash equivalents consist of cash and highly liquid investments with original maturities of three months or less at the date of purchase. The
carrying amounts approximate fair value due to the short maturities of these instruments. Cash and cash equivalents include cash in readily available
checking, savings and money market accounts.
The Company’s restricted cash consists of cash maintained in separate deposit accounts to secure a letter of credit issued by a bank to the landlord
under a lease agreement for the Company’s corporate headquarters.
Short-term Investments
The Company carries short-term investments classified as available-for-sale debt securities at fair value as determined by prices for identical or
similar securities at the balance sheet date. Short-term investments consist of Level 1 financial instruments in the fair value hierarchy (see Note 9 – Fair
Value).
Realized gains or losses of available-for-sale securities are determined using the specific identification method and net realized gains and losses are
included in interest income. The Company periodically reviews available-for-sale securities for other-than-temporary declines in fair value below the cost
basis, and whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company records
unrealized gains and losses on available-for-sale debt securities as a component of other comprehensive loss within the statements of comprehensive loss and
as a separate component of stockholders’ equity on the balance sheets. The Company does not hold equity securities in its investment portfolio.
Fair Value of Financial Instruments
The Company’s financial instruments include cash, cash equivalents, short-term investments, prepaid expenses and other assets, accounts payable,
accrued expenses, accrued compensation and long-term debt. The carrying value of the Company’s cash and cash equivalents, short-term investments, prepaid
expenses and other current assets, other long-term assets, accounts payable, accrued expenses, and accrued compensation approximate fair value due to the
short-term nature of these items. Based on Level 3 inputs and the borrowing rates currently available for loans with similar terms, the Company believes the
fair value of long-term debt approximates its carrying value.
Accounts Receivable, net
Accounts receivable are recorded net of customer allowances for chargebacks, distributor fees and any allowance for doubtful accounts. The
Company estimates the allowance for doubtful accounts based on existing contractual payment terms, actual payment patterns of its customers and individual
customer circumstances. To date, the Company has determined that an allowance for doubtful accounts is not required.
82
Inventory
Inventory, which is recorded at the lower of cost or net realizable value. Cost is determined on a first-in, first-out method. Inventories consist of
OTIPRIO finished goods and work in-process, as well as raw materials used in the manufacture of OTIPRIO. If inventory costs exceed expected market value
due to obsolescence, expiry or quantities in excess of expected demand, write downs are recorded for the difference between cost and market value, less cost
to sell. During the year ended December 31, 2017, the Company recorded an inventory write down of $1.5 million to cost of product sales. During 2018 and
2019, no such write downs were recorded.
Property and Equipment
Property and equipment generally consist of manufacturing equipment, office furniture and equipment, computers, and scientific equipment and are
recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets (generally two to ten years). Leasehold
improvements are recorded at cost and are depreciated on a straight-line basis over the lesser of the remaining term of the related lease or the estimated useful
lives of the assets. Repairs and maintenance costs are charged to expense as incurred.
Impairment of Long-Lived Assets
The Company assesses the value of its long-lived assets for impairment on an annual basis and whenever events or changes in circumstances and the
undiscounted cash flows generated by those assets indicate that the carrying amount of such assets may not be recoverable. While the Company’s current and
historical operating losses and negative cash flows are indicators of impairment, the Company believes that future cash flows to be received support the
carrying value of its long-lived assets. No impairment of long-lived assets was recorded during the years ended December 31, 2019 and 2018. During the year
ended December 31, 2017, the Company recorded an impairment of its long-lived assets of approximately $0.4 million in cost of product sales related to
OTIPRIO manufacturing equipment.
Right-of-Use Assets and Lease Liabilities
Effective January 1, 2019, as required by Accounting Standards Update (ASU) No. 2016-02, Leases (ASU 2016-02), the Company adopted
Accounting Standards Codification (ASC) 842, Leases (ASC 842), using a modified retrospective method as of the adoption date. Consequently, financial
information will not be updated, and the disclosures required under ASU 2016-02 will not be provided for dates and periods prior to January 1, 2019. ASC
842 supersedes nearly all previously existing lease guidance under GAAP and requires lessees to recognize leases on the balance sheet and disclose key
information about leasing arrangements.
ASC 842 establishes a right-of-use (ROU) model that requires a lessee to recognize an ROU asset and lease liability on the balance sheet for all
leases with a term longer than 12 months. ASU 2016-02 provides a number of optional practical expedients and accounting policy elections. The Company
elected the package of practical expedients requiring no reassessment of whether any expired or existing contracts are or contain leases, the lease
classification of any expired or existing leases, or initial direct costs for any existing leases.
The adoption of ASC 842 had a material effect on the Company’s balance sheets; however, it did not have a material effect on its statements of
operations, comprehensive loss and cash flows. Upon adoption of ASC 842 as of January 1, 2019, the Company recognized (i) ROU assets of $16.7 million,
net of $3.0 million of deferred rent, and (ii) lease liabilities of $19.7 million.
The Company has operating leases for its facility and certain equipment and finance leases for certain computer equipment. Effective January 1,
2019, the Company determines if an arrangement is or contains a lease at the commencement date. Operating leases are included in ROU assets, Leases,
current, and Leases, net of current on the balance sheets. Finance leases are included in Property and equipment, Leases, current, and Leases, net of current on
the balance sheets. The Company elected not to recognize short-term leases (one year or less) on the balance sheets.
83
ROU assets and operating lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at the
commencement date. When the implicit rate of the lease is not provided or cannot be determined, the Company uses a collateralized incremental borrowing
rate based on the information available at the commencement date, including lease term, in determining the present value of future payments. The Company
considers payments for common area maintenance, real estate taxes and management fees to be variable non-lease components, which are expensed as
incurred. Lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise that option. Lease expense
for minimum lease payments is recognized on a straight-line basis over the lease term.
Clinical Trial Expense Accruals
As part of the process of preparing the Company’s financial statements, the Company is required to estimate expenses resulting from the Company’s
obligations under contracts with vendors, contract research organizations (CROs) and consultants and under clinical site agreements in connection with
conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment
flows that do not match the periods over which materials or services are provided under such contracts.
The Company’s objective is to reflect the appropriate clinical trial expenses in its financial statements by recording those expenses in the period in
which services are performed and efforts are expended. The Company accounts for these expenses according to the progress of the trial as measured by
patient progression and the timing of various aspects of the trial. The Company determines accrual estimates through financial models taking into account
discussion with applicable personnel and outside service providers as to the progress or state of its trials. During the course of a clinical trial, the Company
adjusts its clinical expense if actual results differ from its estimates.
Revenue Recognition
Effective January 1, 2018, the Company adopted ASC Topic 606, Revenue from Contracts with Customers (ASC 606), using the full retrospective
approach. The Company’s accounting for revenue under ASC 606 is materially consistent with the accounting for revenue under ASC 605, Revenue
Recognition, and therefore the cumulative effect of adoption was immaterial.
To recognize revenue the Company performs the following five steps: (i) identify the contract(s) with a customer, (ii) identify the performance
obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v)
recognize revenue when (or as) the Company satisfies a performance obligation. The Company only applies the five-step model to arrangements that meet the
definition of a contract with a customer under ASC 606 and when it is probable the Company will collect the consideration exchanged for the goods or
services transferred to the customer. At contract inception, the Company assesses the goods or services promised within each contract and determines those
that are performance obligations, and then it assesses whether each promised good or service is distinct. The Company recognizes as revenue the amount of
the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied.
OTIPRIO is sold to a limited number of specialty wholesale distributors. The Company recognizes revenue when its customers obtain control of
OTIPRIO, typically upon delivery by the Company to these distributors. The Company has determined the delivery of OTIPRIO to its customers constitutes a
single performance obligation and no other performance obligations are present. The Company’s customer contracts have standard payment terms. The
Company does not offer prompt pay discounts or financing on sales and has not identified any credit risk issues.
Hospitals, ambulatory surgery centers and physician offices order OTIPRIO from the Company’s distributors and are the end users of OTIPRIO. The
Company permits product returns from the distributors only if the product is damaged or is shipped or ordered in error. Product returns based on expiry are
not permitted. To date, product returns have been immaterial.
84
Sales commissions and other incremental costs of obtaining customer contracts are expensed as incurred as the amortization periods would be less
than one year or the amount is immaterial.
Transaction Price and Reserves for Variable Consideration
Revenue from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which
reserves are established. Components of variable consideration include trade discounts and allowances, government chargebacks, discounts and rebates and
other fee for service amounts that are detailed within customer contracts relating to the sale of OTIPRIO. These reserves, as detailed below, are based on the
amounts earned or accrued on the Company’s sales. Variable consideration is estimated using the most likely method, which is the single most likely outcome
under the Company’s contracts and takes into consideration contractual fees, historical chargeback activity and historical Medicaid rebates. Overall, these
reserves reflect the Company’s best estimates of the amount of consideration to which the Company is entitled based on the terms of the respective underlying
contracts.
The amount of variable consideration included in the transaction price may be constrained and is included in the net sales price only to the extent that
it is probable a significant reversal in the amount of the cumulative revenue recognized under the contract will not occur in a future period. The Company’s
analyses also contemplate application of the constraint in accordance with the guidance, under which the Company determined a material reversal of revenue
would not occur in a future period. Reserves are established for these discounts and allowances upon delivery of OTIPRIO by the distributor and are
classified as: (i) an allowance against accounts receivable if the amount is payable to the distributor or (ii) an accrued liability if the amount is payable to a
party other than the distributor. Allowances against accounts receivable relate to chargebacks and distributor fees and accruals relate primarily to government
rebates. Actual amounts of consideration ultimately received may differ from the Company’s estimates. If actual results in the future vary from original
estimates, the Company will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.
Trade Discounts and Allowances. The Company’s customers are specialty wholesale distributors with whom the Company has contracted to pay a fee
based on a percentage of wholesale acquisition cost for sales order management, data, and distribution services. The Company determined such services
received to date are not distinct from the sale of products to customers and, therefore, these payments have been recorded as a reduction of revenue within the
statement of operations. This fee for service is recorded as an allowance against accounts receivable at the time of sale based on the contracted percentage.
Chargebacks. The Company estimates allowances against accounts receivable for chargebacks related to agreements with group purchasing
organizations and federal contracts. Under these agreements, the Company credits distributors a chargeback amount which represents the difference between
the wholesale acquisition cost and the discounted price at which eligible purchasers purchased from the distributors. At the time of sale, estimated
chargebacks are recorded based on historical chargeback activity, the projected payer mix, patient population industry data and the identification of entities
purchasing OTIPRIO that are eligible for discounted pricing.
Government Rebates. The Company estimates a rebate liability in connection with a Medicaid Drug Rebate Agreement with the Centers for
Medicare & Medicaid Services, which provides a rebate to participating states based on covered purchases of OTIPRIO. At the time of sale, estimated
Medicaid rebates are recorded based on historical government rebate activity, the projected payer mix and Medicaid patient population industry data.
Concentration of Major Customers
The Company sells OTIPRIO to specialty wholesale distributor customers. The following table summarizes the Company’s sales to its largest
customers for each of the periods presented:
First largest
Second largest
Third largest
2019
2018
2017
38%
33%
24%
44%
33%
21%
34%
34%
30%
85
Collaborative Arrangements
The Company has entered into co-promotion agreements and research agreements that fall under the scope of ASC Topic 808, Collaborative
Arrangements (ASC 808).
Co-promotion agreements can include payments and reimbursements for a proportion of product support expenses to the Company and profit sharing
payments by the Company. Payments to or by the Company are recognized in selling, general and administrative expenses in the statements of operations.
Research agreements can include reimbursements to or by the Company, which are recognized in research and development expenses in the
statements of operations.
Research and Development
Research and development expenses include the costs associated with the Company’s research and development activities, including salaries,
benefits, stock-based compensation expense and occupancy costs. Also included in research and development expenses are third-party costs incurred in
conjunction with contract manufacturing for the Company’s research and development programs and clinical trials, including the cost of clinical trial drug
supply, costs incurred by CROs and regulatory expenses. Research and development costs are expensed as incurred.
Selling, General and Administrative
Selling, general and administrative expenses include the costs associated with the Company’s executive, administrative, finance and human resource
functions including salaries, benefits, stock-based compensation expense and occupancy costs. Other selling, general and administrative expenses include
costs associated with prosecuting and maintaining the Company’s patent portfolio, corporate legal expenses, costs required for public company activities and
infrastructure necessary for the general conduct of the Company’s business. The Company’s selling, general and administrative expenses also include
OTIPRIO product support expenses, and profit-sharing fees payable to the Company’s partners, which are reduced by payments received from the Company’s
partners under its co-promotion agreements.
Stock-Based Compensation
The Company accounts for stock-based compensation expense related to stock options and employee stock purchase plan (ESPP) rights by estimating
the fair value on the date of grant using the Black-Scholes-Merton option pricing model. Forfeitures are recognized as incurred. For awards subject to time-
based vesting conditions, stock-based compensation expense is recognized using the straight-line method. For performance-based awards to employees,
(i) the fair value of the award is determined on the grant date, (ii) the Company assesses the probability of the individual performance milestones under the
award being achieved and (iii) the fair value of the shares subject to the milestone is expensed over the implicit service period commencing once management
believes the performance criteria is probable of being met.
Income Taxes
The accounting guidance for uncertainty in income taxes prescribes a recognition threshold and measurement attribute criteria for the financial
statement recognition and measurement of tax positions taken or expected to be taken in a tax return. For those benefits to be recognized, a tax position must
be more likely than not to be sustained upon examination by taxing authorities based on the technical merits of the position.
The Company uses the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on
the difference between the financial reporting and the tax reporting basis of assets and liabilities and are measured using the enacted tax rates and laws that are
expected to be in effect when the differences are expected to reverse. The Company provides a valuation allowance against net deferred tax assets
86
unless, based upon the available evidence, it is more likely than not that the deferred tax assets will be realized. When the Company establishes or reduces the
valuation allowance against its deferred tax assets, its provision for income taxes will increase or decrease, respectively, in the period such determination is
made.
Comprehensive Loss
Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non-owner
sources.
Net Loss Per Share
Basic net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of
common shares outstanding during the period, without consideration for potentially dilutive securities. Diluted net loss per share is computed by dividing the
net loss attributable to common stockholders by the weighted-average number of common shares and potentially dilutive securities outstanding for the period
determined using the treasury-stock and if-converted methods. For purposes of the diluted net loss per share calculation, potentially dilutive securities are
excluded from the calculation of diluted net loss per share because their effect would be anti-dilutive and therefore, basic and diluted net loss per share were
the same for all periods presented.
As of December 31, 2019, 2018 and 2017, potentially dilutive securities excluded from the calculation of diluted net loss per share consist of
outstanding options to purchase 7,495,129, 5,019,964 and 4,599,252 shares of the Company’s common stock, respectively.
Recent Accounting Pronouncements
Not Yet Adopted
In June 2016, ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (ASU
2016-13) was issued, as amended. ASU 2016-13 introduces the current expected credit loss model, which will require an entity to measure credit losses for
certain financial instruments and financial assets. ASU 2016-13 will also apply to receivables arising from revenue transactions such as accounts receivable.
ASU 2016-13 is effective for the Company beginning January 1, 2023. The Company does not expect the adoption of ASU 2016-13 to have a material effect
on its financial position, results of operations or cash flows.
Recently Adopted
Effective January 1, 2019, as required, the Company adopted ASU No. 2018-02, Income Statement—Reporting Comprehensive Income (Topic 220):
Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income (ASU 2018-02). ASU 2018-02 provides the option to reclassify
stranded tax effects within accumulated other comprehensive income to retained earnings in each period in which the effect of the change in the U.S. federal
corporate income tax rate in the Tax Reform (or portion thereof) is recorded. The adoption of ASU 2018-02 did not have a material impact on the Company’s
financial position, results of operations or cash flows due to the presence of a full valuation allowance as of the date of adoption.
Effective January 1, 2019, as required, the Company adopted ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to
Nonemployee Share-Based Payment Accounting (ASU 2018-07). The amendments in ASU 2018-07 expand the scope of the standard to include share-based
payment transactions for acquiring goods and services from nonemployees. The adoption of ASU 2018-07 did not have a material impact on its financial
statements or disclosures.
3. Available-for-Sale Securities
The Company invests in available-for-sale debt securities consisting of money market funds, certificates of deposit, U.S. Treasury securities and U.S.
government sponsored enterprise securities. Available-for-sale debt securities are classified as part of either cash and cash equivalents or short-term investments
in the balance sheets.
87
Available-for-sale debt securities with maturities of three months or less from the date of purchase have been classified as cash equivalents, and were $22.1
million and $17.2 million as of December 31, 2019 and 2018, respectively.
Available-for-sale debt securities with maturities of more than three months from the date of purchase have been classified as short-term investments, and
were as follows (in thousands):
December 31, 2019:
U.S. Treasury securities
Total available-for-sale securities
December 31, 2018:
U.S. Treasury securities
Total available-for-sale securities
Amortized
Cost
Unrealized
Gains
Unrealized
Losses
Market Value
$
$
$
$
35,465 $
35,465 $
63,674 $
63,674 $
16 $
16 $
1 $
1 $
(5) $
(5) $
(24) $
(24) $
35,476
35,476
63,651
63,651
As of December 31, 2019, the Company had five securities in a gross unrealized loss position, all of which have been in such position for less than
twelve months. At each reporting date, the Company performs an evaluation of impairment to determine if any unrealized losses are other-than-temporary.
Factors considered in determining whether a loss is other-than-temporary include the length of time and extent to which fair value has been less than the cost
basis, the financial condition of the issuer, and the Company’s intent and ability to hold the investment until recovery of its amortized cost basis. The
Company intends, and has the ability, to hold any investments in unrealized loss positions until their amortized cost basis has been recovered. The Company
determined there were no other-than-temporary declines in the value of any available-for-sale securities as of December 31, 2019. All the Company’s
available-for-sale debt securities mature within one year.
The Company obtains the fair value of its available-for-sale debt securities from a professional pricing service. The fair values of available-for-sale
debt securities are validated by comparing the fair values reported by the professional pricing service to quoted market prices or to fair values obtained from
the custodian bank.
4. Balance Sheet Details
Prepaid and Other Current Assets
Prepaid and other current assets are comprised of the following (in thousands):
Prepaid clinical trial costs
Other
Total
Property and Equipment, Net
Property and equipment, net consists of the following (in thousands):
Laboratory equipment
Manufacturing equipment
Computer equipment and software
Leasehold improvements
Office furniture
Less: accumulated depreciation and amortization
Total
88
December 31,
2019
2018
209 $
2,223
2,432 $
258
2,419
2,677
December 31,
2019
2018
4,179 $
1,111
943
768
1,548
8,549
(4,847)
3,702 $
3,772
1,017
770
736
1,548
7,843
(3,847)
3,996
$
$
$
$
Depreciation expense was $1.1 million, $1.2 million and $1.3 million for the years ended December 31, 2019, 2018 and 2017, respectively.
Accrued Expenses
Accrued expenses consist of the following (in thousands):
Accrued clinical trial costs
Accrued other
Total
5. Restructuring Charges
December 31,
2019
2018
$
$
3,443 $
1,999
5,442 $
1,294
2,494
3,788
During the year ended December 31, 2017, the Company recorded a one-time restructuring charge of $3.8 million to selling, general and
administrative expense. Restructuring costs primarily included severance, health insurance and $1.0 million in stock-based compensation expense. As of
December 31, 2019 and 2018, the Company had no accrued and unpaid severance costs.
6. Commitments and Contingencies
Operating Leases
In December 2016, the Company moved into its current headquarters location in San Diego, California. The lease commenced in December 2016 and
has an initial term of 130 months, with an option by the Company to extend the lease term for an additional five years. The Company has the right to
terminate the lease at the end of the 94th month of the lease term if it is acquired by a third party and pays an early termination fee. The Company is
responsible for payment of taxes and operating expenses for the building, in addition to monthly base rent in the initial amount of approximately $232,000,
with 3% annual increases, which monthly base rent was abated for the first ten months of the lease term. The total estimated base rent payments over the life
of the lease are estimated to be approximately $32.7 million. Upon execution of the lease in May 2015, the Company provided a security deposit in the form
of a letter of credit in the amount of approximately $695,000. Cash collateralizing the letter of credit is classified as noncurrent restricted cash on the balance
sheets. The Company has determined that the lease is an operating lease for accounting purposes.
Intellectual Property Licenses
The Company has acquired exclusive rights to develop patented rights, information rights and related know-how for OTIPRIO, OTIVIDEX, OTO-
311, OTO-313 and OTO-413 and potential future product candidates under licensing agreements with third parties. The licensing rights obligate the Company
to make payments to the licensors for license fees, milestones and royalties. The Company is also responsible for patent prosecution costs, in the event such
costs are incurred.
The Company may be obligated to make additional milestone payments under the Company’s intellectual property license agreements as follows (in
thousands):
Development
Regulatory
Commercialization
Total
$
$
1,500
10,275
1,000
12,775
Under one of these agreements, the Company has achieved seven development milestones and one regulatory milestone, totaling $2.9 million, related
to its clinical trials for OTIPRIO, OTIVIDEX, OTO-311 and OTO-413.
89
In addition, the Company is obligated to pay royalties of less than five percent on net sales of OTIPRIO and on sales of any other commercial
products developed using these licensed technologies. Such royalty expense for OTIPRIO is recorded to cost of product sales. The Company may also be
obligated to pay to the licensors a percentage of fees received if and when the Company sublicenses the technology. As of December 31, 2019, the Company
has not entered into any sublicense agreements for the licensed technologies.
The following table summarizes costs recognized, in research and development, under the Company’s license agreements and other non-cancellable
royalty and milestone obligations (in thousands):
License and other fees
Milestone fees
Total license and related fees
Other Royalty Arrangements
2019
Years Ended December 31,
2018
2017
$
$
— $
100
100 $
— $
—
— $
—
—
—
The Company entered into an agreement related to OTIPRIO under which the Company is obligated to pay royalties of less than one percent on net
product sales of OTIPRIO. The royalties are recorded as selling, general and administrative expense. The royalties are payable until the later of: (i) the
expiration of the last to expire patent owned by the Company in such country covering OTIPRIO; or (ii) 10 years after the first commercial sale of OTIPRIO
after receipt of regulatory approval for OTIPRIO in such country.
In October 2014, the Company entered into an exclusive license agreement with Ipsen that enables the Company to use clinical and nonclinical
gacyclidine data generated by Ipsen to support worldwide development and regulatory filings for OTO-313. Under this license agreement, the Company is
obligated to pay Ipsen low single-digit royalties on annual net sales of OTO-313 by the Company or its affiliates or sublicensees, up to a maximum
cumulative royalty totaling $10.0 million.
Litigation
From time to time, the Company may be involved in various lawsuits, legal proceedings, or claims that arise in the ordinary course of business.
Management believes there are no claims or actions pending against the Company as of December 31, 2019 which will have, individually or in the aggregate,
a material adverse effect on its business, liquidity, financial position, or results of operations. Litigation, however, is subject to inherent uncertainties, and an
adverse result in these or other matters may arise from time to time that may harm the Company’s business.
7. Long-term Debt
On December 31, 2018 (the Closing Date), the Company entered into a Loan and Security Agreement (the Loan Agreement), among the Company,
Oxford Finance LLC, as collateral agent, and the lenders party thereto from time to time.
The Loan Agreement provides for a $15.0 million secured term loan credit facility (the Term Loan). The proceeds of the Term Loan may be used for
working capital and general corporate purposes. The Company has the right to prepay the Term Loan in whole or in part at any time, subject to a prepayment
fee of 3.00% if prepaid on or prior to the first anniversary of the Closing Date, 2.00% if prepaid after the first anniversary of the Closing Date and on or prior
to the second anniversary of the Closing Date, and 1.00% thereafter. Amounts prepaid or repaid under the Term Loan may not be reborrowed. The Term Loan
was fully funded on the Closing Date and matures on December 1, 2023 (the Maturity Date). The Company paid a facility fee of 0.75% and customary
closing fees on the Closing Date.
The Term Loan bears interest at a floating rate equal to the greater of 5.25% and the prime rate as reported in the Wall Street Journal from time to
time, plus 3.75% (9.0% as of December 31, 2019, the minimum interest rate).
90
Interest on the Term Loan is payable monthly in arrears. The Company is permitted to make interest-only payments on the Term Loan for the twenty-four
(24) months following the Closing Date followed by consecutive equal monthly payments of principal and interest in arrears through the Maturity Date. The
interest-only period can be extended by an additional twelve (12) months subject to the achievement of a certain clinical trial milestone. The outstanding
principal amount of the Term Loan, together with accrued and unpaid interest, is due on December 1, 2023.
Upon repayment or acceleration of the Term Loan, a final payment fee equal to 4.00% of the aggregate original principal amount of the Term Loan is
payable (the Final Payment). The Final Payment of $0.6 million, as well as the initial facility fee and all other direct fees and costs associated with the Loan
Agreement, was recognized as a debt discount. The debt discount will be amortized to interest expense over the term of the Loan Agreement using the
effective interest method.
The Company’s obligations under the Loan Agreement are secured by substantially all its assets, excluding intellectual property and subject to certain
other exceptions and limitations.
The Loan Agreement contains customary affirmative covenants, including covenants regarding compliance with applicable laws and regulations,
reporting requirements, payment of taxes and other obligations, and maintenance of insurance. Further, subject to certain exceptions, the Loan Agreement
contains customary negative covenants limiting the ability of the Company to, among other things, sell assets, allow a change of control to occur (if the Term
Loan is not repaid), make acquisitions, incur debt, grant liens, make investments, pay dividends or repurchase stock. The Company has maintained
compliance with all such covenants to date. Upon the occurrence and during the continuance of an event of default, the lenders may declare all outstanding
principal and accrued and unpaid interest under the Loan Agreement immediately due and payable, increase the applicable rate of interest by 5.00%, and
exercise the other rights and remedies provided for under the Loan Agreement and related loan documents. The events of default under the Loan Agreement
include payment defaults, breaches of covenants or representations and warranties, material adverse changes, certain bankruptcy events, cross defaults with
certain other indebtedness, and judgment defaults.
Interest expense, including amortization of the debt discount, related to the Loan Agreement totaled $1.6 million for the year ended December 31,
2019. Accrued interest, included in accounts payable, was $0.1 million as of December 31, 2019. The outstanding Term Loan balance was $15.0 million as of
December 31, 2019, inclusive of accretion of the final payment and net unamortized debt discount.
The estimated aggregate amounts and timing of payments on the Company’s long-term debt obligations as of December 31, 2019 for the next five
fiscal years were as follows:
2020
2021
2022
2023
2024
Subtotal
Unamortized discount
Total long-term debt, net
8. Leases
Operating Leases
$
$
—
4,714
5,143
5,743
—
15,600
(633)
14,967
Effective January 1, 2019, the Company adopted ASC 842 using the modified retrospective approach for leases existing as of the period of adoption.
The Company utilized the available practical expedients, allowing it to, among other things, carry forward its historical assessment of whether existing
agreements are or contain a lease and the classification of existing lease agreements.
91
The Company has existing operating leases for certain office equipment and its facility with initial terms ranging from 48 months to 130 months. The
facility lease has an option for the Company to extend the lease term for an additional five years; however, it is not reasonably certain the Company will
exercise the option to renew when the lease term ends in 2027, and thus, the incremental term was excluded from the calculation of the lease liability. The
Company has the right to terminate the lease at the end of the 94th month of the lease term if it is acquired by a third party and pays an early termination fee.
On March 31, 2019, the Company entered into a lease for certain equipment with an initial term of 24 months, which includes a purchase option at
the end of the lease term based upon the then fair market value of the equipment. The lease payment includes customary principal and interest as well as costs
related to the installation and setup of the equipment. The Company evaluated the lease in accordance with ASC 842 and recorded this lease as an operating
lease in the balance sheets.
The ROU assets associated with all the Company’s operating leases are recognized in the balance sheets. Rent expense was $3.1 million, $3.1 million
and $3.2 million for the years ended December 31, 2019, 2018 and 2017, respectively.
Finance Leases
On March 31, 2019, the Company entered into a lease for certain computer equipment with an initial term of 24 months, which includes an option to
purchase the equipment at the end of the lease term that is expected to be exercised. The lease payment includes customary principal and interest as well as
costs related to the installation and setup of the equipment. The associated ROU asset is recognized within property and equipment, net in the balance sheets
and is being amortized over three years in accordance with the Company’s standard depreciation and amortization policies.
Lease expenses:
Operating lease expenses
Variable lease expenses
Total lease expenses
Other information:
Cash paid for amounts included in the measurement of lease
liabilities:
Operating cash flows from operating leases
Right-of-use assets obtained in exchange for new lease liabilities:
Operating leases
Finance leases
Weighted-average remaining lease term:
Operating leases
Finance leases
Weighted-average remaining discount rate:
Operating leases
Finance leases
92
$
$
$
$
$
December 31, 2019
3,137
942
4,079
December 31, 2019
32
81
134
7.7 years
1.3 years
10.0%
9.2%
Lease Maturities:
Operating Leases
Finance Leases
Total
2020 $
2021
2022
2023
2024
Total minimum lease payments
Thereafter
Imputed interest
Total
Less: leases, current
Leases, net of current
$
3,231 $
3,247
3,333
3,433
3,536
10,284
27,064
(8,529)
18,535
(3,229)
15,306 $
74 $
18
—
—
—
—
92
(5)
87
(73)
14 $
3,305
3,265
3,333
3,433
3,536
10,284
27,156
(8,534)
18,622
(3,302)
15,320
9. Fair Value
The accounting guidance defines fair value, establishes a consistency framework for measuring fair value and expands disclosure for each major asset
and liability category measured at fair value on either a recurring basis or nonrecurring basis. Fair value is defined as the price that would be received to sell
an asset or paid to transfer a liability in an orderly transaction between market participants on the measurement date. Accounting guidance establishes a three-
tier fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair
value. These tiers are based on the source of the inputs and are as follows:
Level 1: Observable inputs such as quoted prices in active markets for identical assets or liabilities.
Level 2: Inputs other than quoted prices in active markets that are observable either directly or indirectly.
Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
As of December 31, 2019 and 2018, the Company held no assets or liabilities measured at fair value on a nonrecurring basis and no liabilities
measured at fair value on a recurring basis. The following fair value hierarchy table presents the Company’s assets measured at fair value on a recurring basis
(in thousands):
December 31, 2019:
Assets
Money market funds
U.S. Treasury securities
Total
December 31, 2018:
Assets
Money market funds
U.S. Treasury securities
Total
Fair Value Measurement at Reporting Date Using
Total
Level 1
Level 2
Level 3
22,121 $
35,476
57,597 $
22,121 $
35,476
57,597 $
17,159 $
63,651
80,810 $
17,159 $
63,651
80,810 $
— $
—
— $
— $
—
— $
—
—
—
—
—
—
$
$
$
$
93
10. Stockholders’ Equity
Common Stock Reserved for Future Issuance
Shares of common stock reserved for future issuance are as follows:
Common stock options issued and outstanding
Common stock options available for future grant
Common stock reserved for issuance under ESPP
Total common stock reserved for future issuance
December 31,
2019
7,495,129
3,548,214
1,977,215
13,020,558
2018
5,019,964
4,492,021
1,642,821
11,154,806
11. Stock-Based Compensation and Equity Plans
2014 Equity Incentive Plan
The Company granted awards under its 2010 Equity Incentive Plan (the 2010 Plan) until June 2014. In July 2014, the Company’s board of directors
adopted and the Company’s stockholders approved its 2014 Equity Incentive Plan (the 2014 Plan), which became effective in August 2014. In connection
with the adoption of the 2014 Plan, the Company terminated the 2010 Plan for future use and provided that no further equity awards were to be granted under
the 2010 Plan. All outstanding awards under the 2010 Plan continue to be governed by their existing terms.
The 2014 Plan permits the grant of incentive stock options to the Company’s employees and the grant of nonstatutory stock options, restricted stock,
restricted stock units, stock appreciation rights, performance units and performance shares to the Company’s employees, directors and consultants. Options
granted under the 2014 Plan are generally scheduled to vest over four years, subject to continued service, and subject to certain acceleration of vesting
provisions, expire no later than 10 years from the date of grant. Options granted under the 2014 Plan must have a per share exercise price equal to at least
100% of the fair market value of a share of the common stock as of the date of grant.
Under the evergreen provision of the 2014 Plan, the number of shares available for issuance under the 2014 Plan includes an annual increase on the
first day of each fiscal year equal to the lesser of (i) 2,500,000 shares; (ii) 5% of the outstanding shares of common stock as of the last day of the immediately
preceding fiscal year; or (iii) such other amount as the Company’s board of directors may determine. Effective January 1, 2020, the number of shares
available for future issuance was increased by 1,540,710 shares so that the total available for future issuance as of January 1, 2020 was 5,088,924 shares.
As of December 31, 2019, 3,548,214 options were available for grant under the 2014 Plan. The following table summarizes stock option activity for
the year ended December 31, 2019 (in thousands except per share amounts and years):
Outstanding as of December 31, 2018
Granted
Exercised
Forfeited
Outstanding as of December 31, 2019
Options vested and expected to vest as of
December 31, 2019
Options exercisable as of December 31, 2019
Options
Weighted-
Average
Exercise Price
5,020 $
2,656 $
(3) $
(178) $
7,495 $
7,495 $
3,912 $
5.62
2.08
1.76
3.19
4.43
4.43
5.62
94
Weighted-
Average
Remaining
Contractual
Term
(In Years)
Aggregate
Intrinsic Value
7.1 $
6,279
7.1 $
5.7 $
6,279
1,782
The following table summarizes certain information regarding stock options (in thousands, except per share data):
Weighted-average grant date fair value per share of
options granted during the period
Cash received from options exercised during the
period
Intrinsic value of options exercised during the period
Performance-based Awards
2019
Years Ended December 31,
2018
2017
$
1.64 $
4.36 $
5
2
32
76
9.14
448
623
In February 2018, the Company granted its chief executive officer a stock option for the purchase of 250,000 shares of the Company’s common stock
which is subject to time-based vesting and certain performance-based conditions. Specifically, subject to continued service the option was scheduled to vest
upon achievement of a clinical development milestone. On the grant date, the Company determined the fair value of the award and determined achievement
of the milestone was probable of occurrence and recognized stock-based compensation expense, based upon the grant date fair value, over the implicit service
period. The milestone was achieved, and the option grant vested and was fully expensed as of December 31, 2018.
Option Exchange
On December 20, 2017, the Company commenced an option exchange program (Option Exchange) which allowed eligible employees to exchange
certain outstanding stock options (Eligible Options), whether vested or unvested, with an exercise price greater than $12.00 per share, for new stock
options. Non-employee members of the Company’s board of directors were not eligible to participate in the Option Exchange. The Option Exchange expired
on January 19, 2018. The closing price of the Company’s common stock on that date was $5.675 per share.
Pursuant to the terms and conditions of the Option Exchange, the Company accepted for exchange Eligible Options to purchase a total of 1,992,000
shares of the Company’s common stock, representing approximately 81.51% of the total shares of common stock underlying the Eligible Options. All
surrendered options were canceled effective as of the expiration of the Option Exchange and in exchange on January 19, 2018, the Company granted new
options to purchase an aggregate of 1,570,328 shares of the Company’s common stock with an exercise price of $5.675 per share pursuant to the terms of the
Option Exchange and the 2014 Plan.
These new options vest over one to three years, subject to the terms of the Option Exchange and expire eight years from the date of grant. The
Company determined this option exchange was an option modification. The exchange of these stock options was treated as a modification for accounting
purposes. The difference in the fair value of the canceled options immediately prior to the cancelation and the fair value of the modified options resulted in
incremental value, of approximately $0.6 million, which was calculated using the Black-Scholes-Merton option pricing model. Total stock-based
compensation expense to be recognized over the requisite service period is equal to the remaining unrecognized expense for the exchanged option, as of the
exchange date, plus the incremental value of the modification to the award.
2014 Employee Stock Purchase Plan
In July 2014, the Company’s board of directors adopted and the stockholders approved the Company’s 2014 Employee Stock Purchase Plan (the
ESPP), which became effective upon adoption by the Company’s board of directors. The ESPP allows eligible employees to purchase shares of the
Company’s common stock at a discount through payroll deductions of up to 15% of their eligible compensation, subject to any plan limitations. The offering
periods generally start on the first trading day on or after June 1 and December 1 of each year and end on the first trading day on or before June 1 and
December 1 approximately twenty-four months later, and include six-month purchase periods.
95
The number of shares available for issuance under the ESPP includes an annual increase on the first day of each fiscal year, equal to the lesser of
(i) 800,000 shares; (ii) 1.5% of the outstanding shares of common stock as of the last day of the immediately preceding fiscal year; or (iii) such other amount
as the Company’s board of directors may determine. Effective January 1, 2020, the number of shares available for future issuance was increased by 462,213
shares so that the total available for future issuance as of January 1, 2020 was 2,439,428 shares.
As of December 31, 2019, the Company had issued 457,831 shares of common stock under the ESPP and had 1,977,215 shares available for future
issuance.
Stock-Based Compensation Expense
The following are the weighted-average underlying assumptions used to determine the fair value of stock options and ESPP rights using the Black-
Scholes-Merton option pricing model:
Stock Options:
Risk-free interest rate
Expected dividend yield
Expected volatility
Expected term (in years)
Employee Stock Purchase Plan:
Risk-free interest rate
Expected dividend yield
Expected volatility
Expected term (in years)
2019
Years Ended December 31,
2018
2017
2.5%
0.0%
98.1%
6.1
2.0%
0.0%
69.5%
1.3
2.6%
0.0%
100.6%
5.4
2.6%
0.0%
116.0%
1.3
2.1%
0.0%
69.8%
6.1
1.4%
0.0%
106.6%
1.2
Risk-Free Interest Rate. The Company bases the risk-free interest rate assumption on observed interest rates appropriate for the expected term of the
option grants.
Expected Dividend Yield. The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no
present intention to pay cash dividends.
Expected Volatility. The expected volatility assumption is based on volatilities of a peer group of similar companies whose share prices are publicly
available. The peer group was developed based on companies in the biopharmaceutical industry.
Expected Term. The expected term represents the period of time that options are expected to be outstanding. Because the Company does not have
historical exercise behavior, it determines the expected life assumption using the simplified method, which is an average of the contractual term of the option
and its ordinary vesting period.
Total non-cash stock-based compensation expense recognized in the statements of operations is as follows (in thousands):
Cost of product sales
Research and development
Selling, general and administrative
Total stock-based compensation
2019
Years Ended December 31,
2018
2017
$
$
12 $
2,085
2,793
4,890 $
12 $
4,447
7,955
12,414 $
20
3,763
9,878
13,661
As of December 31, 2019, unrecognized compensation cost related to stock options was $7.5 million which is expected to be recognized over a
remaining weighted-average vesting period of 2.2 years. As of December 31, 2019, unrecognized compensation cost related to ESPP rights was $0.1 million
which is expected to be recognized over a remaining weighted-average vesting period of 0.8 years.
96
12. Collaboration Agreements
Co-Promotion Agreements
The Company entered into a co-promotion agreement with Mission Pharmacal Company (Mission) in August 2018 and with Glenmark Therapeutics
Inc., USA (Glenmark) in April 2019 (each, a Co-Promotion Agreement) to support the promotion of OTIPRIO for the treatment of AOE in physician offices.
In July 2019, Glenmark informed the Company of its early discontinuation of OTIPRIO promotional support activities due to the delay in FDA approval of
its Ryaltris allergy product, and the impact of such delay on its business operations. In September 2019, the Company reached a settlement with Glenmark
regarding the financial and contractual terms impacted by this decision that included committed payments by Glenmark totaling $1.0 million. In August 2019,
Mission informed the Company of its non-renewal of the co-promotion agreement.
The Co-Promotion Agreements are within the scope of ASC 808, as the parties were active participants and exposed to the risks and rewards of the
collaborative activity. Mission and Glenmark (each, a Partner) made non-refundable, non-creditable payments to the Company as partial consideration of the
OTIPRIO product support activities provided by the Company and as reimbursement for certain expenses incurred by the Company to obtain and maintain
FDA approval for use of OTIPRIO in AOE. In addition, each Partner reimbursed the Company for a proportion of product support expenses. All such
payments are recognized proportionately with the performance of the underlying services and accounted for as reductions to selling, general and
administrative expense. Each Partner agreed to bear the costs incurred for its promotion of OTIPRIO. In exchange for its promotional services, each Partner
was entitled to receive a share of gross profits totaling more than 50% from the sale of OTIPRIO to each Partner’s accounts. The Company’s payments to
each Partner for its portion of the gross profit has been recognized as selling, general and administrative expense in the Company’s statements of operations.
The Company was the principal in the product sale of OTIPRIO and recognized all revenue and related cost of product sales. The Company retained and
continues to retain all commercial rights for other customer segments for AOE and for use of OTIPRIO in other indications.
The Company does not consider performing product support services for its Partners to be a part of its ongoing major or central operations and, thus,
the associated payments are not considered revenue, nor do they fall under ASC 606. The Company considers these activities to be collaborative activities
under the scope of ASC 808, and recognizes the shared profits and losses in the periods in which they occurred. For the years ended December 31, 2019 and
2018, the Company recognized reductions in selling, general and administrative expenses related to the Co-Promotion Agreements of $2.6 million and $0.6
million, respectively.
AGTC collaboration
In October 2019, the Company announced a strategic collaboration with AGTC to co-develop and co-commercialize an adeno-associated virus
(AAV)-based gene therapy to restore hearing in patients with sensorineural hearing loss caused by a mutation in the gap junction beta 2 gene (GJB2). Under
the collaboration agreement, the Company and AGTC will equally share the program costs and any revenue or other proceeds related to the program. As of
December 31, 2019, the Company had no amounts payable to or receivable from AGTC.
13. Income Taxes
Pursuant to Internal Revenue Code (IRC) Sections 382 and 383, annual use of the Company’s net operating loss and research and development credit
carryforwards may be limited in the event that a cumulative change in ownership of more than 50% occurs within a three-year period. The Company has
completed a preliminary IRC Section 382/383 analysis, regarding the limitation of net operating loss and research and development credit carryforwards as of
December 31, 2019 and does not believe there to have been an ownership change during the year then ended. The Company will continue to consider changes
in ownership that may cause losses of tax attributes in the future.
97
Significant components of the Company’s deferred tax assets are as follows (in thousands):
Deferred tax assets:
Net operating loss carryforwards
Research and development credits
Depreciation and amortization
Accrued expenses
Lease liabilities
Deferred rent
Stock compensation
Other, net
Total deferred tax assets
Less: valuation allowance
Total deferred tax assets, net of valuation allowance
Deferred tax liability:
Right-of-use assets
Total deferred tax liability
Total
December 31,
2019
2018
$
$
78,768 $
8,920
12,608
381
4,349
—
4,395
181
109,602
(105,990)
3,612
(3,612)
(3,612)
— $
67,574
7,963
15,376
623
—
742
6,349
514
99,141
(99,141)
—
—
—
—
Due to the Company’s history of losses and uncertainty regarding future earnings, a full valuation allowance has been recorded against the
Company’s net deferred tax assets, as it is more likely than not that such net assets will not be realized. A valuation allowance of approximately $106.0
million and $99.1 million has been established as of December 31, 2019 and 2018, respectively.
At December 31, 2019, the Company had federal and state net operating loss carryforwards of approximately $337.4 million net of IRC Section 382
limitations and $131.7 million, respectively. Of the federal net operating loss carryforwards, approximately $96.8 million were generated after January 1,
2018, and therefore do not expire. Federal net operating losses that occur after January 1, 2018 are subject to a taxable income limitation of 80% in
accordance with the Tax Cuts and Jobs Act of 2017 (the TCJA). The remaining federal and state net operating loss carryforwards will begin to expire in 2030,
unless previously utilized. As of December 31, 2019, the Company also had federal and California research and development credit carryforwards of
approximately $10.9 million net of IRC Section 383 limitations and $5.0 million, respectively. The federal research and development credit carryforwards
will begin expiring in 2030, unless previously utilized. The California research credit will carry forward indefinitely.
The following is a reconciliation of the expected recovery of income taxes between those that are based on enacted tax rates and laws, to those
currently reported for the years ended December 31 (in thousands):
Federal statutory rate
State tax (net of federal benefit)
Permanent items, other
Stock compensation
Other adjustments
Rate change
Research and development credits
Uncertain tax positions
Change in valuation allowance
Provision for income taxes
2019
2018
2017
(9,382) $
299
189
2,470
523
—
(1,595)
638
6,858
0 $
(10,578) $
(4,383)
(2,092)
2,570
—
—
(2,308)
907
15,884
0 $
(30,645)
(462)
1,376
1,720
—
45,421
(1,830)
732
(16,312)
0
$
$
The TCJA was enacted on December 22, 2017. The TCJA amended the IRC to reduce tax rates and modify policies, credits, and deductions for
individuals and businesses. For businesses, the TCJA reduced the corporate tax rate from a maximum of 35% to a flat 21% rate. The rate reduction became
effective on January 1, 2018.
98
The Company remeasured certain deferred tax assets based on the rates at which they are expected to reverse in the future, which is generally 21%.
As a result, the Company reduced its deferred tax asset balance as of December 31, 2017 by $44.5 million. Due to the Company’s full valuation allowance
position as of December 31, 2017, the Company also reduced its valuation allowance by the same amount.
Due to the timing of the enactment and the complexity involved in applying the provisions of the TCJA, the Company made reasonable estimates of
the effects, and recorded provisional amounts in its financial statements as of December 31, 2017. As the Company collected and prepared necessary data,
and interpreted the additional guidance issued by the U.S. Department of the Treasury, the Internal Revenue Service (IRS), and other standard-setting bodies,
it made adjustments, over the course of 2018, to the provisional amounts including refinements to deferred taxes. The accounting for the tax effects of the
TCJA was completed as of December 31, 2018.
The following table summarizes the activity related to the Company’s gross unrecognized tax benefits (in thousands):
Balance at the beginning of the year
Adjustments related to prior year tax positions
Increases related to current year tax positions
Decreases for tax positions from prior years
2019
December 31,
2018
2017
$
$
10,052 $
(80)
767
—
10,739 $
9,098 $
242
712
—
10,052 $
8,391
—
798
(91)
9,098
The Company’s policy is to include interest and penalties related to unrecognized income tax benefits as a component of income tax expense. The
Company has no accruals for interest or penalties in the balance sheets as of December 31, 2019 and 2018 and has not recognized interest or penalties in the
statements of operations for the years ended December 31, 2019, 2018 and 2017.
Due to the valuation allowance recorded against the Company’s net deferred tax assets, future changes in unrecognized tax benefits will not impact
the Company’s effective tax rate. The Company does not expect its unrecognized tax benefits to change significantly in the next 12 months.
The Company is subject to taxation in the United States for federal and state purposes. Due to the net operating loss carryforwards, the U.S. federal
and state returns are open to examination by the IRS and state tax authorities for all years since inception. The Company is not currently under examination
by the federal or any state tax authority.
99
Item 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE
None.
Item 9A. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Management, with the
participation of our Chief Executive Officer and our Chief Financial and Business Officer, evaluated the effectiveness of our disclosure controls and
procedures as of December 31, 2019. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act,
means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it
files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms.
Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a
company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its
principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any
controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management
necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure
controls and procedures as of December 31, 2019, our Chief Executive Officer and our Chief Financial and Business Officer concluded that, as of such date,
our disclosure controls and procedures were effective at the reasonable assurance level.
Management’s Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under
the Exchange Act). Our management conducted an assessment of the effectiveness of our internal control over financial reporting based on the criteria
established in “Internal Control—Integrated Framework” (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission
(COSO). Based on the assessment, management has concluded that our internal control over financial reporting was effective as of December 31, 2019.
The effectiveness of our internal control over financial reporting as of December 31, 2019 has been audited by Ernst & Young LLP, an independent
registered public accounting firm, as stated in its report, which is included herein.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and
15d-15(d) of the Exchange Act that occurred during the quarter ended December 31, 2019 that have materially affected, or are reasonably likely to materially
affect, our internal control over financial reporting.
Inherent Limitations of Disclosure Controls and Internal Control over Financial Reporting
Because of their inherent limitations, our disclosure controls and procedures and our internal control over financial reporting may not prevent
material errors or fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the
objectives of the control system are met. The effectiveness of our disclosure controls and procedures and our internal control over financial reporting is
subject to risks, including that the controls may become inadequate because of changes in conditions or that the degree of compliance with our policies or
procedures may deteriorate.
100
Report of Independent Registered Public Accounting Firm
The Board of Directors and Stockholders of Otonomy, Inc.
Opinion on Internal Control over Financial Reporting
We have audited Otonomy, Inc.’s internal control over financial reporting as of December 31, 2019, based on criteria established in Internal Control
—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our
opinion, Otonomy, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2019, based
on the COSO criteria.
We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the balance
sheets of Otonomy, Inc. as of December 31, 2019 and 2018 and the related statements of operations, comprehensive loss, stockholders’ equity and cash flows
for each of the three years in the period ended December 31, 2019, and the related notes and our report dated February 27, 2020 expressed an unqualified
opinion thereon.
Basis for Opinion
The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the
effectiveness of internal control over financial reporting included in the accompanying Management’s Report on Internal Control Over Financial Reporting.
Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm
registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the
applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.
Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing
and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered
necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal
control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and
fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to
permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are
being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention
or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any
evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree
of compliance with the policies or procedures may deteriorate.
/s/ Ernst & Young LLP
San Diego, California
February 27, 2020
101
Item 9B. OTHER INFORMATION
None.
102
Item 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE
The information required by this item will be contained in our definitive proxy statement to be filed with the Securities and Exchange Commission in
connection with our 2020 annual meeting of stockholders (Proxy Statement), which is expected to be filed not later than 120 days after the end of our fiscal
year ended December 31, 2019, and is incorporated in this report by reference.
Part III
Item 11. EXECUTIVE COMPENSATION
The information required by this item will be set forth in the Proxy Statement and is incorporated herein by reference.
Item 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER
MATTERS
The information required by this item will be set forth in the Proxy Statement and is incorporated herein by reference.
Item 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE
The information required by this item will be set forth in the Proxy Statement and is incorporated herein by reference.
Item 14. PRINCIPAL ACCOUNTING FEES AND SERVICES
The information required by this item will be set forth in the Proxy Statement and is incorporated herein by reference.
103
Item 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES
The following documents are filed as a part of this Annual Report on Form 10-K:
(1) Financial Statements:
PART IV
Our Financial Statements are listed in the “Index to Financial Statements” under Part II, Item 8 of this Annual Report on Form 10-K.
(2) Financial Statement Schedules:
Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial
statements or notes herein.
(3) Exhibits:
The following exhibits, as required by Item 601 of Regulation S-K are attached or incorporated by reference as stated below.
104
Exhibit
Number
2.1#
3.1
3.2
4.1
4.2
4.3
10.1+
10.2+
10.3+
10.4+
10.5+
10.6+
10.7+
10.8+
10.9+
10.10#
10.11#
EXHIBIT INDEX
Description
Form
Incorporation by Reference
File No.
Exhibit
Asset Transfer Agreement between the Registrant and IncuMed, LLC, dated
April 30, 2013.
Amended and Restated Certificate of Incorporation of the Registrant.
Amended and Restated Bylaws of the Registrant.
Third Amended and Restated Investors’ Rights Agreement among the
Registrant and certain of its stockholders, dated April 23, 2014.
Specimen common stock certificate of the Registrant.
Description of securities registered pursuant to Section 12 of the Securities
Exchange Act of 1934.
Form of Indemnification Agreement between the Registrant and each of its
directors and executive officers.
Amended and Restated 2010 Equity Incentive Plan and forms of agreement
thereunder.
2014 Equity Incentive Plan and forms of agreements thereunder.
2014 Employee Stock Purchase Plan and form of agreement thereunder.
Executive Incentive Compensation Plan.
Executive Employment Agreement between the Registrant and David A. Weber,
Ph.D., dated July 30, 2014.
Executive Employment Agreement between the Registrant and Paul E. Cayer,
dated July 31, 2014.
Executive Employment Agreement between the Registrant and Robert Michael
Savel, II, dated July 31, 2014.
Executive Employment Agreement between the Registrant and Kathie Bishop,
Ph.D., dated January 4, 2017.
S-1
S-1
S-1
S-1
S-1
S-1
S-1
S-1
S-1
S-1
S-1
S-1
S-1
333-197365
333-197365
333-197365
333-197365
333-197365
2.1
3.2
3.4
4.1
4.2
Filing Date
7/11/2014
8/1/2014
8/1/2014
7/11/2014
7/28/2014
333-197365
10.1
8/1/2014
333-197365
10.2
8/1/2014
333-197365
333-197365
333-197365
333-197365
10.3
10.4
10.5
10.6
8/1/2014
8/1/2014
7/28/2014
8/1/2014
333-197365
10.7
8/1/2014
333-197365
10.9
8/1/2014
10-Q
001-36591
10.1
5/4/2017
License and Commercialization Agreement between the Registrant and DURECT
Corporation, dated April 30, 2013.
License Agreement between the Registrant and The Regents of the University of
California, dated November 5, 2008, as amended on January 27, 2010, June 9,
2010 and November 7, 2012.
S-1
S-1
333-197365
10.11
7/11/2014
333-197365
10.12
7/11/2014
10.12
Lease Agreement between the Registrant and ARE-SD Region No. 34, LLC,
dated May 11, 2015.
10-Q
001-36591
10.2
5/12/2015
105
Exhibit
Number
10.13
Description
Loan and Security Agreement among the Registrant, Oxford Finance LLC, as
collateral agent, and the lenders party thereto from time to time, dated December
31, 2018.
Form
Incorporation by Reference
File No.
Exhibit
Filing Date
8-K
001-36591
10.1
1/3/2019
10.14
Sales Agreement, dated as of August 1, 2019, between the Registrant and
8-K
001-36591
1.1
8/1/2019
23.1
24.1
31.1
31.2
32.1*
32.2*
Cowen and Company, LLC.
Consent of Independent Registered Public Accounting Firm.
Power of Attorney, incorporated by reference to the signature page hereto.
Certification of Chief Executive Officer pursuant to Exchange Act Rules 13a-
14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002.
Certification of Chief Financial Officer pursuant to Exchange Act Rules 13a-
14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley
Act of 2002.
Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS
XBRL Instance Document.
101.SCH
XBRL Taxonomy Extension Schema Document.
101.CAL
XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF
XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB
XBRL Taxonomy Extension Label Linkbase Document.
101.PRE
XBRL Taxonomy Extension Presentation Linkbase Document.
*
#
+
The certifications attached as Exhibit 32.1 and 32.2 that accompany this Annual Report on Form 10-K are not deemed filed with the Securities and
Exchange Commission and are not to be incorporated by reference into any filing of Otonomy, Inc. under the Securities Act of 1933, as amended, or
the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report on Form 10-K, irrespective of any
general incorporation language contained in such filing.
Portions of the exhibit have been omitted pursuant to an order granted by the Securities and Exchange Commission for confidential treatment.
Indicates management contract or compensatory plan.
Item 16. FORM 10-K SUMMARY
None.
106
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on
Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: February 27, 2020
SIGNATURES
OTONOMY, INC.
By: /s/ David A. Weber
David A. Weber, Ph.D.
President and Chief Executive Officer
POWER OF ATTORNEY
Each person whose signature appears below constitutes and appoints David A. Weber, Ph.D. and Paul E. Cayer, and each of them acting individually,
as his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and
stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto, and other
documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full
power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and
purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his
substitutes, may lawfully do or cause to be done by virtue thereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the
registrant and in the capacities and on the dates indicated:
Signature
/s/ David A. Weber
David A. Weber, Ph.D.
/s/ Paul E. Cayer
Paul E. Cayer
/s/ Jay Lichter
Jay Lichter, Ph.D.
/s/ James Breitmeyer
James Breitmeyer, M.D., Ph.D.
/s/ Vickie Capps
Vickie Capps
/s/ Iain McGill
Iain McGill
/s/ Heather Preston
Heather Preston, M.D.
/s/ Theodore R. Schroeder
Theodore R. Schroeder
Title
President, Chief Executive Officer and Director
(Principal Executive Officer)
Chief Financial and Business Officer
(Principal Financial and Accounting Officer)
Date
February 27, 2020
February 27, 2020
Chairman of the Board of Directors
February 27, 2020
Director
Director
Director
Director
Director
107
February 27, 2020
February 27, 2020
February 27, 2020
February 27, 2020
February 27, 2020
DESCRIPTION OF THE REGISTRANT’S SECURITIES
REGISTERED PURSUANT TO SECTION 12 OF THE
SECURITIES EXCHANGE ACT OF 1934
Exhibit 4.3
General
The following description summarizes the most important terms of our capital stock as set forth in our amended and restated certificate of
incorporation and amended and restated bylaws. This summary does not purport to be complete and is qualified in its entirety by the provisions of our
amended and restated certificate of incorporation and amended and restated bylaws. For a complete description of our capital stock, you should refer to our
amended and restated certificate of incorporation, amended and restated bylaws and third amended and restated investors’ rights agreement, that are filed as
exhibits to the registration statement relating to our initial public offering, and to the applicable provisions of Delaware law. Our authorized capital stock
consists of 200,000,000 shares of common stock, $0.001 par value per share, and 10,000,000 shares of undesignated preferred stock, $0.001 par value per
share.
Common Stock
Dividend Rights and Policy
Subject to preferences that may be applicable to any then outstanding convertible preferred stock, holders of our common stock are entitled to receive
dividends, if any, as may be declared from time to time by our board of directors out of legally available funds.
We have never declared or paid cash dividends on any of our capital stock. We currently intend to retain all available funds and any future earnings, if
any, for the operation and expansion of our business and, therefore, we do not anticipate declaring or paying cash dividends in the foreseeable future. In
addition, we may become subject to covenants under future debt arrangements that place restrictions on our ability to pay dividends. The payment of
dividends, if any, will be at the discretion of our board of directors and will depend on our results of operations, capital requirements, financial condition,
prospects, contractual arrangements, any limitations on payment of dividends present in our future debt agreements, and other factors that our board of
directors may deem relevant.
Voting Rights
Pursuant to our amended and restated certificate of incorporation, each holder of our common stock is entitled to one vote for each share on all
matters submitted to a vote of stockholders; provided, however, that, except as otherwise required by law, holders of our common stock, as such, shall not be
entitled to vote on any amendment to our amended and restated certificate of incorporation that relates solely to the terms of one or more outstanding series of
preferred stock if the holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon
pursuant to our amended and restated certificate of incorporation. Pursuant to our amended and restated certificate of incorporation and amended and restated
bylaws, corporate actions can generally be taken by a majority of our board and/or stockholders holding a majority of our outstanding shares, except as
otherwise indicated in the section entitled “Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws,” where certain
amendments to our amended and restated certificate of incorporation and amended and restated bylaws require the vote of at least two-thirds of our then
outstanding voting securities. Additionally, our stockholders do not have cumulative voting rights in the election of directors. Accordingly, holders of a
plurality of the votes cast at a meeting of stockholders will be able to elect all of the directors then standing for election.
Right to Receive Liquidation Distributions
In the event of our liquidation, dissolution or winding up, holders of our common stock are entitled to share ratably in the net assets legally available
for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference granted to the
holders of any then outstanding shares of preferred stock.
Rights and Preferences
Holders of our common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions
applicable to our common stock. The rights, preferences and privileges of the holders of our common stock are subject to, and may be adversely affected by,
the rights of the holders of shares of any series of our preferred stock that we may designate in the future.
Fully Paid and Nonassessable
All of our outstanding shares of common stock are, and the shares of common stock to be issued pursuant to this offering, when paid for, will be fully
paid and nonassessable.
Preferred Stock
Our board of directors has the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more
series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion
rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting any series or the designation of
such series, any or all of which may be greater than the rights of common stock. The issuance of preferred stock by us could adversely affect the voting power
of holders of common stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of
preferred stock could have the effect of delaying, deferring or preventing a change of control of our company or other corporate action. No shares of preferred
stock are outstanding, and we have no present plan to issue any shares of preferred stock.
Exclusive Jurisdiction
Unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum
for: (1) any derivative action or proceeding brought on behalf of us; (2) any action asserting a claim of breach of a fiduciary duty owed by any of our
directors, officers or other employees to us or our stockholders; (3) any action asserting a claim against us arising pursuant to any provision of the Delaware
General Corporation Law or our amended and restated certificate of incorporation or amended and restated bylaws; (4) any action asserting a claim against us
governed by the internal affairs doctrine. The enforceability of similar choice of forum provisions in other companies’ certificates of incorporation has been
challenged in legal proceedings, and it is possible that, in connection with any action, a court could find the choice of forum provisions contained in our
amended and restated certificate of incorporation to be inapplicable or unenforceable in such action.
Registration Rights
Certain holders of shares of our common stock, including shares of common stock issuable upon the exercise of outstanding options and warrants, or
their permitted transferees, are entitled to rights with respect to the registration of such shares under the Securities Act. We refer to these shares as “registrable
securities.” These rights are provided under the terms of our third amended and restated investors’ rights agreement between us and the holders of registrable
securities, and include demand registration rights, “piggyback” registration rights and Form S-3 registration rights.
Generally, we are required to pay the registration expenses (other than underwriters’ and brokers’ discounts and commissions) in connection with the
registrations described below, including the reasonable fees and disbursements of one counsel for the selling holder or holders of registrable securities. In an
underwritten offering, the underwriters have the right to limit the number of shares registered by the holders of registrable securities for marketing reasons,
subject to certain limitations.
Demand Registration Rights
Upon the written request of at least a majority of the then outstanding registrable securities that we file a registration statement under the Securities
Act (provided that the anticipated aggregate offering price of such shares is greater than $5.0 million), we will be obligated to notify all holders of registrable
securities of such request and to use our reasonable best efforts to register the sale of all registrable securities that holders may request to be registered. We are
only obligated to file up to two registration statements which are declared or ordered effective in connection with the exercise of these demand registration
rights. These demand registration rights are subject to specified conditions and limitations, including the right of the underwriters to limit the number of
shares included in any such registration under certain circumstances.
Piggyback Registration Rights
If we propose to register any of our securities under the Securities Act in connection with the public offering of such securities, the holders of
registrable securities will be entitled to certain “piggyback” registration rights allowing such holders to include their shares in such registration, subject to
certain limitations. As a result, whenever we propose to file a registration statement under the Securities Act, other than with respect to a registration related
to either to the sale of securities to our employees pursuant to a stock plan, stock purchase or similar plan or a registration related to a corporate
reorganization or transaction under Rule 145 of the Securities Act of registrable securities are entitled to notice of the registration and have the right to include
their shares in the registration. These registration rights are subject to specified conditions and limitations, including the right of the underwriters to limit the
number of shares included in any such registration statement under certain circumstances.
Form S-3 Registration Rights
Upon the written request from the holders of at least 10% of the outstanding shares of registrable securities, holders of registrable securities have the
right to demand that we file a registration statement on Form S-3 so long as the aggregate amount of shares to be offered and sold under such registration
statement on Form S-3 is at least $1.0 million (net of any underwriters’ discounts or commissions). We are not required to effect a registration on Form S-3 if
we have already effected two registrations on Form S-3 for the holders pursuant to Form S-3 registration rights within the twelve-month period preceding the
date of the request. Additionally, we are not required to effect such registration in any jurisdiction in which we would be required to qualify to do business or
execute a general consent of process in effecting such registration.
Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws
The provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws may have the effect of
delaying, deferring or discouraging another person from acquiring control of our company. These provisions, which are summarized below, may have the
effect of discouraging takeover bids. They are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our board of
directors. We believe that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the
disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an improvement of their terms.
Delaware Law
We are subject to the provisions of Section 203 of the Delaware General Corporation Law regulating corporate takeovers. In general, Section 203
prohibits a publicly-held Delaware corporation from engaging, under certain circumstances, in a business combination with an interested stockholder for a
period of three years following the date the person became an interested stockholder unless:
•
•
•
prior to the date of the transaction, the board of directors approved either the business combination or the transaction which resulted in the
stockholder becoming an interested stockholder;
upon completion of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least
85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting
stock outstanding, but not for determining the outstanding voting stock owned by the interested stockholder, (1) voting stock owned by persons
who are directors and also officers, and (2) voting stock owned by employee stock plans in which employee participants do not have the right to
determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange offer; or
at or subsequent to the date of the transaction, the business combination is approved by the board of directors and authorized at an annual or
special meeting of stockholders, and not by written consent, by the affirmative vote of at least 66 2/3% of the outstanding voting stock which is
not owned by the interested stockholder.
Generally, a business combination includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested
stockholder. An interested stockholder is a person who, together with affiliates and associates, owns or, within three years prior to the determination of
interested stockholder status, did own 15% or more of a corporation’s outstanding voting stock. These provisions may have the effect of delaying, deferring or
preventing a change in our control.
Amended and Restated Certificate of Incorporation and Amended and Restated Bylaw Provisions
Our amended and restated certificate of incorporation and our amended and restated bylaws include a number of provisions that could deter hostile
takeovers or delay or prevent changes in control of our management team, including the following:
•
•
Board of directors vacancies. Our amended and restated certificate of incorporation and amended and restated bylaws authorize only our board of
directors to fill vacant directorships, including newly created seats. In addition, the number of directors constituting our board of directors is
permitted to be set only by a resolution adopted by our board of directors. These provisions prevent a stockholder from increasing the size of our
board of directors and then gaining control of our board of directors by filling the resulting vacancies with its own nominees. This makes it more
difficult to change the composition of our board of directors but promotes continuity of management.
Classified board. Our amended and restated certificate of incorporation and amended and restated bylaws provide that our board is classified into
three classes of directors. A third party may be discouraged from making a tender offer or otherwise attempting to obtain control of us as it is
more difficult and time consuming for stockholders to replace a majority of the directors on a classified board of directors.
•
•
•
•
•
•
Stockholder action; special meeting of stockholders. Our amended and restated certificate of incorporation provides that our stockholders may not
take action by written consent, but may only take action at annual or special meetings of our stockholders. As a result, a holder controlling a
majority of our capital stock is not be able to amend our amended and restated bylaws or remove directors without holding a meeting of our
stockholders called in accordance with our amended and restated bylaws. Our amended and restated certificate of incorporation and amended and
restated bylaws further provide that special meetings of our stockholders may be called only by a majority of our board of directors, the Chairman
of our Board of Directors, our Chief Executive Officer or our President (in the absence of a Chief Executive Officer), thus prohibiting a
stockholder from calling a special meeting. These provisions might delay the ability of our stockholders to force consideration of a proposal or for
stockholders controlling a majority of our capital stock to take any action, including the removal of directors.
Advance notice requirements for stockholder proposals and director nominations. Our amended and restated bylaws provide advance notice
procedures for stockholders seeking to bring business before our annual meeting of stockholders or to nominate candidates for election as
directors at our annual meeting of stockholders. Our amended and restated bylaws also specify certain requirements regarding the form and
content of a stockholder’s notice. These provisions might preclude our stockholders from bringing matters before our annual meeting of
stockholders or from making nominations for directors at our annual meeting of stockholders if the proper procedures are not followed. We expect
that these provisions may also discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer’s own slate of
directors or otherwise attempting to obtain control of our company.
Directors removed only for cause. Our amended and restated certificate of incorporation provides that stockholders may remove directors only for
cause.
No cumulative voting. The Delaware General Corporation Law provides that stockholders are not entitled to the right to cumulate votes in the
election of directors unless a corporation’s certificate of incorporation provides otherwise. Our amended and restated certificate of incorporation
does not provide for cumulative voting.
Amendment of charter provisions. Any amendment of the above provisions in our amended and restated certificate of incorporation would require
approval by a majority of our board of directors and the holders of at least two-thirds of our then outstanding voting securities.
Issuance of undesignated preferred stock. Our board of directors will have the authority, without further action by the stockholders, to issue up to
10,000,000 shares of undesignated preferred stock with rights and preferences, including voting rights, designated from time to time by our board
of directors. The existence of authorized but unissued shares of preferred stock would enable our board of directors to render more difficult or to
discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or other means.
Transfer Agent and Registrar
The transfer agent and registrar for our common stock is EQ Shareowner Services. The transfer agent and registrar’s address is EQ Shareowner
Services, 1110 Centre Pointe Curve, Suite 101, Mendota Heights, MN 55120-4101. Our shares of common stock are issued in uncertificated form only,
subject to limited circumstances.
Market Listing
Our common stock is listed on The NASDAQ Global Select Market under the symbol “OTIC.”
Consent of Independent Registered Public Accounting Firm
Exhibit 23.1
We consent to the incorporation by reference in the following Registration Statements:
(1)
(2)
Registration Statement (Form S-3 No. 333-227269) of Otonomy, Inc., and
Registration Statement (Form S-8 Nos. 333-223522, 333-216401, 333-209990, 333-202851 and 333-198116) pertaining to the 2014 Equity
Incentive Plan, the 2014 Employee Stock Purchase Plan and the Amended and Restated 2010 Equity Incentive Plan;
of our report dated February 27, 2020, with respect to the financial statements of Otonomy, Inc., included in this Annual Report (Form 10-K) of Otonomy,
Inc. for the year ended December 31, 2019.
/s/ Ernst & Young LLP
San Diego, California
February 27, 2020
CERTIFICATION OF PERIODIC REPORT UNDER SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
I, David A. Weber, Ph.D., certify that:
Exhibit 31.1
1.
2.
3.
4.
I have reviewed this Annual Report on Form 10-K of Otonomy, Inc.;
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report;
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined
in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
and 15d-15(f)) for the registrant and have:
(a)
(b)
(c)
(d)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us
by others within those entities, particularly during the period in which this report is being prepared;
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles;
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such
evaluation; and
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s
most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is
reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting,
to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)
(b)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s
internal control over financial reporting.
Date: February 27, 2020
/s/ David A. Weber
David A. Weber, Ph.D.
President and Chief Executive Officer
CERTIFICATION OF PERIODIC REPORT UNDER SECTION 302 OF
THE SARBANES-OXLEY ACT OF 2002
I, Paul E. Cayer, certify that:
Exhibit 31.2
1.
2.
3.
4.
I have reviewed this Annual Report on Form 10-K of Otonomy, Inc.;
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered
by this report;
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material
respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined
in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)
and 15d-15(f)) for the registrant and have:
(a)
(b)
(c)
(d)
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our
supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us
by others within those entities, particularly during the period in which this report is being prepared;
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with generally accepted accounting principles;
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about
the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such
evaluation; and
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s
most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is
reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting,
to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)
(b)
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are
reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s
internal control over financial reporting.
Date: February 27, 2020
/s/ Paul E. Cayer
Paul E. Cayer
Chief Financial and Business Officer
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Exhibit 32.1
Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of
Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), I, David A. Weber, Ph.D., President and Chief Executive Officer of Otonomy, Inc. (the
“Company”), hereby certify that:
1.
2.
The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, to which this Certification is attached as Exhibit
32.1 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and
The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of
the Company.
Date: February 27, 2020
By:
Name:
Title:
/s/ David A. Weber
David A. Weber, Ph.D.
President and Chief Executive Officer
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Exhibit 32.2
Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and Section 1350 of
Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), I, Paul E. Cayer, Chief Financial and Business Officer of Otonomy, Inc. (the
“Company”), hereby certify that:
1.
2.
The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, to which this Certification is attached as Exhibit
32.2 (the “Periodic Report”), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and
The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of
the Company.
Date: February 27, 2020
By:
Name:
Title:
/s/ Paul E. Cayer
Paul E. Cayer
Chief Financial and Business Officer